TABLE OF CONTENTS

Annual Report 2018

Section of:
Section of Cardiology ................................................................. 04
Section of Cardiovascular Research .................................................. 12
Section of Endocrinology, Diabetes and Metabolism .......................... 22
Section of Epidemiology and Population Sciences ............................ 28
Section of Gastroenterology and Hepatology .................................. 36
Section of General Internal Medicine ............................................. 48
Section of Geriatrics ................................................................. 60
Section of Health Services Research ............................................. 64
Section of Hematology-Oncology .................................................. 80
Section of Immunology, Allergy and Rheumatology .......................... 90
Section of Infectious Diseases ...................................................... 96
Section of Nephrology ............................................................... 106
Section of Pulmonary, Critical Care and Sleep Medicine .................... 112
Section of Transition Medicine .................................................... 116
OUR FACULTY
Baylor St. Luke’s Medical Center
Service Line Chief:
Juan Carlos Plana Gomez

General Cardiology
Basant Arya
Hamid Afshar
Mahboob Alam
Yochai Birnbaum
Ali Denktas
John Farmer
Ihab Hamzeh
Srikanth Koneru
Alireza Nazeri
Juan Plana Gomez
Jennifer Loveless
Florence Griffin

Heart Failure
Andrew Civitello
Ajith Nair
Selby Oberton
Guilherme Silva
Leo Simpson
Ziad Taimeh
Jennifer Cabrera
Saleema Ali

Hall-Garcia
Neil Strickman
Jose Diez
Shelia Heinle
Virendra Mathur
Michael Mihalick
Joanna Molina Razavi
Joseph Navarjo
Abdi Rasekh
Mehdi Razavi
Mohammad Saeed
Raymond Stainback

Ben Taub
Nasser Lakkis
Olivia Delossantos
Ihab Hamzeh
Vanessa Medrano
Arunima Misra
Allison Pritchett
Rashed Tabbaa
Lily Zhang
Waleed Kayani

VA
Anita Deswal
Biykem Bozkurt
Alvin Blaustein
Savitri Fedson
Rita Marr
Vijay Nambi
Gabriel Habib
David Paniagua
Tony Ma
Irakli Giorgberidze
Hani Jneid
Ali Denktas
Hamid Afshar
Salim Virani
Paul Schurmann
Tina Shah
Glenn Levine
Biswajit Kar
Umar Khalid

Woodlands North Houston Heart Center
Vincent Aquino
Bruce Lachterman
Christopher Lavergne
Brenda Peabody
Bernardo De La Guardia
Chacko Alexander
Margit Nemeth
George Kantis
Kedar Vaidya
Christopher Nguyen
Scott Greenberg
Jessica Brown

Fellowship Program Leadership
BCM General Cardiology
Salim Virani,
Program Director
Tina Shah,
Associate Program Director, Houston VAMC
Ihab Hamzeh,
Associate Program Director, Ben Taub
Mahboob Alam,
Associate Program Director, BSLMC

BCM Interventional
Hani Jneid,
Program Director

BCM/THI EP
Mohammad Saeed, Program Director

BCM/THI Advanced Heart Failure
Andrew Civitello, Program Director

THI Baylor GME General Cardiology
Stephanie Coulter, Program Director
George Younis, Associate Program Director

THI Interventional
David Fish, Program Director
AWARDS & HONORS

- **Alam:** Founding Member, Houston Chapter, International Society of Endovascular Specialists
- **Alam:** Norton Rose Fulbright Faculty Excellence Award, Teaching and Evaluation, Baylor College of Medicine
- **Alam:** Member, Academy of Distinguished Educators, Baylor College of Medicine
- **Alam:** Early Career Award for Excellence in Patient Care, Baylor College of Medicine
- **Alam:** Top Doctors, Texas Monthly Magazine
- **Ballantyne:** Houston Chronicle Top Doctors 2017
- **Ballantyne:** Castle Connolly Top Doctors: Southeast Texas, Castle Connolly Medical Ltd., 2017
- **Ballantyne:** Castle Connolly Top Doctors in Texas for the Speciality of Cardiovascular Disease, Castle Connolly Medical Ltd., 2017
- **Ballantyne:** Castle Connolly Top Doctors in America, Castle Connolly Medical Ltd., 2018
- **Ballantyne:** Selected by his peers for inclusion in Best Doctors in America®, Best Doctors, Inc., Aiken, South Carolina, 2018
- **Ballantyne:** 2017 Highly Cited Researcher presented by Clarivate Analytics, Web of Science, top 1% of researchers most cited
- **Bozkurt:** Women of Excellence recognition, Baylor College of Medicine, 2018
- **Bozkurt:** Top Doctor, Houstonia, 2017
- **Denktas:** Top Doctor, Houstonia, 2017
- **Denktas:** Star Award for Excellence in Patient Care, Baylor College of Medicine, 2018
- **Deswal:** Houston Top Doctors, 2017
- **Diez:** Cigna High Evidence Based Medicine Score and National Committee for Quality Assurance NCQA Physician Recognition, 2017
- **Diez:** United Healthcare Premium Care Physician, 2017
- **Hamzeh:** Nasser Lakkis Excellence in Teaching Award, Baylor College of Medicine, 2017
- **Hamzeh:** Top Doctors, Houstonia, 2017
- **Lakkis:** Excellence in Teaching Award, General Cardiology, 2017
- **Lakkis:** Excellence in Teaching Award, Interventional Cardiology, 2017
- **Lakkis:** Top cardiologist in Houston, Houstonia, 2018
- **Levine:** Master Clinician Award, Baylor College of Medicine, 2018
- **Levine:** Fulbright & Jaworski Faculty Excellence Award – Full Professor, 2018
• Levine: Visiting Professor, Cleveland Clinic, Cleveland, OH, 2018
• Levine: Visiting Professor, Mt. Sinai Medicinal Center, New York, NY, 2017
• Nair: Star Award for Clinical Excellence, Baylor College of Medicine, 2018
• Nair: That’s The Way Award: Promoting Positive Patient Experience, Baylor College of Medicine, 2018
• Nazeri: Fellow, American College of Cardiology
• Nazeri: Fellow, Heart Rhythm Society
• Shah: Norton Rose Fulbright Faculty Excellence Award, Teaching and Evaluation, Baylor College of Medicine
• Shah: Norton Rose Fulbright Faculty Excellence Award, Enduring Educational Materials, Baylor College of Medicine
• Shah: Member, Academy of Distinguished Educators, Baylor College of Medicine
• Shah: Leadership Academy, Cohort III, American College of Cardiology
• Shah: Fellow of American Heart Association
• Shah: Fellow of American Society of Echocardiography
• Stainback: Texas “Super Doctors” 2018
• Virani: Norton Rose Fulbright Faculty Excellence Award, Development of Enduring Educational Materials, Baylor College of Medicine
• Virani: Inducted into Best Doctors database
• Wehrens: Outstanding Investigator Award, International Society for Heart Research

PROFESSIONAL ORGANIZATIONS
• Alam: Membership Committee, Society of Cardiac Angiography and Interventions
• Arya: Task Force for Point of Care Ultrasound in Medical Education, American Society of Echocardiography
• Ballantyne: Chair, LDL: Address the Risk Think Tank, American College of Cardiology
• Ballantyne: Writing Committee, Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk, American College of Cardiology
• Ballantyne: Board, American Society for Preventive Cardiology
• Ballantyne: Board, National Lipid Association
• Ballantyne: Scientific Meeting Committee, National Lipid Association
• Ballantyne: Co-chair, Project Review Committee, National Lipid Association
• Birnbaum: Board of Directors, International Society of Electrocardiology
• Bozkurt: Member, Question Writing Committee, Advanced Heart Failure and Cardiac Transplant, American Board of Internal Medicine
• Bozkurt: Member, Clinical Policy Approval Committee, American College of Cardiology
• Bozkurt: Member, Health Failure Therapies App Work Group, American College of Cardiology
• Bozkurt: Member, Informatics and Health IT Task Force, American College of Cardiology
• Bozkurt: Member, Subspecialty Work Group, Membership Committee, American College of Cardiology
• Bozkurt: Member, Science and Quality Operations Subcommittee, American College of Cardiology
• Bozkurt: Chair, Heart Failure and Transplant Council, American College of Cardiology
• Bozkurt: Chair, ACCF/AHA Task Force on Clinical Data Standards
• Bozkurt: Member, ACC/AHA HF Guideline Toolkit Work Group
• Bozkurt: Member, ACCF/AHA Task Force on Clinical Practice Guidelines
• Bozkurt: Member, ACCF/AHA Task Force on Performance Metrics
• Bozkurt: Member, Board of Directors, Heart Failure Society of America
• Bozkurt: Treasurer, Heart Failure Society of America
• Bozkurt: Chair, Finance Committee, Heart Failure Society of America
• Bozkurt: Member, Clinical Research Network Committee, Heart Failure Society of America
• Bozkurt: Member, Development Committee, Heart Failure Society of America
• Bozkurt: Member, Membership Committee, Heart Failure Society of America
• Bozkurt: Member, Nominations Committee, Heart Failure Society of America
• Bozkurt: Member, Strategic Planning Subcommittee, Heart Failure Society of America
• Denktas: Member, Competency Management Committee, American College of Cardiology
• Denktas: Member, Anticoagulation Work Group, American College of Cardiology
• Denktas: Member, Exhibits Committee, American College of Cardiology
• **Denktas:** Member, Education Committee, Society for Cardiovascular Angiography and Interventions
• **Deswal:** Topic Coordinator, Annual Scientific Session Program Committee (Heart Failure), American College of Cardiology
• **Deswal:** Member, Annual Scientific Session Program Committee (Heart Failure), American College of Cardiology
• **Deswal:** Member, Joint American College of Cardiology/American Heart Association Task Force on Clinical Performance Guidelines
• **Deswal:** Member/Immediate Past Chair, Clinical Heart Failure and Transplantation Committee, Council of Clinical Cardiology, American Heart Association
• **Deswal:** Member, National Get with the Guidelines Steering Committee, American Heart Association
• **Deswal:** Member, Heart Failure Working Group, Get with the Guidelines, American Heart Association
• **Deswal:** Member, Guideline and Statements Committee, Heart Failure Society of America
• **Fedson:** Member, Question Writing Committee, Advanced Heart Failure and Cardiac Transplant, American Board of Internal Medicine
• **Fedson:** Member, Ethics Committee, Heart Failure Society of America
• **Fedson:** Member, Guideline and Statements Committee, Heart Failure Society of America
• **Hamzeh:** Member, ABIM Governance: Cardiovascular Disease Item-Writing Task Force
• **Jneid:** Chair-elect, ACCF/AHA Task Force on Clinical Data Standards
• **Jneid:** Member, ACCF/AHA Task Force on Performance Metrics
• **Jneid:** Member, ACCF/NCDR Action Registry Research & Publications Committee
• **Jneid:** Member, Steering Committee, Fellows in Training, American Heart Association
• **Jneid:** Member, International Committee, American Heart Association
• **Jneid:** Member, Organizing Committee, Scientific Sessions, American Heart Association
• **Jneid:** Writing Committee Member, ACC/AHA Chest Pain Guidelines
• **Jneid:** Co-chair, AHA Scientific Statement on Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA)
• **Levine:** Chair, ACC/AHA Task Force on Clinical Practice Guidelines
• **Nair:** Member, Heart Failure and Transplantation Committee, Council on Clinical Cardiology, American Heart Association
• **Nair:** Member, National Standards Committee for Heart Failure Care, Catholic Health Initiatives
• **Plana:** Co-chair, Technology Incubator Task Force, American Society of Echocardiography
• **Plana:** Member, Standards and Guidelines Committee, American Society of Echocardiography
• **Plana:** Member, Scientific Sessions Task Force, American Society of Echocardiography
• **Plana:** Member, Cardiac Imaging and Intervention Committee, American Heart Association
• **Plana:** Member, Board of Directors, American Heart Association–Houston Chapter
• **Plana:** Chair, Cardiac Imaging Subcommittee, Catholic Health Initiatives
• **Shah:** Editorial Team Lead, Clinical Topic Collection, Heart Failure and Transplant Council, American College of Cardiology, ACC.org
• **Shah:** Member, Heart Failure Sessions Planning Committee, 67th Scientific Sessions, American College of Cardiology
• **Stainback:** Director, Board of Directors, American Society of Echocardiography
• **Stainback:** Immediate Past Board Chair, Intersocietal Accreditation Commission
• **Stainback:** President, Greater Houston Echo-Vascular Society
• **Virani:** Chair, Leadership Council and Council for the Prevention of Cardiovascular Disease, American College of Cardiology
• **Virani:** Chair, Research and Publications Committee, PINNACLE Registry, National Cardiovascular Data Registry, American College of Cardiology
• **Virani:** Member, LDL: Address the Risk Think Tank, American College of Cardiology
• **Virani:** Member, Guideline Tool Work Group, 2018 ACC/AHA Cholesterol Guideline, American College of Cardiology
• **Virani:** Member, Research to Practice (R2P) Initiative Work Group, National Cardiovascular Data Registry, American College of Cardiology
• **Virani:** Topic Coordinator (Prevention), Annual Scientific Session Program Committee, American College of Cardiology
• **Virani:** Chair, Heart Disease and Stroke Statistics Committee, American Heart Association
• **Virani:** Member, EPI Leadership Committee, Council on Epidemiology and Prevention, American Heart Association
• **Virani:** Board of Directors, American Society of Preventive Cardiology
• **Wehrens:** Chair, Young Investigator Award competition, American Society of Clinical Investigation
• **Wehrens:** Chair, Research Committee, Heart Rhythm Society
RESEARCH FUNDING

• **Ballantyne** (co-PI): Profiling Cardiovascular Events and Biomarkers in the Very Old to Improve Personalized Approaches for the Prevention of Cardiac and Vascular Disease; NIH/NHLBI (R01); annual direct costs $549,802 (09/01/2016 – 08/31/2020)

• **Ballantyne** (coinvestigator): Atherosclerosis Risk in Communities (ARIC) Study-Field Centers; NIH; annual direct costs $311,673 (11/15/2016–11/14/2021)

• **Ballantyne** (coinvestigator): Monocyte Activation and the Role of CD11c in Obesity-Linked Metabolic Syndrome; NIH/NHLBI (R01); annual direct costs $241,769 (04/01/2015 – 03/31/2020)

• **Ballantyne** (coinvestigator): Diabetes and Prediabetes in Older Adults; NIH/NIDDK (R01); annual direct costs $36,371 (01/01/2016–12/31/2020)

• **Ballantyne** (coinvestigator): miRNAs, Whole Diet, and Coronary Heart Disease; NIH/NHLBI (R56); total direct costs $12,147 (09/01/2016–08/31/2018)

• **Ballantyne** (coinvestigator): Comparative Effectiveness of Physicians versus Non-physicians for the Delivery of Outpatient Diabetes Care: Implications for Access to Care under the Affordable Care Act; American Diabetes Association; total direct costs: $486,957 (01/01/2014–12/31/2017)

• **Ballantyne** (PI): The Familial Hypercholesterolemia Foundation Cascade-FH Registry; Duke University; total direct costs $20,000 (07/01/2014–06/30/2019)

• **Ballantyne** (PI): Measurement of Galectin-3 at Visit 4 and Visit 5 for the Full ARIC Cohort; Abbott Laboratories; total direct costs $31,500 (03/14/2014–07/31/2018)

• **Ballantyne** (PI): hsTroponin Screening at Visit 4 and Visit 5 for the Full ARIC Cohort; Abbott Laboratories; total direct costs $371,965 (05/12/2014–05/11/2019)

• **Ballantyne** (PI): A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD); Akcea Therapeutics; total direct costs $172,510 (02/28/2017–02/27/2020)

• **Ballantyne** (PI): A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients with Hypertriglyceridemia and Established Cardiovascular Disease; Akcea Therapeutics; total direct costs $206,886 (03/08/2018–03/07/2021)

• **Ballantyne** (PI): A Multicenter, Controlled, Open-Label Extension (OLE) Study to Assess the Long-Term Safety and Efficacy of AMG-145; Amgen, Inc; total direct costs $43,965 (6/01/13–2/08/18)

• **Ballantyne** (PI): GAUSS-3A—Double-Blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared with Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of an HMG-CoA Reductase Inhibitor due to Muscle Related Side Effects; Amgen, Inc; total direct costs $60,085 (02/18/2014–03/21/2018)

• **Ballantyne** (PI): A Multicenter, Open-Label, Single-Arm, Extension Study to Assess Long-Term Safety of Evolocumab Therapy in Patients with Clinically Evident Cardiovascular Disease; Amgen Inc; total direct costs $45,670 (8/17/16–12/31/21)

• **Ballantyne** (PI): A Randomized, Double-Blind, Placebo-Controlled, Multicenter Long-Term Safety and Tolerability Study of ETC 1002 in Patients with Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy; Esperion Therapeutics; total direct costs $62,963 (06/27/2016–06/29/2018)

• **Ballantyne** (PI): A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant; Esperion Therapeutics; total direct costs $40,614 (05/17/2017–04/30/2020)

• **Ballantyne** (PI): A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of bempedoic acid (ETC1002) 180 mg/day as add-on to ezetimibe therapy in patients with elevated LDL-C; Esperion Therapeutics; total direct costs $29,253 (6/07/17– 4/25/18)

• **Ballantyne** (PI): A Randomized, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 mg + Ezetimibe 10 mg Fixed-dose Combination Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy; Esperion Therapeutics; total direct costs $21,194 (11/29/2017–11/17/2018)

• **Ballantyne** (PI): A Multicenter Open-Label Extension (OLE) Study to Assess the Long-Term Safety and Efficacy of Bempedoic Acid (ETC1002) 180 mg; Esperion Therapeutics; total direct costs $22,400 (08/07/2017–12/31/2019)

• **Ballantyne** (PI): A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events among Stable Post-Myocardial Infarction Patients with Elevated hsCRP; Novartis Pharmaceutical Company; total direct costs $125,877 (04/25/2011–12/31/2020)

• **Birnbaum** (PI): Prospective ARNI versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events after Myocardial infarction; Novartis Pharmaceuticals; total direct costs $200,000 (01/01/2018–04/01/2021)

• **Bozkurt** (Site PI): Genomic Response Analysis of Heart Failure Therapy in African Americans; NIH/NHLBI; $84,000 (6/01/16–05/30/19)
• Bozkurt (PI): A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Active-Controlled 8-Week Study to Evaluate the Effect of Sacubitril and Valsartan (LCZ696) versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF) (PIONEER-HF); Novartis; total direct costs $126,000 (06/01/2016–12/31/2018)

• Deswal (Site PI): Influenza Vaccine to Effectively Stop CardioThoracic Events and Decompenated Heart Failure (INVESTED); NIH/NHLBI (U05), VA Consortium; $45,000 (02/15/2016–01/31/2021)

• Hamzeh (PI): CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients with Type 2 Diabetes Mellitus at High Vascular Risk; Boehringer Ingelheim; total direct costs $32,426 (10/01/2014–04/24/2018)

• Hamzeh (PI): A Long-Term Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH); Astra Zeneca; total direct costs $117,000 (05/01/2015–04/30/2020)

• Hamzeh (PI): Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes; Kowa Pharmaceuticals; total direct costs $30,561 (05/01/2017–04/30/2022)

• Misra (PI): A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Active-Controlled 8-Week Study to Evaluate the Effect of Sacubitril and Valsartan (LCZ696) versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF) (PIONEER-HF); Novartis; total direct costs $297,000 (07/30/2016–12/31/2018)

• Misra (PI): A Multicenter, Randomized, Double-Blind, Active-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril Morbidity and Mortality in High Risk Patients Following an Acute Myocardial Infarction; Novartis; total direct costs $35,000 (09/01/17–8/31/2020)

• Misra (PI): A Multicenter, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction; Amgen; total direct costs $168,362 (12/01/2017–11/30/2020)

• Nambi (PI): Biomarker Guided Therapies in Stage A/B Heart Failure; VA Office of Research and Development; annual direct costs $14,189 (04/01/2014–03/31/2019)

• Nambi (PI): TIMI 55/REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid-Modification): A Large Scale, Randomized, Placebo-Controlled Trial of the Clinical Effects of Anacetrapib among People with Established Vascular Disease; Brigham and Women’s Hospital; total direct costs $150,000 (11/01/2011–02/28/2019)

• Nazeri (PI): VIVÔ™ View Into Ventricular Onset Atrial Trial; Catheter Precision, Inc.

• Virani (PI): Comparative Effectiveness of Physicians versus Non-physicians for the Delivery of Outpatient Diabetes Care: Implications for Access to Care under the Affordable Care Act; American Diabetes Association; total direct costs: $486,957 (01/01/2014–12/31/2017)

• Virani (PI): Determining and Targeting Reasons for Low Statin Use to Improve Guideline-Concordant Statin Therapy in High-Risk Patients; VA Merit Award; total direct costs: $1,097,703 (07/01/2017–06/30/2021)

• Zhang (PI): A Multicenter, Randomized, Double-Blind, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) with Preserved Ejection Fraction; Novartis Pharmaceuticals; total direct costs $40,550 (09/13/2013–08/31/2021)

**PUBLICATIONS & PRESS**

• Civitello: Invited lecture, “Mechanical Circulatory Support to Manage Heart Failure,” Cardio Academic—in collaboration with American College of Cardiology and European Society of Cardiology, Mexico City, Mexico

• Civitello: Invited lecture, “Diagnosis of Device Thrombosis,” AATS—Mechanical Circulatory Support Symposium, Houston, TX

• Civitello: Invited lecture, “Timing the Transition from Short to Long Term Mechanical Circulatory Support to Transplant,” AATS—Mechanical Circulatory Support Symposium, Houston, TX

• Civitello: Invited lecture, “Update in Advanced Heart Failure Management,” Internal Medicine Grand Rounds Conference, Houston, TX

• Civitello: Invited lecture, “Utility of Counterpulsation in AMI in the Current Era,” 1st Annual Houston Shock Symposium, Houston, TX

• Civitello: Invited lecture, “Latest Advances in Treating Heart Failure Medically,” 17th Update in Cardiovascular Advancements, Houston, TX

• Deswal: Abstract reviewer, 2018 Annual Scientific Sessions, American College of Cardiology

• Deswal: Abstract reviewer, 2018 Annual Scientific Sessions, American Heart Association

• Deswal: Abstract reviewer, 2018 Annual Scientific Sessions, Heart Failure Society of America

• Deswal: Presentation, “Foundations of HFpEF,” national webinar, Get with the Guidelines—Heart Failure

• Deswal: Faculty, Study Session for Maintenance of Certification (MOC): ABIM 2017-2018 Update in Cardiovascular Disease, Annual Scientific Sessions, American College of Cardiology, Orlando, FL

• Deswal: Presentation, “Challenging Cases in Diabetes Management in Heart Failure,” Annual Scientific Sessions, American College of Cardiology, Orlando, FL
• Deswal: Co-Chair for session “Heart Failure with Preserved Ejection Fraction: Where Do We Go from Here?,” Annual Scientific Sessions, American College of Cardiology, Orlando, FL
• Deswal: Poster Professor for session “A Focus on Heart Failure Hospitalization,” Annual Scientific Sessions, American Heart Association, Anaheim, CA
• Deswal: Co-Chair for Session, “Pulmonary Comorbidities of HF: COPD and Sleep Apnea,” Annual Scientific Sessions, Heart Failure Society of America, Dallas, TX
• Diez: Invited lecture, “Combined TAVR and supraavalvular therapy,” Latest Advances in Treatment of Structural Heart Disease, ISEVS 2018, Houston, TX
• Diez: Invited lecture, “TAVR in Special Scenarios: CHF and Pulmonary HTN,” San Francisco University, Quito, Ecuador
• Diez: Invited lecture, “TAVR: Expanding Clinical Indications,” Cardio Academic in collaboration with American College of Cardiology and European Society of Cardiology, Mexico City, Mexico DF, Mexico
• Diez: Abstract reviewer, 2018 Annual Scientific Sessions, American College of Cardiology
• Diez: Abstract reviewer, 2018 Annual Scientific Sessions, Transcatheter Therapies – TCT
• Diez: Poster presentation, “Clinical Predictors of Coronary Slow Flow in the Absence of Epicardial CAD,” International Academy of Cardiology 2018 Annual Scientific Sessions, Boston, MA
• Fedson: Presentation, “New Models of Palliative Care in Heart Failure,” 2018 Annual Scientific Sessions, American College of Cardiology, Orlando, FL
• Fedson: Presentation, Reversing Frailty: Can Mechanical Circulatory Support Reverse the Frailty Phenotype,” 2018 Scientific Sessions, International Society of Heart and Lung Transplant, Nice
• Fedson: Co-Chair for Session, “Reading the Tea Leaves: Prediction in Heart Failure,” 2018 Scientific Sessions, International Society of Heart and Lung Transplant, Nice
• Fedson: Co-Chair, “An Amalgamation of Support in Heart Failure,” International Society of Heart and Lung Transplantation, San Diego, CA
• Fedson: Co-Chair, Comorbidities of HFP EF, Heart Failure Society of America, Dallas TX
• Hamzeh: Invited presentations, 9th Annual ECHO Boot Camp
• Hamzeh: Primary investigator, Ben Taub General Hospital, ISCHEMIA Trial
• Hamzeh: Primary investigator, Ben Taub General Hospital, CARMELINA Trial
• Hamzeh: Primary investigator, Ben Taub General Hospital, STRENGTH Trial
• Hamzeh: Primary investigator, Ben Taub General Hospital, PROMINENT Trial
• Hamzeh: Mentor for fellow Dr. Mostafa El-Refai on QI project Improving Anticoagulation in Patients with Atrial Fibrillation/Flutter Received Health Care Innovation Seed grant from Department of Internal Medicine
• Jneid: Member, Emerging Faculty, American College of Cardiology, 2017
• Jneid: Abstract reviewer, 2018 Annual Scientific Sessions, American Heart Association
• Jneid: Abstract reviewer, 2018 Annual Scientific Sessions, American College of Cardiology
• Jneid: Course Director, Rice University community course, “Heart Health: Prevention, Treatments, Innovations
• Jneid: Speaker/Moderator at AHA, ACC, ACC Oklahoma Chapter, C3, SCAI meetings
• Lakkis: Renewal of Chest Pain/STEMI with PCI Center Accreditation by ACC 2018–2021
• Lakkis: 2018 Quality Achievement Award, Gold Plus Mission Lifeline STEMI receiving Center
• Lakkis: 2018 Quality Achievement Award, Gold Mission Lifeline NSTEMI
• Lakkis: Presentation: “Controversies in Anticoagulation,” Pri-Med Southwest Annual Conference, Houston, TX
• Misra: Speaker and Session Moderator, “Chest Pain Evaluation in the Office Setting,” Pri-Med Southwest Annual Conference, Houston, TX
• Nair: Lecture, “Heart Failure with Preserved Ejection Fraction,” Baylor St Luke’s Transplant Grand Rounds, Houston, TX
• Nair: Lecture, “When Right is Not Right: Pulmonary Hypertension and Right Ventricular Support,” Igor F. Palacios, MD Lectureship in Cardiology, Houston, TX
• Nair: Lecture, “Class III Patients Should Undergo LVAD Implantation: Pro/Con Debate,” Mechanical Circulatory Support Symposium, American Association for Thoracic Surgery, Houston, TX
• **Nair:** Lecture, “Pulmonary Hypertension in Women: What the Clinician Needs to Know,” Annual Women’s Heart and Vascular Symposium, Texas Heart Institute, Houston, TX

• **Shah:** Faculty and Course Developer, “Concerns in the management of chronic heart failure: staying on the path to optimal medical therapy,” CME activity by American College of Cardiology in partnership with Haymarket Medical Education

• **Shah:** Abstract reviewer, 2018 Annual Scientific Sessions, American Heart Association

• **Shah:** Abstract reviewer, 2018 Annual Scientific Sessions, American College of Cardiology

• **Stainback:** Course Director, 9th annual Houston Echo Board Review: Boot Camp for the 2018 Echo Board

• **Stainback:** Session Speaker and Session Chair, American Society of Echocardiography Scientific Sessions, 2018

• **Virani:** Invited speaker, Global Cardiovascular Disease Prevention webinars in Indonesia, Malaysia, Vietnam, and UAE

• **Wehrens:** Invited lecture, Cardiovascular Research Theme symposium, UCLA, Los Angeles, CA

• **Wehrens:** Invited lecture, AAV Gene Therapy Symposium, Houston, TX

• **Wehrens:** Invited lectures (2), Heart Rhythm Society, Boston, MA

• **Wehrens:** Invited lecture, 37th Annual Conference of the North American Section of the International Society for Heart Research, Halifax, Canada

**EDITORIAL POSITIONS**

• **Ballantyne:** Editorial Director, lipidsonline.org

• **Ballantyne:** Editorial Board, Circulation

• **Ballantyne:** Editorial Board, Clinical and Translational Science

• **Ballantyne:** Editorial Board, Current Cardiology Reviews

• **Ballantyne:** Editorial Board, Future Lipidology

• **Birnbaum:** Associate Editor, Cardiovascular Drugs and Therapy

• **Birnbaum:** Special Section Editor, “Clinical Trials,” Journal of Electrocardiology

• **Bozkurt:** Editorial Advisory Board, American Family Physician Journal

• **Bozkurt:** Senior Associate Editor, Circulation

• **Bozkurt:** Associate Editor, Circulation Heart Failure

• **Bozkurt:** Editorial Board, CurrentMD

• **Bozkurt:** Editorial Board, Journal of American College of Cardiology

• **Bozkurt:** Section Editor, “Heart Failure,” Journal of American College of Cardiology

• **Denktas:** Editorial Board, Anatolian Cardiology Journal

• **Denktas:** Editorial Board, Marmara University Journal

• **Deswal:** Guest Editor, Circulation Heart Failure

• **Deswal:** Consultant, Journal of American College of Cardiology

• **Deswal:** Editorial Board, Journal of Cardiac Failure

• **Diez:** Editorial Board, Texas Heart Institute Journal

• **Jneid:** Senior Associate Editor, Journal of the American Heart Association

• **Jneid:** Editorial Board, American Journal of Cardiology

• **Jneid:** Editorial Board, Cardiovascular System

• **Jneid:** Editorial Board, Journal of Geriatric Cardiology

• **Jneid:** Editorial Board, Journal of the American College of Cardiology

• **Virani:** Associate Editor, Innovations, ACC.org

• **Virani:** Editorial Team Member and Chair for Digital Strategy, Cardiovascular Prevention Section, ACC.org (educational web portal for the American College of Cardiology)

• **Virani:** Advisory Board, Advances in Therapy

• **Virani:** Guest Editor, Circulation

• **Virani:** Editorial Board, Circulation

• **Virani:** Section Editor, “Coronary Heart Disease,” Current Atherosclerosis Report

• **Virani:** Associate Editor, Journal of Clinical Lipidology (Section specialty: Cardiovascular Outcomes and Guidelines)

• **Virani:** Associate Editor, Global Heart (Official Journal of the World Heart Federation)

• **Wehrens:** Editorial Board, Acta Pharmacologica Sinica

• **Wehrens:** Editorial Board, Circulation Research

• **Wehrens:** Editorial Board, Heart Rhythm

• **Wehrens:** Editorial Board, JACC Basic and Translational Research

• **Wehrens:** Editorial Board, Journal of Molecular and Cellular Cardiology
Section of Cardiovascular Research

OUR FACULTY

Atherosclerosis and Vascular Medicine
Christie Mitchell Ballantyne
Gerd Brunner
John Foreyt
Ron Cornelis Hoogeveen
Peter Howard Jones
Na Li
Joel D. Morrisett
Vijay Nambi
Xinchun Pi
Louis C. Smith
Giles W. Vick
Salim S. Virani
Huaizhu Wu
Liang Xie
Chao-Yuh Yang

Cardiovascular Sciences
Mark Entman
Robert Bryan, Jr.
Katarzyna Cieslik
Sandra Haudek
Lloyd Michael
Anilkumar Reddy
George Taffet
Joann Trial

Hypertension and Clinical Pharmacology
Addison Taylor
James Pool
Charlyne Wright

Thrombosis Research
Miguel Cruz
Vinod Vijayan
Trung Nguyen
Mona Shah
Wayne Smith
Jun Teruya
Perumal Thiagarajan
Donald Yee

AWARDS & HONORS

• Ballantyne: Houston Chronicle Top Doctors 2017
• Ballantyne: Castle Connolly Top Doctors: Southeast Texas, Castle Connolly Medical Ltd., 2017
• Ballantyne: Castle Connolly Top Doctors in Texas for the Speciality of Cardiovascular Disease, Castle Connolly Medical Ltd., 2017
• Ballantyne: Castle Connolly Top Doctors in America, Castle Connolly Medical Ltd., 2018
• Ballantyne: Selected by his peers for inclusion in Best Doctors in America®, Best Doctors, Inc., Aiken, South Carolina, 2018
• Ballantyne: 2017 Highly Cited Researcher presented by Clarivate Analytics, Web of Science, top 1% of researchers most cited
• Entman: International Academy of Cardiovascular Sciences Lifetime Achievement Award in Cardiovascular Science, Medicine and Surgery, August 2017
• Li: University of Houston Teaching Excellence Award for Group Teaching, 2017-2018
• Virani: Norton Rose Fulbright Faculty Excellence Award, Development of Enduring Educational Materials, Baylor College of Medicine
• Virani: Inducted into Best Doctors database

PROFESSIONAL ORGANIZATIONS

• Ballantyne: Chair, LDL: Address the Risk Think Tank, American College of Cardiology
• Ballantyne: Writing Committee, Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk, American College of Cardiology
• Ballantyne: Board, American Society for Preventive Cardiology
• Ballantyne: Board, National Lipid Association
• Ballantyne: Scientific Meeting Committee, National Lipid Association
• Ballantyne: Co-chair, Project Review Committee, National Lipid Association
• **Brunner**: Member, Grant Peer Review Committee, Innovative Project Award (IPA) Committee, American Heart Association
• **Jones**: Chief Science Officer, National Lipid Association
• **Virani**: Chair, Leadership Council and Council for the Prevention of Cardiovascular Disease, American College of Cardiology
• **Virani**: Chair, Research and Publications Committee, PINNACLE Registry, National Cardiovascular Data Registry, American College of Cardiology
• **Virani**: Member, LDL: Address the Risk Think Tank, American College of Cardiology
• **Virani**: Member, Guideline Tool Work Group, 2018 ACC/AHA Cholesterol Guideline, American College of Cardiology
• **Virani**: Member, Research to Practice (R2P) Initiative Work Group, National Cardiovascular Data Registry, American College of Cardiology
• **Virani**: Topic Coordinator (Prevention), Annual Scientific Session Program Committee, American College of Cardiology
• **Virani**: Chair, Heart Disease and Stroke Statistics Committee, American Heart Association
• **Virani**: Member, EPI Leadership Committee, Council on Epidemiology and Prevention, American Heart Association
• **Virani**: Board of Directors, American Society of Preventive Cardiology
• **Wu**: Member, Grant Peer Review Committee, Lipids BSc 2 Committee, American Heart Association

**RESEARCH FUNDING**

• **Ballantyne** (co-PI): Profiling Cardiovascular Events and Biomarkers in the Very Old to Improve Personalized Approaches for the Prevention of Cardiac and Vascular Disease; NIH/NHLBI (R01); annual direct costs $549,802 (09/01/2016–08/31/2020)
• **Ballantyne** (coinvestigator): Atherosclerosis Risk in Communities (ARIC) Study–Field Centers; NIH; annual direct costs $311,673 (11/15/2016–11/14/2021)
• **Ballantyne** (coinvestigator): Monocyte Activation and the Role of CD11c in Obesity-Linked Metabolic Syndrome; NIH/NHLBI (R01); annual direct costs $241,769 (04/01/2015–03/31/2020)
• **Ballantyne** (coinvestigator): Diabetes and Prediabetes in Older Adults; NIH/NIDDK (R01); annual direct costs $36,371 (01/01/2016–12/31/2020)
• **Ballantyne** (coinvestigator): miRNAs, Whole Diet, and Coronary Heart Disease; NIH/NHLBI (R56); total direct costs $12,147 (09/01/2016–08/31/2018)
• **Ballantyne** (coinvestigator): Comparative Effectiveness of Physicians versus Non-physicians for the Delivery of Outpatient Diabetes Care: Implications for Access to Care under the Affordable Care Act; American Diabetes Association; total direct costs: $486,957 (01/01/2014–12/31/2017)
• **Ballantyne** (PI): The Familial Hypercholesterolemia Foundation Cascade-FH Registry; Duke University; total direct costs $20,000 (07/01/2014–06/30/2019)
Research Funding continued

- **Ballantyne (PI):** Measurement of Galectin-3 at Visit 4 and Visit 5 for the Full ARIC Cohort; Abbott Laboratories; total direct costs $31,500 (03/14/2014–07/31/2018)

- **Ballantyne (PI):** hsTroponin Screening at Visit 4 and Visit 5 for the Full ARIC Cohort; Abbott Laboratories; total direct costs $371,965 (05/12/2014–05/11/2019)

- **Ballantyne (PI):** A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD); Akcea Therapeutics; total direct costs $172,510 (02/28/2017–02/27/2020)

- **Ballantyne (PI):** A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients with Hypertriglyceridemia and Established Cardiovascular Disease; Akcea Therapeutics; total direct costs $206,886 (03/08/2018–03/07/2021)

- **Ballantyne (PI):** A Multicenter, Controlled, Open-Label Extension (OLE) Study to Assess the Long-Term Safety and Efficacy of AMG-145; Amgen, Inc; total direct costs $43,965 (06/01/2013–02/08/2018)

- **Ballantyne (PI):** GAUSS-3A—Double-Blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared with Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of an HMG-CoA Reductase Inhibitor due to Muscle Related Side Effects; Amgen, Inc; total direct costs $60,085 (02/18/2014–03/21/2018)

- **Ballantyne (PI):** A Multicenter, Open-Label, Single-Arm, Extension Study to Assess Long-Term Safety of Evolocumab Therapy in Patients with Clinically Evident Cardiovascular Disease; Amgen Inc; total direct costs $45,670 (08/17/2016–12/31/2021)

- **Ballantyne (PI):** A Randomized, Double-Blind, Placebo-Controlled, Multicenter Long-Term Safety and Tolerability Study of ETC 1002 in Patients with Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy; Esperion Therapeutics; total direct costs $62,963 (06/27/2016–06/29/2018)

- **Ballantyne (PI):** A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant; Esperion Therapeutics; total direct costs $40,614 (05/17/2017–04/30/2020)

- **Ballantyne (PI):** A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of bempedoic acid (ETC1002) 180 mg/day as add-on to ezetimibe therapy in patients with elevated LDL-C; Esperion Therapeutics; total direct costs $29,253 (06/07/2017–04/25/2018)

- **Ballantyne (PI):** A Randomized, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 mg + Ezetimibe 10 mg Fixed-dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy; Esperion Therapeutics; total direct costs $21,194 (11/29/2017–11/17/2018)

- **Ballantyne (PI):** A Multicenter Open-Label Extension (OLE) Study to Assess the Long-Term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 mg; Esperion Therapeutics; total direct costs $22,400 (08/07/2017–12/31/2019)

- **Ballantyne (PI):** A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events among Stable Post-Myocardial Infarction Patients with Elevated hsCRP; Novartis Pharmaceutical Company; total direct costs $125,877 (04/25/2011–12/31/2020)

- **Brummer (PI):** Microvascular Perfusion Assessment of Ischemic Diabetic Ulcers Using MRI; NIH/NHLBI (K25); annual direct costs $154,958 (12/01/2014–12/31/2019)

- **Brummer (PI):** MRI Based Calf Muscle Perfusion to Assess Patients with Symptomatic PAD; NIH/NHLBI (R01); annual direct costs $350,417 (08/01/2017–07/31/2022)

- **Brummer (coinvestigator):** Biomarker Guided Therapies in Stage A/B Heart Failure; VA Office of Research and Development; annual direct costs $14,189 (04/01/2014–03/31/2019)

- **Cieslik (co-PI):** Trafficking Leukocytes in the Aging Mouse Heart: in Vivo MRI and Flow Cytometry; BCM Cardiovascular Research Institute Pilot Award (09/01/2017–06/30/2018)

- **Cieslik (coinvestigator):** Role of Blood-Borne Fibroblast Precursors in Ischemic Cardiomyopathy; NIH/NHLBI (R01); annual direct costs $250,000 (07/01/2007–11/30/2017)

- **Cieslik (PI):** A Spontaneous Mutation in Nnt Gene Promotes Cardiac Fibrosis in the Aging Heart; The Medallion Foundation; total direct costs $50,000 (07/01/2015–12/31/2018)

- **Cruz (multi-PI):** Microvascular Thrombosis in Systemic Inflammation; NIH/NIGMS (R01); annual direct costs $220,000 (09/25/2014–05/31/2019)

- **Cruz (co-PI):** Role of Vimentin in Thrombosis and Stroke; NIH/NINDS (R01); annual direct costs $381,958 (09/01/2016–05/31/2021)

- **Entman (PI):** Role of Blood-Borne Fibroblast Precursors in Ischemic Cardiomyopathy; NIH/NHLBI (R01); annual direct costs $250,000 (07/01/2007–11/30/2017)

- **Entman (PI):** Researching the Aging Heart; The Curtis and Doris K. Hankamer Foundation; annual direct costs $40,000 (01/01/2001–12/31/2018)
- **Foreyt (PI):** Study of Health Outcomes of Weight-Loss (Look AHEAD) Trial; NIH/NIDDK (U01); annual direct costs $152,265 (09/01/1999–01/31/2019)
- **Foreyt (PI):** Vitamin D to Prevent Type 2 Diabetes (D2d Study); NIH/NIDDK (U01); annual direct costs $45,309 (06/01/2013–01/31/2019)
- **Hoogeveen (coinvestigator):** Atherosclerosis Risk in Communities (ARIC) Study—Field Centers; NIH/NHLBI; annual direct costs $311,673 (11/15/2016–11/14/2021)
- **Hoogeveen (coinvestigator):** Diabetes and Pre-diabetes in Older Adults; NIH/NIDDK (R01); total direct costs $200,000 (09/01/2016–12/31/2020)
- **Hoogeveen (coinvestigator):** Endogenous Hormones and Postmenopausal Breast Cancer: Etiologic Insights and Improving Risk Prediction; NIH/NCI; annual direct costs $76,772 (06/15/2017–03/31/2022)
- **Hoogeveen (PI):** Relation of Lipoprotein(a) and Small Dense LDL-C (sdLDL-C) to Incident CHD and Stroke: the ARIC Study; Denka Seiken Co, Ltd; annual direct costs $18,021 (10/01/2010–12/31/2017)
- **Hoogeveen (PI):** Relationship of Small-Dense LDL Cholesterol (sdLDL-C) and Lp(a) with Progression of Atherosclerosis in the Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin versus Atorvastatin (SATURN) Trial; Denka Seiken Co, Ltd (11/01/2013–12/31/2017)
- **Hoogeveen (PI):** Lipoprotein Subfractions Study: the ARIC Study; Denka Seiken Co, Ltd; annual direct costs $56,750 (11/01/2015–08/31/2018)
- **Jones:** A Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA Intervention Trial); Amarin Pharmaceuticals; total direct costs $25,000 (06/01/2012–12/31/2018)
- **Li (PI):** Inflammasome Mediated Pathogenesis of Atrial Fibrillation; NIH/NHLBI (R56); annual direct costs $250,000 (09/01/2016–08/31/2018)
- **Li (PI):** The Role of Inflammasome in the Pathogenesis of Atrial Fibrillation; NIH/NHLBI (R01); annual direct costs $379,069 (09/01/2017–06/30/2021)
- **Li (PI):** Transcriptional Regulation of Ryanodine Receptor 2 in Atrial Fibrillation; American Heart Association Scientist Development Grant; annual direct costs $379,069 (09/01/2017–06/30/2021)
- **Li (coinvestigator):** Novel Roles of FE2+, 2-Oxoglutarate-Dependent Dioxygenases in Cardiac Function; NIH/NHLBI (R01); annual direct costs $250,000 (09/01/2015–08/31/2020)
- **Li (coinvestigator):** Pitx2 in Atrial Fibrillation; NIH/NHLBI (R01); annual direct costs $327,304 (02/01/2018–02/28/2023)
- **Nambi (PI):** Biomarker Guided Therapies in Stage A/B Heart Failure; VA Office of Research and Development; annual direct costs $14,189 (04/01/2014–03/31/2019)
- **Nambi (PI):** TIMI 55/REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid-Modification): A Large Scale, Randomized, Placebo-Controlled Trial of the Clinical Effects of Anacetrapib among People with Established Vascular Disease: Brigham and Women’s Hospital; total direct costs $150,000 (11/01/2011–02/28/2019)
- **Pi (PI):** LRP1 and Endothelial Function; NIH/NHLBI (R01); annual direct costs $250,000 (08/01/2013–05/31/2019)
- **Pi (PI):** Signaling in Endothelial Growth and Angiogenesis; NIH/NHLBI (R01); annual direct costs $250,000 (12/18/2013–12/31/2018)
- **Trial (coinvestigator):** Role of Blood-Borne Fibroblast Precursors in Ischemic Cardiomyopathy; NIH/NHLBI (R01); annual direct costs $250,000 (07/01/2007–11/30/2017)
- **Vijayan (PI):** Serine/Threonine Phosphatases and Platelet Physiology; NIH/NHLBI (R01); annual direct costs $250,000 (03/01/2013–02/28/2019)
- **Vijayan (multi-PI):** Microvascular Thrombosis in Systemic Inflammation; NIH/NIGMS (R01); annual direct costs $220,000 (09/25/2014–05/31/2019)
- **Vijayan (PI of subcontract to Baylor College of Medicine):** Aspirin-PC for Chemoprevention of Colorectal Cancer; NIH/NCI (R42); annual direct costs $86,000 (05/01/2017–04/30/2019)
- **Vijayan (PI):** PP2B Modulates RhoA Activation and Platelet Function by Targeting RhoGD; American Heart Association; annual direct costs $70,000 (07/01/2017–06/30/2019)
- **Virani (PI):** Comparative Effectiveness of Physicians versus Non-physicians for the Delivery of Outpatient Diabetes Care: Implications for Access to Care under the Affordable Care Act; American Diabetes Association; total direct costs: $486,957 (01/01/2014–12/31/2017)
- **Virani (PI):** Determining and Targeting Reasons for Low Statin Use to Improve Guideline-Concordant Statin Therapy in High-Risk Patients; VA Merit Award; total direct costs: $1,097,703 (07/01/2017–06/30/2021)
- **Wu (PI):** Monocyte Activation and the Role of CD11c in Obesity-Linked Metabolic Syndrome; NIH/NHLBI (R01); annual direct costs $241,769 (04/01/2015–03/31/2020)
- **Wu (PI):** ApoCIII, Triglyceride-Rich Lipoproteins and Atherogenesis; American Heart Association; total direct costs $140,000 (07/01/2016–06/30/2019)
- **Wu (PI):** Macrophage/Dendritic Cell Activation and Inflammation in Diet-Induced Obesity; American Diabetes Association; annual direct costs $104,546 (01/01/2017–12/31/2019)
Research Funding continued

- **Wu** (co-PI): Imaging Monocyte Tracking into Atherosclerosis and Adipose Tissue in Mice; BCM Cardiovascular Research Institute Pilot Award; total direct costs $15,000 (09/01/2017–06/30/2018)
- **Xie** (PI): Novel Roles of FE2+, 2-Oxoglutarate-Dependent Dioxygenases in Cardiac Function; NIH/NHLBI (R01); annual direct costs $250,000 (09/01/2015–08/31/2020)
- **Xie** (co-investigator): LRP1 and Endothelial Function; NIH/NHLBI (R01); annual direct costs $250,000 (08/01/2013–05/31/2019)
- **Xie** (co-investigator): Signaling in Endothelial Growth and Angiogenesis; NIH/NHLBI (R01); annual direct costs $250,000 (12/18/2013–12/31/2018)

**PUBLICATIONS & PRESS**

- Fretz A, Hoogeveen R, **Ballantyne C**, et al. Relation of lifestyle factors and Life's Simple 7 score to temporal reduction in troponin levels measured by a high-sensitivity assay (from the Atherosclerosis Risk in Communities Study). *Am J Cardiol* 2018;121:430–436
- **Trial J, Cieslik K.** Changes in cardiac resident fibroblast physiology and phenotype in aging. *Am Physiol Heart Circ Physiol* 2018 [Epub ahead of print]
- Puri R, **Ballantyne C**, Hoogeveen R, et al. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. *Atherosclerosis* 2017;263:137–144


• Vijayan K. Myosin IIa signal von Willebrand factor release. *Blood* 2018;131:592–593


• Saeed A, Ballantyne C. Bempedoic acid (ETC-1002): a current review. *Cardiol Clin* 2018;36:257–264

• Wang Q, Quick A, Li N, et al. Oxidized CaMKII (Ca2+/calmodulin-dependent protein kinase II) is essential for ventricular arrhythmia in a mouse model of Duchenne muscular dystrophy. *Circ Arrhythm Electrophysiol* 2018;11:e005682


• LeBlanc E, Pratley R, Foreyt J, et al. Baseline characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: a contemporary prediabetes cohort that will inform diabetes prevention efforts. *Diabetes Care* 2018 [Epub ahead of print]

• Vaughan E, Johnston C, Foreyt J, et al. Integrating CHWs as part of the team leading diabetes group visits: a randomized controlled feasibility study. *Diabetes Educ* 2017;43:589–599


Publications & Press continued

- Angeli A, Pi X, Xie L. Dioxygen and metabolism; dangerous liaisons in cardiac function and disease. *Front Physiol* 2017 Dec 12;8:1044
- Saeed A, Virani S. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein. *Front Biosci (Landmark Ed)* 2018;23:1099–1112
- Chelu M, Li N. Biomarkers (plasma trimethylamine-N-oxide) to predict atrial fibrillation: are we there yet? *Int J Cardiol* 2018 [Epub ahead of print]
- Nambi V, Bhatt D. Primary prevention of atherosclerosis: time to take a selfie? *J Am Coll Cardiol* 2017;70:2992–2994
- Navaneethan S, Virani S. Omega-3 fatty acids (fish oil) supplementation and albuminuria: not a slam dunk. *J Am Heart Assoc* 2017;6:e006020
Section of Cardiovascular Research

- Lam F, Da Q, Guillory B, Cruz M. The binding of recombinant vimentin to P-selectin blocks neutrophil capture and rolling on platelets and endothelium. *J Immunol* 2018;200:1718–1726
Publications & Press continued

- Li N, Dobrev D. Targeting atrial fibrillation promoting atrial structural remodeling: is this a viable strategy in patients with heart failure? *Naunyn Schmiedebergs Arch Pharmacol* 2018;391:231–233
- Faza N, Virani S, Nambi V, Shah T. Aberrant course of pacemaker leads: when left is left. *Tex Heart Inst J* 2018;45:52–53

**ADDITIONAL PUBLISHED ACCOMPLishments**

- **Brunner:** Reviewer, Biomedical Imaging Technology Study Section–A, Center for Scientific Review, NIH, Bethesda, MD
- **Brunner:** Reviewer and “Application Chair,” ZRG1 MOSS-D (82) A NIH study Section (Musculoskeletal, Oral, Skin, Rheumatology and Rehab Sciences [R15])
- **Brunner:** Invited Keynote Speaker, “Skeletal Calf Muscle Perfusion Measurement To Assess Peripheral Arterial Disease,” 10th European Symposium Of Vascular Biomaterials Strasbourg, France
- **Brunner:** Invited Guest Speaker, Special Seminar on Magnetic Resonance Imaging in Peripheral Artery Disease, Penn State Heart and Vascular Institute, Penn State Health Milton S. Hershey Medical Center, Hershey, PA
- **Brunner:** Invited Speaker, “Inflammation, Microvascular Perfusion, and Peripheral Arterial Disease,” George and Angelina Kostas Research Center for Cardiovascular Nanomedicine, Annual International Meeting, Houston, TX
- **Brunner:** Invited Presenter, “Inflammation, Microvascular Perfusion and Peripheral Arterial Disease,” American Heart Association Reverse Site Visit as one of the 9 finalists the Clinical Project of the Strategically Focused Vascular Disease Research Network (Center Director: John P. Cooke), Dallas, TX
- **Brunner:** Invited Presenter, “Advanced Physics, Fourier Transformation Parallel Imaging, and MRI Safety,” Houston Methodist Cardiovascular Magnetic Resonance Workshop, DeBakey Institute for Cardiovascular Education & Training, Houston Methodist Hospital, Houston, TX
- **Brunner:** Didactic Lectures, Cardiovascular sciences graduate course (GS-CS-411)— Cardiovascular Physiology, and Structural Basis of Human Diseases (GS-SB-423), BCM
- **Brunner:** Poster Judge, 3rd Annual VA Research Poster Session. Michael E. DeBakey VA Medical Center, Houston, TX
- **Cruz:** Invited lecture, “A Novel Target to Prevent Microvascular Thrombosis and Multiple Organ Dysfunction Syndrome in Sepsis,” Microbiology & Immunology, UTMB
- **Cruz:** Invited lecture, “Novel Targets to Prevent Microvascular Thrombosis in Sepsis,” CVRI seminar series, BCM
- **Li:** Ad hoc reviewer, 2018 NIH ESTA Study Section
- **Li:** Ad hoc reviewer, 2017 Farouk Jabre Research Proposal
- **Li:** Invited lecture, “The inflammasome in AF,” Heart Failure Association Winter Meeting on Translational Heart Failure Research 2018, Les Diablerets, Switzerland
- **Li:** Invited lecture, “Emerging role of the inflammasome as novel target in atrial fibrillation therapy,” American Heart Association Scientific Session 2017, Anaheim, CA
- **Li:** Invited lecture, “Role of Cardiac Inflammasome in the Pathogenesis of Atrial Fibrillation,” IMBS 2018 Research Conference and Retreat, BCM
- **Li:** Invited lecture, “Emerging Role of Cardiac Inflammasome in the Development of Atrial Fibrillation,” CVRI seminar series, BCM
- **Li:** Invited conference moderator, Ion Channels and Arrhythmias session, American Heart Association Basic Cardiovascular Sciences (BCVS) Council Scientific Sessions 2017, Portland, OR
- **Pi:** Invited lecture, “A secret life of the vascular endothelium,” Society of Chinese Bioscientists in America–Texas Chapter annual symposium
• **Pi:** Invited lecture, “The role of vascular endothelium in metabolic health,” Texas Heart Institute seminar series
• **Pi:** Course organizer, TBMM graduate program Bench to Bedside Series, Term 3: Current topics in translational cardiovascular medicine
• **Pi:** Seminar host, TBMM graduate program Bench to Bedside Series. “Ahoy CRISPR” presented by Dr. Joseph M. Miano, University of Rochester
• **Pi:** Poster judge, CVRI 2018 Symposium, BCM
• **Pi:** Grant proposal reviewer, CVRI Pilot Awards, BCM
• **Pi:** Reviewer of graduate student candidates, Molecular Physiology & Biophysics Graduate Program, BCM
• **Pi:** Member of Graduate student committee for Nirva Mumcuyan, Developmental Biology Program, BCM
• **Virani:** Invited speaker, Global Cardiovascular Disease Prevention webinars in Indonesia, Malaysia, Vietnam, and UAE
• **Wu:** Member, NIH/NIGMS SCORE Grant Review Panel
• **Wu:** Member, American Heart Association Grant Peer Review Committee, Lipids BSc Committee
• **Wu:** Member, Immunology Graduate Program Qualifying Exam Committee, BCM
• **Wu:** Member, Immunology Graduate Admission Committee, BCM
• **Wu:** English language interviewer, J1 visa candidates, BCM
• **Wu:** Poster judge, CVRI 2018 Symposium, BCM
• **Wu:** Didactic Lecture, Cardiovascular Disease and Pathology (GS-CS-412), BCM
• **Wu:** Judge, Young Investigator Award Oral Presentation, 2018 CAAC-MPVD-ATVB Symposium, San Francisco, CA

**EDITORIAL POSITIONS**

- **Ballantyne:** Editorial Director, lipidsonline.org
- **Ballantyne:** Editorial Board, *Circulation*
- **Ballantyne:** Editorial Board, *Clinical and Translational Science*
- **Ballantyne:** Editorial Board, *Current Cardiology Reviews*
- **Ballantyne:** Editorial Board, *Future Lipidology*
- **Cruz:** Editorial Board, *Thrombosis & Haemostasis: Research*
- **Foreyt:** Editorial Board, *American Journal of Health Behavior*
- **Foreyt:** Editorial Board, *American Journal of Health Promotion*
- **Foreyt:** Editorial Board, *American Journal of Lifestyle Medicine*
- **Foreyt:** Editorial Board, *Childhood Obesity*
- **Foreyt:** Editorial Board, *Nutrition Today*
- **Foreyt:** Editorial Board, *Obesity and Weight Management*
- **Foreyt:** Editorial Board, *Obesity Research and Clinical Practice*
- **Jones:** Associate Editor, *Journal of Clinical Lipidology*
- **Pi:** Guest Editor, *Oxidative Medicine and Cellular Longevity*
- **Pi:** Review Editor, *Arteriosclerosis, Thrombosis and Vascular Biology*
- **Pi:** Review Editor, *Frontiers*
- **Pi:** Review Editor, *Journal of Molecular and Cellular Cardiology*
- **Pi:** Review Editor, *Nature Communications*
- **Virani:** Associate Editor, Innovations, ACC.org
- **Virani:** Editorial Team Member and Chair for Digital Strategy, Cardiovascular Prevention Section, ACC.org (educational web portal for the American College of Cardiology)
- **Virani:** Advisory Board, *Advances in Therapy*
- **Virani:** Guest Editor, *Circulation*
- **Virani:** Editorial Board, *Circulation*
- **Virani:** Section Editor, “Coronary Heart Disease,” *Current Atherosclerosis Reports*
- **Virani:** Associate Editor, *Journal of Clinical Lipidology* (Section specialty: Cardiovascular Outcomes and Guidelines)
- **Virani:** Associate Editor, *Global Heart* (Official Journal of the World Heart Federation)
- **Wu:** Guest Associate Editor, *Frontiers in Immunology* (T cell biology in adipose tissue)
- **Wu:** Editorial Board, *Archives of Inflammation*
- **Wu:** Editorial Board, *International Journal of Hematology Research*
- **Wu:** Editorial Board, *Journal of Pediatric Endocrinology*
- **Wu:** Editorial Board, *SM Journal of Endocrinology and Metabolism*
- **Wu:** Editorial Board, *SM Journal of Endocrinology and Metabolism*
Section of
Endocrinology, Diabetes and Metabolism

OUR FACULTY
Neeti Agarwal
Mandeep Bajaj
Ashok Balasubramanyam
Jasmine Boparai
Rui Chen
Nancy Greta Renee Dufrane
Ruchi Gaba
Alan J Garber
Nguyen Ha
Sean Hartig
Bryan Jiang
Marco Marcelli
Siripoom McKay
Sanjay Mediwala
Munira Mehta
Massimo Pietropaolo
Nalini Ram
Susan Leanne Samson
Rajagopal Viswanath Sekhar
Zheng Sun
Madhuri Vasudevan
Dennis Villareal
Reina Villareal
Li Zhang

Together with the entire faculty of the Endocrinology, Diabetes & Metabolism Section, I would like to welcome everybody to our 2018 Annual Report. 2018 has been an eventful year for us, with new unique contributions in research, scholarship, clinical care and education. The section has published more than 50 papers, many of them in top journals, and has been the recipient of an unprecedented six NIH R01 grants. We have been active in national and international meetings and organizations and offer daily medical care to the Houston community at the Baylor St. Luke's Medical Center, the Michael E. DeBakey VA Medical Center, Ben Taub General Hospital, Smith Clinic and the St. Thomas Street Clinic. Our trans-institutional fellowship program with MD Anderson Cancer Center and Texas Children Hospital graduates five outstanding new endocrine fellows every year. As we are about to enter the third decade of the XXI century, our faculty is 100% committed to advance the science and clinical practice of endocrinology, diabetes & metabolism to the next level. Please enjoy and thank you for your interest.

Marco Marcelli M.D.
Interim chief
Section of Endocrinology, Diabetes & Metabolism
AWARDS & HONORS

- **Bajaj:** Prof. Sevim Büyükdervim Lecture, Turkish Diabetes Association 54th National Diabetes Congress, Antalya, Turkey
- **Bajaj:** The Best Doctors in America, Best Doctors 2017-18
- **Bajaj:** Top Doctors, Houstonia Magazine 2017
- **Garber:** Albert Nelson Marquis Lifetime Achievement Award
- **Garber:** Master of the American College of Endocrinology
- **Garber:** Who's Who in the World
- **Hartig:** Baylor College of Medicine Nominee, ADA Pathway to Stop Diabetes Award
- **Marcelli:** Best Doctors in America
- **Ram:** Norton Rose Award in Teaching and Evaluation Spring 2018
- **Ram:** Houston’s Top Physicians 2017 Castle Connolly
- **Sekhar:** Second Place, Baylor Medicine Research Symposium, April 2018. Optimal glycemic control may not be enough to prevent risk of diabetic complications – novel role of glutathione and oxidative stress
- **Sekhar:** Second Place, Baylor Medicine Research Symposium, April 2018. Reversing accelerated aging in HIV patients - metabolic and mitochondrial mechanisms
- **Sekhar:** Star Award For Excellence in Patient Care, Baylor College of Medicine, 2017
- **R. Villareal:** Research Award: “Certificate of Excellence,” Director’s Townhall Meeting, November 1, 2017, MEDVAMC
- **Wang:** AACR Workshop on Integrative Molecular Epidemiology, Boston, MA

PROFESSIONAL ORGANIZATIONS

- **Garber A:** American Association of Clinical Endocrinologists
- **Garber A:** American College of Endocrinology
- **Garber A:** American Diabetes Association
- **Garber A:** American Medical Association
- **Garber A:** National Lipid Association
- **Garber A:** The Endocrine Society
- **Garber A:** AACE/ACE Committees/Task Forces
  - Board of Directors
  - Advisor to the President
  - Lipids Scientific Committee
  - Obesity Scientific Committee
  - Obesity Resource Center
  - Chair, AACE/ACE Task Force to Update the Comprehensive Diabetes Management Algorithm
  - Finance Committee
  - Diabetes Scientific Committee
  - Task Force on Consensus Conference on the Endocrinology of Aging
  - Task Force to Develop AACE’s Position on the Integration of Insulin Pumps and Continuous Glucose Monitoring
  - Task Force to Update the Insulin Pump Management Consensus Statement
  - ACE Center for Transcultural Endocrinology Steering Committee
  - Nominating Committee
  - Task Force to Develop the AACE/ACE Lipids Algorithm
  - Chair, AACE Journals Task Force
• Hartig S: Faculty, The Endocrine Society Career Development Workshop
• Hartig S: Abstract reviewer, The Endocrine Society’s 100th Annual Meeting, Chicago, IL
• Hartig S: Ad-hoc member, NIH CSR Cellular Aspects of Diabetes and Obesity Study Section (CADO)

• Marcelli M: Abstract reviewer, The Endocrine Society’s 100th Annual Meeting, Chicago, IL
• Marcelli M: The Endocrine Society
• Marcelli M: Elected member Southern Society of Medical Investigation

• Pietropaolo M: Reviewer, Special Emphasis Panel (SEP) Study Section [ZRG1-EMNR-B (50) M]. PAR-16-121: “Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01)” 3/2017.
• Pietropaolo M: Reviewer for R01 and R21 grants. Kidney, Nutrition, Obesity and Diabetes Study Section (KNOD, NIDDK); 05/2018
• Pietropaolo M: Chair, Immunology, Immunogenetics, & Transplantation Planning Committee for the 2018 National Conference of the American Diabetes Association, Orlando, FL
• Samson S: Elected Member, Board of Directors of the American Association of Clinical Endocrinologists
• Samson S: Member, Board of Trustees, American College of Endocrinology
• Samson S: Elected member, Council of the American Program Directors of Endocrinology and Metabolism (APDEM)
• Samson S: Member, American Board of Internal Medicine, Self-assessment committee
• Samson S: Member, American Board of Internal Medicine, Item-writing Task Force
• Samson S: Chair, American Association of Clinical Endocrinologists National Congress Annual Program Committee Annual Congress, American Association of Clinical Endocrinologists
• Samson S: Vice-Chair, Endocrine University Planning Committee of the American College of Endocrinology
• Samson S: Member, Expert Group on Pituitary Tumors, The Pituitary Society
• Samson S: Member, Committee for Professional Education, The Pituitary Society

• Villareal R: American College of Physicians
• Villareal D: National Institute on Aging Clinical Trials Advisory Panel (CTAP)
• Villareal D: Task Force on Sarcopenia and Frailty, International Conference on Sarcopenia and Frailty, Miami, FL
• Villareal D: Data and Safety Monitoring Board for the following NIH grant projects
  • “Maintenance of Skeletal Integrity in Frail Elders” (RO1-AG050302)
  • “Skeletal Muscle and Insulin Resistance in Aging (RO1-AG021961)”
  • Chairperson of the DSMB
  • “Combining Testosterone Therapy to Improve Function Post Hip Fracture” (RO1 AG051647)
• Villareal R: “Empowered with Movement to Prevent Obesity & Weight Regain” (RO1AG051624)

RESEARCH FUNDING

GRANTS AND CONTRACTS AWARDED
• Balasubramanyam (PI): Year 4: adipose tissue is a significant reservoir for HIV. R33-AI116208-03 Amd 3. NIH. 9/1/2017 -8/31/2018. Total awarded $111,012.00
• Balasubramanyam (PI): (Mpi) year 3: role of islet injury and autoimmunity in t2d beta cell dysfunction. R01-DK104832- 03. NIH. 9/1/2017-8/31/2018. Total grant $353,493.00
• Garber (PI): 16th annual symposium on advanced metabolic disease management for endocrine fellows. 023350 NCE. Novo Nordisk, Inc. 6/1/2018-6/30/2018. Total grant $0.00
• Garber (PI): 17th annual symposium on advanced diabetes management for endocrine fellows. MED-DIA-24942. Novo Nordisk, Inc. 6/21/2018-6/20/2019. Total grant $345,000.00
• Marcelli (PI): Endocrine grand rounds. IME-USA-17539. Shire Human Genetic Therapies, Inc. 10/4/2017-10/3/2018. Total grant $3,750.00
• Marcelli (PI): Persistent hormonal changes in veterans with gulf war illness. W81XWH-17-1-0368 (Jorge R., PI). Department of Defense. 9/2017-9/2020. Total grant $615,171.00
• Pietropaolo (PI): Year 3/4: perl - a multicenter clinical trial of allopurinol to prevent gfr loss in t1d. UC4-DK101108-01 Amd 4. Center for Medicare & Medicaid Innovation (DHHS). 8/1/2017-9/30/2017. Total grant $5,939.00

• Pietropaolo (PI): Perl-yr1(spino): a multicenter clinical trial of allopurinol to prevent gfr loss in tld. UC4-DK101108 02. NIH. 9/1/2017-8/31/2018. Total grant $30,669.00

• Samson (PI): The effect of pasireotide and combination with a glucagon-like peptide 1 receptor agonist on islet function and structure. NCE. Novartis Pharmaceuticals Corp. 12/30/2017-6/1/2020. Total grant $0.00

• Sekhar (PI): Age-related mild cognitive impairment and the protective role of glutathione: implications for Alzheimer’s disease. R01-AG054131 02. NIH. 6/1/2018-5/31/2019. $477,413.00

• Sun (PI): Obesity-epigenome interaction in heart failure. 16GRNT30970064 Yr2. American Heart Association, Inc. 7/1/2017-6/30/2018. Total grant $77,000.00


• Sun (PI): De facto target of histone deacetylase inhibitors. R21-CA215591-01. NIH. 9/1/2017-8/31/2018. Total grant $172,369.00


• Villareal, Dennis T. (PI): Testosterone replacement to augment lifestyle therapy in obese older veterans. 1101 CX000906-01. VA Merit Review. 01/1/15-12/31/18. Total grant $483,794.00

• Villareal, Reina (PI): Aromatase inhibitors and weight loss in severely obese men with hypogonadism. R01-HD093047-01. NIH. 8/7/2017-5/31/2018. Total grant $387,081.00


CASH AWARDS

• Bajaj (PI): Excel (exenatide study of cardiovascular event lowering trial)- a randomized, placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. Amylin Pharmaceuticals. 2018. $3,692.31

• Bajaj (PI): The effect of dapagliflozin on inflammation and endothelial dysfunction. AstraZeneca. 2018. $32,461.54

• Samson (PI): Amendment: a phase 3, randomized, open-label, active controlled, multicenter study to evaluate maintenance of response, safety and patient reported outcomes in acromegaly patients treated with octreotide capsules, and in patients treated with standard of care parenteral somatostatin receptor ligands who previously tolerated and demonstrated a biochemical control on both treatments. Chiasma, Inc. 2018. $12,277.78

• Samson (PI): A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate safety and efficacy of octreotide capsules in patients who previously tolerated and demonstrated biochemical control on injectable somatostatin receptor ligands (srl) treatment protocol ooc-acm-303. Chiasma, Inc. 2018. $8,500.00


• Bajaj (PI): Effect of liraglutide treatment on gut microbiota and adipose tissue inflammation in patients with type 2 diabetes mellitus. Novo Nordisk Pharmaceuticals. 2018. $1,230.77

• Samson (PI): A phase 3, multicenter study designed to evaluate the efficacy and safety of a long acting hgh product (mod-4023) in adult subjects with growth hormone deficiency (protocol number: cp-4-005). Prolor Biotech, Ltd. 2018. $4,827.09

Total Research Funding Received $5,105,170.90

PUBLICATIONS & PRESS


• Bai S, Fu K, Sun Z, et al. Sox30 initiates transcription of haploid genes during late meiosis and spermiogenesis in mouse testes. Development 2018;145


• Birnbaum Y, Bajaj M, Yang H, Ye Y. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Diabetes Cardiovasc Drugs Ther 2018;32:135

Section of Endocrinology, Diabetes and Metabolism
• Birnbaum Y, Ye Y, Bajaj M. Type 2 Diabetes and CVD: A Metabolic Overview of Recent Clinical Trials. J Diabetes Complications 2017;31:291


• Chen E, Tsai TH, Saha P, et al. PLIN2 is a Key Regulator of the Unfolded Protein Response and Endoplasmic Reticulum Stress Resolution in Pancreatic β Cells. Scientific Reports. 2017;7:40855

• Chen Y, Chen H, Bajaj M, et al. Aleglitazar, a dual PPARα and PPARγ agonist, protects cardiomyocytes against the adverse effects of hyperglycemia. Diab Vasc Dis Res 2017;14:152


• Colleluori G, Napoli N, Villareal D. Effect of weight loss, exercise, or both on undercarboxylated osteocalcin and insulin secretion in frail, obese older adults. Oxid Med Cell Longev 2017;4807046


• Garcia J, Biller B, Marcelli M, et al. Validation of Macimorelin as a Diagnostic Test for Adult Growth Hormone Deficiency (AGHD): A Phase 3 Study in Comparison with the Insulin Tolerance Test (ITT). J Clin Endocrinol Metab 2018;103:3083


• James E, Pietropaolo M, Mamula M. Immune recognition of β-Cells: Neoepitopes as key players in the loss of tolerance. Diabetes. 2018;67:1035


• Jia X, Alam M, Ye Y, Bajaj M, Birnbaum Y. GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. Cardiovasc Drugs Ther 2018;32:65


• Mitre T, Pietropaolo M, Khadra A. The dual role of autoimmune regulator in maintaining normal expression level of tissue-restricted autoantigen in the thymus: A modeling investigation. *Math Biosci* 2017;287:12


• Szafran T, Marcelli M, Mancini M. High content screening of a library of 145 FDA approved drugs for the identification of novel inhibitors of AR and AR variant-7. The *Prostate* 2017;77:82


• Wei Q, Lee JH, Bajaj M, et al. Adiponectin is required for maintaining normal body temperature in a cold environment. *BMC Physiol* 2017;17:8


**EDITORIAL POSITIONS**

• Bajaj: Editorial Board, The Journal of Clinical Endocrinology and Metabolism

• Bajaj: Associate Editor, British Medical Journal Open Diabetes Research and Care

• Garber: Editor, Endocrine Today

• Garber: Editor (Emeritus), Diabetes, Obesity and Metabolism

• Marcelli: Associate Editor: Journal of Investigative Medicine

• Pietropaolo: Associate Editor, Diabetes

• Pietropaolo: Associate Editor, *PLoS ONE*

• Pietropaolo: Editorial Board, American Journal of Clinical and Experimental Immunology

• Pietropaolo: Editorial Board, Autoimmunity Highlights

• Sun: Editor, Research Topic: Type 2 Diabetes Management: A Focus on Metabolic Defects. Frontiers in Physiology. 2018

• Villareal R: Associate Editor, Frontiers in Endocrinology

• Villareal D: Associate Editor, Journal of Nutrition in Geriatrics and Gerontology

• Villareal D: Academic Editor, Current Developments in Nutrition

• Villareal D: Associate Editor, Journal of Gerontology – Medical Science

• Villareal D: Section Editor: Obesity and Aging, Journal of Nutrition in Health and Aging
AWARDS & HONORS

• **Amos:** Selzman Endowed Chair of Medicine, Baylor College of Medicine
• **Amos:** Keynote Speaker, First US-Sino International Conference on Lung Cancer
• **Amos:** International Speaker, Integrative Analysis of Lung Cancer Risk and Etiology, Zhengzhou and Henan Hospital, China
• **Bondy:** Visiting Scholar Award, National Cancer Institute
• **Dong:** AACR Workshop on Integrative Molecular Epidemiology, Boston, MA
• **Ostrom:** AACR Workshop on Integrative Molecular Epidemiology, Boston, MA
• **Ostrom:** Doctoral Excellence Award in Epidemiology and Biostatistics, Case Western Reserve University School of Medicine
• **Ostrom:** Junior Investigator Travel Award, Brain Tumor Epidemiology Consortium
• **Schraw:** 2nd Place Oral Abstract Presentation, Texas Children's Cancer and Hematology Centers Annual Symposium
• **Schraw:** Junior Investigator Award, Brain Tumor Epidemiology Consortium
• **Schraw:** Selected Participant, American Society of Preventative Oncology New Investigator Workshop
• **Wang:** AACR Workshop on Integrative Molecular Epidemiology, Boston, MA

OUR FACULTY

**Epidemiology & Population Science**
Melissa Bondy
Yanhong Li
Margaret Spitz
Aaron Thrift

**Institute for Clinical and Translational Research**
Chris Amos
Younghun Han
Yafang Li

**Postdoctoral Fellows**
Jeremy Schraw
Jing Dong
Zhensheng Wang
Quinn Ostrom

Section of Epidemiology and Population Sciences
PROFESSIONAL ORGANIZATIONS

- Bondy: AACR, MEG Steering Committee, Chairperson
- Bondy: American College of Epidemiology, Board of Directors
- Bondy: American Society of Prevention Oncology (ASPO) Program Committee
- Bondy: Central Brain Tumor Registry of the United States, Board Member
- Bondy: Duke Cancer Institute External Scientific Advisory Committee
- Bondy: Kimmel Cancer Center External Scientific Advisory Committee
- Bondy: Masonic Cancer Center External Advisory Board
- Bondy: NCI Board of Scientific Advisors, Subcommittee on Global Cancer Research
- Bondy: OSUCCC IRP Population Science Review Committee
- Bondy: Perlmutter Cancer Center External Advisory Board
- Bondy: St. Jude Children's Hospital, Memphis, TN, External Advisor
- Bondy: Susan G. Komen for the Cure, Scientific Advisory Board, Houston Medical Advisory Council, & Strategic Mission Committee
- Bondy: University of Minnesota Cancer Center, External Scientific Advisory Board,
- Bondy: University of Washington EDGE Center Scientific Advisory Board
- Liu: American Society of Human Genetics 2017 Essay Contest, Program Reviewer
- Ostrom: North American Association of Central Cancer Registries, Data Assessment Working Group
- Spitz: MD Anderson Cancer Center, Prostate Cancer SPORE, External Advisory Committee
- Spitz: National Cancer Advisory Board, Subcommittee on Population Science, Epidemiology, and Disparities
- Spitz: Northwestern University, T32 for Behavioral and Psychosocial Research Training in Cancer Prevention and Control, External Advisory Board
- Spitz: Tisch Cancer Center, Mount Sinai Medical Center, External Advisory Committee
- Spitz: University of Chicago Comprehensive Cancer Center, External Advisory Committee
- Spitz: University of Kentucky Markey Cancer Center, External Advisory Committee
- Spitz: Yale Cancer Center, Lung Cancer SPORE, External Advisory Board
- Thrift: Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), Steering Committee
RESEARCH FUNDING

- **Amos (PI):** Data Coordinating and Management Group for Molecular Characterization of Screen Detected Lesions Network, Supplement 1 Molecular Studies and Single Cell Sequencing; NIH/NCI; $432,000 annually (9/1/2018 - 8/31/2020)
- **Amos (PI):** Data Coordinating and Management Group for Molecular Characterization of Screen Detected Lesions Network; NIH/NCI; $300,000 annually (9/1/2015 - 8/31/2020)
- **Amos (PI):** Genome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC); NIH/NCI; $473,538 annually (04/01/2015 - 06/30/2019)
- **Amos (PI):** Integrative Analysis of Lung Cancer Etiology and Risk; NCI; $473,538 annually (9/1/17 - 5/30/22)
- **Amos (Subcontract PI):** Genetic Susceptibility and Risk Model for Pancreatic Cancer; NIH/NCI; $13,193 annually (7/1/14 - 6/30/18)
- **Bondy (Cointvestigator):** Baylor College of Medicine Cancer Center; NIH/NCI; $2,020,895 annually (07/01/2007 - 06/30/2020)
- **Bondy (Cointvestigator):** Center for Translational Environmental Health Research; NIH/NIEHS; $84,000 (04/01/2013 - 12/31/2018)
- **Bondy (Cointvestigator):** Toxicity Profiling: Creating Novel Paradigms to Personalize Cancer Treatment; 06/07/13 - 03/31/18
- **Bondy (PI):** Breast Cancer Risk Assessment Using Copy Number Variation; Susan G. Komen Foundation; $160,000 annually (09/01/2011 - 08/31/2017)
- **Bondy (PI):** Risk Prediction for ER Negative Breast Cancer Recurrence; NIH/NCI; $2,977,314 (01/01/2013 - 12/31/2017)
- **Liu (PI):** Lung Cancer Prediction Models Incorporating Exome Data from Extreme Phenotypes; NIH/NCI; (08/2014 - 08/2019)
- **Spitz (Cointvestigator):** Incorporating Biomarkers to Improve Lung Cancer Risk Prediction; NIH; $21,647 (12/01/2015 - 11/30/2018)
- **Spitz (Cointvestigator):** Integrative Molecular Epidemiology Workshop; AACR; $249,213 annually (09/01/2013 - 08/31/2018)
- **Spitz (PI):** Cancer Prevention Post-Graduate Training Program in Integrative Epidemiology; Cancer Prevention and Research Institute of Texas; $300,401 (03/01/2016 - 02/28/2021)
- **Thrift (Cointvestigator):** DCC HHS Smoking Cessation Treatment Program; NCI P30 Cancer Center Administrative Supplement for Tobacco Use Treatment in Cancer Patients; total direct costs $315,457 (07/01/2017 - 06/30/2019)
- **Thrift (Cointvestigator):** Prevalence and predictors of nonalcoholic fatty liver disease (NAFLD) in Veterans; VA CSR&D Research Awards; total direct costs $600,000 (10/01/2017 - 09/30/2021)
- **Thrift (PI):** Admixture mapping of cirrhosis and Hepatocellular carcinoma in African Americans; Dan L. Duncan Comprehensive Cancer Center Pilot Grant; total direct costs $50,000 (06/01/2018 - 05/30/2019)
- **Thrift (PI):** PREVENT HCC – through Screening, Vaccination and Treatment of Viral Hepatitis; Cancer Prevention and Research Institute of Texas (CPRIT) Prevention Program; total direct costs $1,492,052 (08/31/2016 - 08/30/2019)
- **Thrift (PI):** Risk and Predictors of Esophageal and Esophagogastroduodenal Adenocarcinomas in HIV-infected Individuals; NAID/NIH/DHHS; total direct costs $299,992 (06/01/2016 - 05/31/2018)

PUBLICATIONS & PRESS


• Frost HR, Amos CI. Gene set selection via LASSO penalized regression (SLPR). Nucleic Acids Res. 2017 Jul 7;45(12):e114


Publication & Press continued


Publication & Press continued


A Includes Quinn Ostrom, MPH, PhD
B, C Includes Chris Amos, PhD

BOOKS AND BOOK CHAPTERS

- Ostrom QT, Barnholtz-Sloan J. Biospecimen Repositories in the Precision Medicine Era: Perspectives from a Biobanker in the “Trenches.” Specimen Science: Ethics and Policy Implications
- Thrift AP. Epidemiology of Esophageal Adenocarcinoma in RB Cameron, O Olevsky, D
PRESS


• Bondy: CW39 Houston. Wristbands at Baylor College of Medicine helps to study Harvey.


• Bondy: News Week. Are Hurricane Harvey floodwaters making people sick? These wristbands could tell. https://www.newsweek.com/after-hurricane-harvey-these-wristbands-could-tell-houston-residents-if-theyve-673962


• Ostrom: ScienceDaily. Men and women have different genetic risk factors for developing brain cancer. https://www.sciencedaily.com/releases/2018/06/180628151931.htm


• Wang: AARC. Short-acting calcium channel blockers were associated with increased risk of pancreatic cancer in postmenopausal women. https://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=1185#.W23E6VVKUk

• Wang: Healio. Calcium channel blockers may increase risk for pancreatic cancer. https://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/online/%7Befa4c934-a723-4d9f-9a79-52bad6e74c56%7D/calcium-channel-blockers-may-increase-risk-for-pancreatic-cancer


The Section of Gastroenterology and Hepatology had a very successful year. Section members had over $10 million in research funding in 2018. The Section serves as the clinical home for the NIH funded Digestive Disease Center, one of 17 federally funded centers focusing on research in GI diseases.

Our top-notch faculty received many accolades at the local and national levels. We represent BCM in all major professional societies; our faculty holds several leadership positions within the American Gastroenterological Association, American Association for the Study of Liver Diseases, American Society of Gastroenterological Association, and the Crohn's and Colitis Foundation. The Section also serves as the home for the journal *Clinical Gastroenterology and Hepatology,* one of the major clinical journals in the field.

We continue to provide high quality, compassionate healthcare at Baylor St. Luke's Medical Center (BSLMC), Ben Taub General Hospital, and Michael E. DeBakey Veterans Affairs Medical Center. BSLMC ranked nationally for gastroenterology service this year. In 2018, we introduced several innovations in our practices, including cutting edge advanced endoscopic procedures, multidisciplinary treatment of complex GI disorders, and population-based management programs. Our faculty continues to play an important role in advancing our understanding of digestive and liver diseases and training future clinicians and researchers.

This annual report outlines some of the achievements and recognition received during 2018.

Fasiha Kanwal, MD, MSHS, AGAF Professor of Medicine  
Chief, Gastroenterology and Hepatology  
Baylor College of Medicine, Houston TX  
Houston Veterans Affairs HSR&D  
Center of Excellence Michael E. DeBakey VA Medical Center
AWARDS & HONORS

• Agarwal, Arevalo Santana, Chan, Hou, Othman, Patel: Top Gastroenterologist in the City of Houston

• Agarwal: Associate Program Director for Baylor St. Luke’s Medical Center Anandasabapathy: Texas Executive Women’s 2017 Class of Women on the Move Anandasabapathy: Houston Top Doctors and Texas Top Doctors

• Bradford: Clinical Supervisor between the Section of Gastroenterology and Hepatology and the Department of Psychiatry

• Cole: Woman of Excellence at Baylor College of Medicine

• Estes: Two Prestigious American Gastroenterological Association Recognitions: William Beaumont Prize in Gastroenterology and Distinguished Mentor Award

• Husain: Facilitator for the Critical Thinking and Problem Solving Course within the first year curriculum for medical students

• Othman: Star Faculty Award for Excellence in Patient Care


• Shukla: Ben Taub Internal Medicine Core Clerkship Site Director

• Vierling: Elected to Fellowship in the American Gastroenterological Association

• Vierling: Dr. Charles S. Lieber Lecture at DDW 2018. “Mechanisms of Autoimmune-Associated Liver Injury – How Are PBC, PSC and Autoimmune Hepatitis Alike and Different?”
Our faculty continues to play an important role in advancing our understanding of digestive and liver diseases and training future clinicians and researchers.
EL-SERAG
• The Texas Hepatocellular Carcinoma Consortium (THCCC). Cancer Prevention & Research Institute of Texas (CPRIT). RP150587. 6/1/2018-5/31/2019
• Effect of Aspirin on Biomarkers of Barrett’s Esophagus after Successful Eradication of Barrett’s Esophagus with Radiofrequency Ablation. National Cancer Institute (NCI); HHSN-26120120003414929. 6/15/2016-6/14/2019
• Center of Gastrointestinal Infection and Injury. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); P30-DK056338. 3/1/2018-2/28/2019
• Extrahepatic manifestations of hepatitis C. Merck, Sharp & Dhome, Corp. 09/01/2016-12/31/2018

FINNELL
• Folate Pathway Neural Tube Defects. March of Dimes; 6-FY16-169. 6/1/2018-5/31/2019
• Intervention Strategies for Non-Folate Responsive Neural Tube Defects. National Institute of Child Health and Human Development (NICHD); R01-HD083809. 2/1/2019-8/1/31/2019
• Folic Acid, Parental Mutation Rates and the Risk for Neural Tube Defects. National Institute of Child Health and Human Development (NICHD); R01-HD081216. 7/1/2018-6/30/2019

HOU
• Patient-Centered Comparative Effectiveness of Colorectal Cancer Surveillance in IBD. AHCPR- Agency for Healthcare Research and Quality (AHRQ); K08-HS024122. 8/1/2018-7/31/2019
• Advanced IBD Fellowship; Baylor College of Medicine. Pfizer, Inc; Pfizer Fellowship. 7/1/2018-6/30/2019
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 For Indication and Maintenance Therapy in subjects with Moderately to Severely Active Ulcerative Colitis. Abbvie Inc. 2019
• A Multi Center Open-Label Extension Study to Assess the Safety and Tolerability of LYC-30937-EC in Subjects with Active Ulcerative Colitis. Lycera Corp. 2019

KANWAL
• A Personalized Surveillance program for Hepatocellular Carcinoma. American Cancer Society; RSG-17-022-01-CPPB. 7/1/2018-6/30/2019
• Cirrhosis Quality Collaborative. American Association for the Study of Liver Disease. 9/1/2018-8/31/2021
• Patient Centered Care for Individuals with Advanced Liver Disease. HSR&D IIR 16-075; I01 HX-002204-01. 4/01/18-3/31/2021
• Effectiveness of Zepatier™ (elbasvir (EBR)/grazoprevir (GZR)) co-administered with Ribavirin (RBV) treatment for 16 weeks duration in chronic hepatitis C virus (HCV) genotype 1a (GT1a)-infected patients with selected baseline NSSA resistance associated substitutions: A retrospective observational analysis of the US Veterans Health Administration (VHA) National Data. Merck, Sharp & Dhome, Corp. 01/01/2018-08/31/2018
• Real-world effectiveness and impact of elbasvir/grazoprevir on outcomes among HCV-infected patients. Merck, Sharp & Dhome, Corp. 09/01/2016-12/31/2018

KAUR
• A Phase 2B, Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn’s Disease. Janssen Research & Development, LLC. 2019
• A Phase 4 Open-Label Study to Evaluate Vendolizumab IV Dose Optimization on Treatment Outcomes in Nonresponders with Moderately to Severely Active Ulcerative Colitis (Enterpret). Takeda Global Research & Development Center, Inc. 2019

LO
• Transcription Factors in Intestinal Differentiation and Cancer. National Cancer Institute (NCI); F99-CA212443. 9/21/2016-8/31/2018

MITTAL
• Prevent HCC – By Screening, Vaccination and Treatment of Viral Hepatitis. Cancer Prevention & Research Institute of Texas (CPRIT); PP160089. 8/31/2017-8/30/2018

OPEKUN
• QA Purity, Activity and Ancillary Testing of Commercially Available Gras-Listed Enzymes (Does Not Include Human or Animal Studies). Association in Transformational Oncology Management (ATOM); Testing Agreement. 3/1/2016-3/11/2019
Research Funding continued

**OTHMAN**

- Population Screening for Familial Chylomicronemia Syndrome ("FCS"). Akcea Therapeutics, Inc. 3/13/2018-3/12/2019
- Phase IIa Trial Evaluating the Safety of Intratumoral Injection of Nanopac in Subjects with Locally Advanced Pancreatic Adenocarcinoma. US Biotest, Inc. 2019

**SHROYER**

- MPI-Investigation of Regional Identity in Human Intestinal Stem Cells—Subcontract. National Institutes of Health (NIH); U01-DK103117. 9/1/2017-8/31/2018
- Nutrigenomics of Intestinal Vitamin D Action. National Institutes of Health (NIH); R01-DK112365. 4/1/2018-3/31/2019

**THRIFT**

- Prevent HCC – By Screening Vaccination and Treatment of Viral Hepatitis. Cancer Prevention & Research Institute of Texas (CPRIT); PP160089. 8/31/2017-8/30/2018

**VIERLING**

- A Follow-Up Study To Assess Resistance And Durability Of Response To Abbvie Direct-Acting Antiviral Agent (DAA) Therapy In Subjects Who Participated In Phase 2 Or 3 Clinical Studies For The Treatment Of Chronic Hepatitis C Virus (HCV) Infection. Abbvie M13-102. 7/2013 – 12/2016
- A Phase II, Randomized, Open-Label Clinical Trial To Study The Efficacy And Safety Of The Combination Regimen Of MK-5172 And MK-3682 With Either MK-8742 Or MK-8408 In Subjects With Chronic HCV GT1 And GT2 Infection. Merck 3682-011. 8/2015 – 01/2017
- A Phase 3, Double Blind, Placebo Controlled Trial And Long Term Safety Extension Of Obeticholic Acid In Patients With Primary Biliary Cirrhosis. Intercept 747-301. 1/2012 – OPEN
- A Long-Term Follow-Up Study Of Subjects Who Participated In A Clinical Trial In Which BMS- 650032 And/or BMS-790052 Was Administered For The Treatment Of Chronic Hepatitis C. BMS AI444-046. 2/2012 – OPEN
- A Long-Term Follow-Up Study To Evaluate The Durability Of Virologic Response And/or Viral Resistance Patterns Of Subjects With Chronic Hepatitis C Who Have Been Previously Treated With MK-5172 In A Prior Clinical Trial. Merck MK5172-017. 1/2013 – OPEN
- Multicenter, Randomized Phase 2B Study To Evaluate The Efficacy, Safety And Tolerability Of OCR- 002 (Ornithine Phenylacetate) In Hospitalized Patients With Cirrhosis And Associated Hyperammonemia With An Episode Of Hepatic Encephalopathy (STOP-HE). Ocera Therapeutics OCR002-HE209. 10/2013 – 2/2017
- A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure. EISAI E5501- G000-310. 4/2014 – 3/2017
- An Open-Label Study To Evaluate the Safety and Efficacy of Ombitasvir/AB450/Ritonavir and Dasabuvir with or without Ribavirin (RBV) in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, with Severe Renal Impairment or End-Stage Renal Disease (RUBY-II). AbbVie M14-226. 9/2014 – 1/2017
- A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis. Intercept 747-302. 12/2014 – OPEN
- A Randomized, Open-Label, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection (SURVEYOR-II). AbbVie M14-868. 1/2015 – 3/2017
• Clinical Study Of The Breathid® System To Train The Algorithm For The ¹³C-Octanoate Breath Test With Or Without The ¹³C-Methacetin Breath Test (OBT And MBT Respectively) For Correlation With Histological Findings Of Non-Alcoholic Fatty Liver Disease (NAFLD). Exalenz NASH-EX-1114. 5/2015 – 8/2017

• A Phase II, Randomized, Open-Label Clinical Trial To Study The Efficacy And Safety Of The Combination Regimen Of MK-5172 And MK-3682 With Either MK-8742 Or MK-8408 In Subjects With Chronic HCV GT3 Infection. Merck 3682-012. 7/2015 – 1/2017

• A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Clinical Trial To Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients with NASH Cirrhosis. The NASH-CX Trial. GALECTIN GT-026. 9/2015 – OPEN

• A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults with Non-alcoholic Steatohepatitis. BMS MB130045. 9/2015 – 1/2018

• A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection (SURVEYOR-II). AbbVie M14-868. 1-2015 – 3/2017

• Clinical Study Of The Breathid® System To Train The Algorithm For The ¹³C-Octanoate Breath Test With Or Without The ¹³C-Methacetin Breath Test (OBT And MBT Respectively) For Correlation With Histological Findings Of Non-Alcoholic Fatty Liver Disease (NAFLD). Exalenz NASH-EX-1114. 5/2015 – 8/2017

• A Phase II, Randomized, Open-Label Clinical Trial To Study The Efficacy And Safety Of The Combination Regimen Of MK-5172 And MK-3682 With Either MK-8742 Or MK-8408 In Subjects With Chronic HCV GT3 Infection. Merck 3682-012. 7/2015 – 1/2017

• A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients with NASH Cirrhosis. The NASH-CX Trial. GALECTIN GT-026. 9/2015 – OPEN

• A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults with Non-alcoholic Steatohepatitis. BMS MB130045. 9/2015 – 1/2018

• Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis. The REGENERATE Study: Intercept 747-303. 10/2015 – OPEN

• A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Ribavirin in Adults with Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3). AbbVie M13-594. 10/2015 – 7/2017

• A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection. Gilead Polaris 1 GS-US-367-1171. 10/2015 – 7/2017

• A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection. Polaris 2 GS-US-367-1172. 10/2015 – 2/2017

• A Phase II, Randomized, Open-Label Clinical Trial to Study The Efficacy and Safety of the Combination Regimen of MK-3682B (MK-5172 + MK-3682 + MK-8408 Fixed Dose Combination (FDC)) in Subjects with Chronic HCV GT1 or GT3 Infection who have failed a Direct Acting Antiviral Regimen. Merck 3682-021. 1/2016 – OPEN

• A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor. Gilead Polaris 4 GS-US-367-1170. 3/2016 – 2/2017

• A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis Patients who are Refractory or Intolerant to Current Therapies. TaiwanJ JKB-122AIH. 6/2016- OPEN

• A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients with Primary Sclerosing Cholangitis (PSC). NGM 15-0106. 6/2016 – 8/2017

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan (IDN-6556), an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis. Conatus IDN-6556-12. 03/2016 – OPEN

• A Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects with Hepatorenal Syndrome Type 1 (The Confirm Study). Mallinckrodt Pharmaceuticals, Inc. MNK 19013058. 6/2016 – OPEN

• A Randomized, Double-Blind, Placebo Controlled, 2- Part, Adaptive Design, Multicenter 12-Week Study To Assess Safety, Tolerability And Efficacy Of LJN452 In Patients With Non-Alcoholic Steatohepatitis (NASH). Novartis CLJN425A2202. 06/2016 – OPEN
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study To Evaluate The Efficacy And Safety Of Elafibranor In Patients With Non-Alcoholic Steatohepatitis (Nash) And Fibrosis. Genfit GFT505-315-1. NASH. 09/2016 – OPEN


An 8-week, dose ranging, open label, randomized, Phase 2 study with an 18-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA). CymaBay Therapeutics, Inc. CB8025-21629. 2/2017 – OPEN

A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH). Shire SHP626-201. 3/2017 – OPEN


A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection. Gilead GS-US-337-1431 - LTFU with Cirrhosis. 4/2017 – OPEN

Procurement of Blood Samples from Subjects with Diagnosed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) for Use in the Development of a Liver Fibrosis Test. Prometheus 16HEP01. 5/2017 – OPEN


A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Elafibranor at Doses of 80mg and 120mg After 12 Weeks of Treatment in Patients With Primary Biliary Cholangitis and Inadequate Response to Ursodeoxycholic Acid. GenFit GFT505B-216-1. 6/2017 – OPEN

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. Gilead Sciences, Inc. GS-US-384-1943. 6/2017 – OPEN


A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis. Conatus IDN-6556-17. 6/2017 - OPEN

A Phase 2a, randomized, double-blind, placebo-controlled, dose-ranging, parallel group study to evaluate safety, tolerability, and pharmacodynamics of PF 05221304 administered daily for 16- weeks to adult subjects with nonalcoholic fatty liver disease. Pfizer C1171002. 8/2017 - OPEN

A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with Persistently Elevated Alkaline Phosphatase. Genkyotex GSN000300. 02/2018 – OPEN


A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate Safety, Pharmacokinetics and Efficacy of DAX-1106 in Subjects with Decompensated Cirrhosis. Intercept 747-305. 5/2018 – OPEN

A Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis. Intercept 747-304. 5/2018 – OPEN

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis with Fibrosis. Intercept 747-117. 5/2018 – 6/2018

A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER). Novartis VAY B2201. 5/2018 – OPEN

A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of DAX-1106 in Subjects with Nonalcoholic Steatohepatitis. Intercept 747-307. 5/2018 – OPEN
PUBLICATIONS & PRESS


- **Graham D.** Letter: questions regarding the diagnostic performance of serum assays for atrophic gastritis. *Aliment Pharmacol Ther.* 2017 Dec;46(11-12):1117-1118


• Pratt P Jr, David N, Kourkoumpetis T, et al. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy. *Inflamm Bowel Dis.* 2018 Jan 18;24(2):380-386


• Mindikoglu A, Pappas S. New Developments in Hepatorenal Syndrome. *Clin Gastroenterol Hepatol.* 2018 Feb;16(2):162-177.e1


• Graham DY, Dore MP. Update on Use of Vonoprazan: a Competitive Acid Blocker (P-CAG). *Gastroenterology.* 2018 Feb;154(3):462-466


- Chew E, Vorgese B, Sealock R. Pancreatic duct rendezvous with pancreatoscopy through the minor papilla. VideoGIE. 2018 Apr 1;3(4):132-4
With over 100 papers in scientific journals and over 70 presentations at the national meetings this year, the Section is a leader in research in gastrointestinal and liver diseases.
PRESS


• Hussain: National VA Transplant Conference. (Feb 2018)


• Hernaez: VA Liver Cancer Team Educational Seminar Series. “Curative and Palliative Therapies for HCC.” (Apr 2018)


• Qureshi: BCM DocTalk. “Colorectal Cancer Awareness Month.” (Mar 2018)

• Graham: Fifth Annual Ertan Lectureship at UT McGovern Medical School. “Helicobacter Pylori as a Bacterial Cause of Gastric Cancer.” (Apr 2018)


• Graham: Gastrointestinal Endoscopy and Video GIE. “Meet the Master.” https://youtu.be/VoRLbLt6PU (May 2018)


OUR FACULTY

Baylor Clinic – Faculty Group Practice
Daniel Murphy (Director)
Eloy Cavazos Jr. Sharon Chen Sobia Khan Derek Meeks Ralph Rosenbaum

Baylor St. Luke’s Medical Center
Umar Waheed (Director)
Titilola Adio Neeraj Agrawal Khannan Athreya* Heather Bartsch Alok Bhattarai Chris Brann Kinjal Changela Allison Heinen Chimutha Ibe Elie Jarrouge Roopa Nalam Shira Sachs

Harris Health System
David Hyman (Section Chief)

MEDVAMC Hospitalists
Andrew Caruso (Director)
Rajeev Balchandani Glynda Reynaldo Lindsey Jordan Jing Kees Jung Hyung Park Cory Ritter Atur Sheth Michelle Siblee Bryan Sowers Diana Stewart Mini Varughese

Women’s Health Center
Rola El-Serag (Director)
Safar Hossam Jonmenjoy Biswas Mega Edmonsdon Richa Gupta Bryan Kenjura Kelly Thomas Rajavi Shah

EC IM
Safar Hossam Jonmenjoy Biswas Mega Edmonsdon Richa Gupta Bryan Kenjura Kelly Thomas Rajavi Shah

*Also works on VAMC Hospitalist Team

Primecare
Himabindu Kadiyala (Director)

Other Faculty
Jeffrey Bates Joan Friedland Molly Horstman Jay Kalavar James Scheurich Anne Utech

MEDVAMC – Pharm
Feibi Chi (Director)
The mission of the Baylor College of Medicine Department of Medicine (DOM) Section of General Internal Medicine (SGIM) mirrors that of the DOM – that is, our Section creates and applies knowledge through research, scientific discovery, and medical education and training locally and globally; all done with innovation and compassion to advance health and wellness.

The Section of General Internal Medicine operates at the Baylor Clinic, the Baylor St. Luke’s Medical Center, Harris Health System (Ben Taub and Smith Clinic), and the MEDVAMC. With a large, diverse group of over 130 employed faculty and 24 voluntary faculty, our Section’s scope of clinical practice includes hospital medicine and outpatient primary care. Our faculty members serve in educational leadership roles for medical students, residents, faculty and other health professionals. Our faculty members engage in a variety of scholarly endeavors including innovative chronic disease management, quality improvement, medical education scholarship, environmental health and narrative advocacy.

Numerous members of our Section have earned recognition for their excellence in teaching and clinical work. Our faculty has presented locally, regionally, nationally and internationally and published on topics ranging from medical education, clinical vignettes, professionalism, health policy and social determinants of health.

The Section has made significant progress in achieving action items based on the strategic plan. We hope you will enjoy reading our annual report for the academic year 2017–2018.

David Hyman, MD, MPH, Professor of Medicine
Chief, Section of General Internal Medicine,
Department of Medicine Baylor College of Medicine
Baylor Clinic – Primary Care Outpatient Faculty Group Practice

The General Internal Medicine Faculty Group Practice (FGP) moved to McNair Clinic in January 2018. After being at the Baylor Clinic location for over 10 years, the Department of Medicine relocated most of the Medicine sections to the new, long awaited McNair Campus on January 16, 2018. It is located across the street from the MEDVAMC. The new address for General Internal Medicine, outpatient clinic is 7200 Cambridge, 8th Floor, Houston, TX, 77030. The GIM FGP includes a dedicated group of 8 clinicians who practice not only general internal medicine providing evidence-based, high quality care for the prevention and treatment of chronic medical conditions but also specialize in a variety of areas including women’s health, diabetes and adolescent care. In addition, several FGP members work on quality improvement projects and health services research.

PATIENT GROWTH AND PREVENTIVE CARE QUALITY IN FY2018

The Baylor Clinic General Internal Medicine Faculty Group Practice has provided care to approximately 7975 patients, with an increase of 1,048 new patients over the past year. GIM continues to provide high Preventive Care Quality Scores in Blood Pressure Control, Diabetes Control and Tobacco Screening Cessation.

Baylor St. Luke’s Medical Center Hospitalist Group

The concept for the Baylor St. Luke’s Medical Center (BSLMC) Hospitalist group was originally proposed in the fall of 2015. Background work, which was done to initiate the Baylor hospitalist group at BSLMC hospital, included contractual relationships with the hospital and with the existing hospitalist groups. The driving force for the Baylor group to initiate a hospitalist program at BSLMC was the hospital’s desire to achieve improvement in quality metrics (reduction of length of stay, readmissions, mortality, complications and improvement in HCAPS and other quality measures.)

In June 2016, BCM went into an official contract with BSLMC to provide a hospitalist service that will cover all non-ICU and non-managed care patients. In October 2016, BCM hospitalist group sub-contracted with two existing hospitalist groups so they can work under the BCM umbrella to deliver hospitalist services and desirable results for BSLMC hospital. Improvement in metrics were visible within a few months after the program started. Hospitalist services were expanded to maximize efficiency, throughput and patient safety. At the request of BSLMC hospital, the hospitalist program has made several changes from an admitting/rounding model to a model where the same attending who will follow patients daily will do admissions.

The BSLMC hospitalist group has created schedule and throughput processes to make sure patients are taken care of by the appropriate attendings and consult services. The group has strived hard to build relationships with Baylor and private attendings alike. In June 2018, the BSLMC Hospitalist team started the resident hospitalist team also known as RITE team at Baylor St. Luke’s Medical Center. The BSLMC hospitalists are actively involved in hospital committees and the utilization management committee is chaired by one of the BSLMC hospitalists, Dr. Jarrouge. In addition to hospital committees, various hospitalists are involved in scholarly activity and quality improvement projects at BSLMC.

Harris Health System

Harris Health System (HHS) is the largest public health care system in Houston and Harris County with a focus on serving a primarily low resource/underserved patient population. The Section of General Internal Medicine (SGIM) faculty at Ben Taub and Smith Clinic saw a combined total of 94,699 patients visits in FY18 and generated a total of 123,700 WRVUs. This is a combination of all inpatient- teaching and hospitalist as well as outpatient services at Smith Clinic. The Harris Health SGIM group was over 100% of expected productivity for the 2018 academic year. Section members at HHS serve as leaders on numerous HHS committees including patient safety, health information management, pharmacy and therapeutics and ethics.

“

All done with innovation and compassion to advance health and wellness.

“
HOT (HOSPITALIST ONLY TEAM) INPATIENT CARE
The HOT service is comprised of general internists specializing in inpatient hospital management without trainees. We provide high quality care to complex medical patients at Ben Taub General Hospital with five rounding teams, one admitting team and a night service. In the 2018 academic year our HOT service has provided care for approximately 35,000 patients.

As members of Baylor and Harris Health, the HOT faculty precept students as part of a commitment to medical education and frequently attend on teaching wards. We hold monthly meetings focusing on patient outcomes, case management, and are in the process of joining our hospitalist partners at St. Luke’s and the VA in forming a quarterly journal club. Faculty on the HOT service actively serve on hospital committees to provide crucial input in policy development. Our members work closely with nursing and hospital leadership to improve medical delivery to the bedside. We additionally meet monthly with Emergency Department leadership to streamline the transition from our triage department to the wards.

INPATIENT TEACHING SERVICE
Baylor College of Medicine faculty provides supervision of inpatient medical care for hundreds of residents and students annually. The inpatient teaching service includes 8 ward teams, a consult service and a special rotation for upper level residents to learn hospital medicine (RITE) team. The inpatient teaching service regularly receives fantastic evaluations from students and residents. For many, the Ben Taub inpatient service is the ‘crown jewel’ among all the great clinical opportunities in the Baylor system.

HHS SMITH (OUTPATIENT) CLINIC
Smith Medicine Clinic is a Harris Health System primary care clinic where ninety-three internal medicine residents spend their three-year residency taking care of their continuity patients. Smith Medicine Clinic also has medical students rotating through during their ambulatory internal medicine clerkship. The majority of our core clinic faculty work is in both inpatient (Ben Taub General Hospital) and outpatient (Smith Medicine Clinic). In this continuity clinic, house staff learn preventive medicine such as cancer screening and vaccinations, in addition to taking care of chronic diseases such as hypertension, diabetes, heart failure, coronary heart disease, etc. They perform PAP smears and procedures such as arthrocentesis and incision/drainage of abscesses. Furthermore, they hone their counseling skills in the setting of encouraging patients to stop smoking and modify dietary lifestyle in reducing weight, or advanced life directives, etc. The mean patient volume ranges from 1000 to 1100 visits per month. In this past academic year, our Smith clinic house staff, with GI service assistance, implemented a successful Quality Improvement Project in using a PPI tapering set in reducing the number of chronic PPI use.

In addition to being actively involved in the residency program’s Wednesday school ambulatory curriculum, our clinic faculty led by Drs. Michelle Schmidt, Cara Foldes, and Meroe Morse started an “Intern Spotlight” session in which interns are assigned to review recently published articles on ambulatory care topics. Dr. Schmidt hosts a book club to discuss new books and novels. Dr. Foldes teaches evidence-based medicine in interpreting literature. Dr. Morse is developing an initiative, a comprehensive integrative chronic pain management program to help physicians manage chronic non-cancer pain. Drs. Jaime Rueda and Ordonez often teach our house staff in performing procedures such as arthrocentesis. Dr. Lu, the medical director of Smith Clinic, collaborates with Harris Health leaders in increasing specialty resources through E consults and has written the textbook Leading an Academic Medical Practice.

Michael E. DeBakey VA Medical Center (MEDVAMC)

INPATIENT – HOSPITALIST SERVICE
The MEDVAMC Academic Section of Hospital Medicine began in 2012 with 7 FTE positions and has presently grown to a group of nearly 14 FTE. Our section of clinician educators focuses on BCM medical resident supervision while attending on the Inpatient Medicine service. We currently cover 50% of the general medicine inpatient teams and are adding an additional team this August. Additionally, we provide coverage on-site nightly to supervise the admitting resident, facilitate rapid response and code blue calls, proactively aid patient flow through the Emergency Department and independently perform admissions. Our ranks are made of individuals who have taken on increasing leadership roles in education and include 2 Associate Program Directors for the IM Residency Program, the VA based Chief Resident in Quality and Safety (CRQS) Director, the BCM IM Core Clerkship Director and Associate Sub Internship Director, the UT IM Residency Program Site Director and Associate Site Director, the VA BCM Student Site Director as well as numerous PPS3 facilitators and student mentoring community leaders. From an administrative and service perspective, our section participates in numerous high value committees at the VA and recently initiated a Physician Unit Advisor program to liaison with medical nursing unit administration. In June 2018, Dr. Andrew Caruso accepted the Chief role for the Section of Hospital Medicine, and Dr. Cory Ritter is our new Associate Chief.
Our group recently completed a recruitment cycle, and we are excited to welcome three new Hospitalists. Dr. Lindsay Vaclavik joins us after recently completing her year of service to the VA and BCM as one of two Chief Residents in Quality and Service and is also an alumna of the BCM Residency Program from 2017. Dr. Paras Mehta and Dr. Eric Wu just completed their BCM Residency Program training this June and will be joining us this summer. We are additionally recruiting a mid-level provider to be a part of our first endeavor into an inter-professional team.

The MEDVAMC Section of Hospital Medicine is looking forward to further expansion and integration with the hospitalists at Ben Taub and Baylor St. Luke’s Medicine Center and are proud to be a growing part of the Section of General Internal Medicine.

Inpatient – Hospitalist Service continued

Our group recently completed a recruitment cycle, and we are excited to welcome three new Hospitalists. Dr. Lindsay Vaclavik joins us after recently completing her year of service to the VA and BCM as one of two Chief Residents in Quality and Service and is also an alumna of the BCM Residency Program from 2017. Dr. Paras Mehta and Dr. Eric Wu just completed their BCM Residency Program training this June and will be joining us this summer. We are additionally recruiting a mid-level provider to be a part of our first endeavor into an inter-professional team.

The MEDVAMC Section of Hospital Medicine is looking forward to further expansion and integration with the hospitalists at Ben Taub and Baylor St. Luke’s Medicine Center and are proud to be a growing part of the Section of General Internal Medicine.

PRIMARY CARE – PRIMECARE

Primary Care is one of the foundational services at Michael E. DeBakey VA Medical Center (MEDVAMC). The section has highly dedicated staff who provide excellent pro-active, team based, patient-centered care to our Veterans and take pride in working for the Veterans Health Administration, which is the largest integrated health care system in America. Below are some of the biggest accomplishments of this 2018 academic year:

- When Hurricane Harvey hit Houston in August 2017, MEDVAMC remained open and several of our Primary Care staff went above and beyond to take care of veterans in the most challenging of circumstances in the hospital, GRB Convention Center and in unconventional locations such as tents and Mobile Medical Units.
- Excellent Performance on HEDIS Quality Performance Measures, Access Metrics and ACSC hospitalizations.
- Lowest Opioid use - While there is an epidemic of prescription opioid overdoses in the country, MEDVAMC has one of the lowest opioid prescriptions.
- Primary Care – Mental Health Integration: At MEDVAMC, we have excellent integration of Primary Care and Mental Health services to increase access to mental health care, de-stigmatize mental health disorders and provide a more holistic and successful approach to mental and physical health problems. Our patients can see a Mental Health Provider on the same day they see their Primary Care Provider.
- Same day Mammograms – Our designated Women’s Health Providers provide comprehensive general primary care and gender-specific care to our female veterans. We currently have Mammogram services on site, and our veterans can get screening and diagnostic mammograms on the same day as their Primary Care appointment.
- VA Video Connect Visits – As part of a national VHA mandate, our Primary Care Providers at MEDVAMC are utilizing the VA Video Connect Visits to provide telehealth services using a secure video connection to address nearly any issue that does not require an in-person visit. The VA Video Connect can be used by any veteran who has video-capable technology such as a smartphone, tablet or computer.
- Musculoskeletal Clinic: In the past academic year, we have started a musculoskeletal clinic in Primary Care. Dr. Hendiani, who did a Sports Medicine Fellowship, evaluated more than 200 veterans for various musculoskeletal conditions. Several of them received corticosteroid or hyaluronic injections in various joints. We are planning on expanding the services utilizing ultrasound and orthobiologics.
- Whole Health Initiative – The Whole Health initiative continues to build momentum and engagement in Primary Care and Health Promotion programs at MEDVAMC. Our staff are trained by Dr. Daniel DeBrule, who is our Health Behavior Coordinator/Whole Health Director, regarding the model with emphasis on personalized health planning and connection with Complementary Medicine approaches such as Yoga, Tai Chi, Acupuncture and Guided Imagery. Personalized Health Planning has been conducted by several PCPs in Primary Care.
- Expansion of trainees in Primary Care Continuity Clinic: We currently have over 100 Internal Medicine residents from BCM and UT who have a rich learning experience from deserving and appreciative patients and are precepted by top notch Faculty.
- CoEPC: MEDVAMC is one of the seven Centers of Excellence in Primary Care Education, the main goal of which is to develop and test innovative structural and curricular models that foster transformation of health care training from profession-specific silos to inter-professional, team based educational and care delivery models in primary care settings. Our current trainees include Internal Medicine residents, NP residents, NP students, Pharmacy residents, Social work interns, Psychology Fellow, Psychology intern and RN students.

... highly dedicated staff who provide excellent proactive, team based, patient-centered care to our Veterans and take pride in working for the Veterans Health Administration.
Environmental Health Service

Healthcare: EHS continues to operate two Environmental Health Clinics, one for children and one for adults, which provide assessment and intervention services to individuals with health conditions that are caused or exacerbated by the environment, including asthma and lead poisoning. EHS is now in the final stages of negotiations with the UnitedHealthcare Community Plan of Texas to provide and be reimbursed for comprehensive asthma management services (including home visits and supplies) for UHC members. The partners are also developing an innovative outcomes-based payment system to cover the services, which is expected to serve as a model for other asthma programs and health plans across the country.

Community: Immediately after Hurricane Harvey, the EHS team was called on to help understand the immediate health risks caused by contact with floodwater and sediment and to explain these risks—and appropriate safety precautions—to the community. Along with partners at the Houston Health Department and Rice University, the EHS was in the field with New York Times Investigative journalists just days after the flood, collecting water and sludge samples from some of the most affected communities across Houston and interpreting the results.

Nearly 100 members of the community came together on May 1 (World Asthma Day) for the first-ever Houston-Area Town Hall on Asthma. The community spoke about the burden of asthma and helped create a list of actions to make Houston more lung healthy. The Houston mayor’s office presented BCM with a proclamation naming May “Asthma Awareness Month.” The event was hosted by EHS and the Harris Health System and funded through grants from The Jacob and Terese Hershey Foundation, the National Institute of Environmental Health Sciences and the Patient-Centered Outcomes Research Institute.

Education: The director of EHS, Dr. Winnie Hamilton, delivered a lecture titled “Environmental Health: Time for an Upstream Approach,” on April 26 for the Determinants, Disparities, and Social/Population Health (DDASH) foundational sciences course at BCM. Dr. Abi Oluyomi, EHS faculty member, in partnership with colleagues at the Southwest Center for Occupational and Environmental Health at UTHSC School of Public Health, presented a comprehensive review of the environment and the use of geographic information system (GIS) applications in the healthcare field on June 1, 2018.

Research: EHS has several ongoing and newly funded research projects such as Environmental Exposures, Health and Resilience before and after Hurricane Harvey in a Houston-Area Cohort of African-American Adults with Poorly Controlled Asthma (NIEHS); Environmental Health Outcomes Research among Hurricane Harvey Survivors; Protecting the Health of Houstonians and Texas Gulf Coast Residents (NIEHS); Geospatial analysis of high-risk areas for vector-borne transmission utilizing satellite imaging technology; Pathways Linking Neighborhood Environments to Activity Behaviors (American Cancer Society), and Houston Home-Based Integrated Intervention Targeting Better Asthma Control for African Americans (PCORI).

The BCM Resource Stewardship and Sustainability Program (RSSP) has had another successful year and has maintained its rank as one of the leading colleges in the annual RecycleMania competition. After implementing a new LDPE/HDPE plastics recycling stream on BMC’s main campus, the program has been awarded a bench from TREX Collegiate Recycling Program for their efforts. RSSP held a very successful lab coat and scrubs recycling event, in addition to the annual Earth Day event that was well attended. RSSP has also been able to maintain and recruit new volunteers for the recycling program on campus.

VA Pharm D Program

Pharmacy residents presented their research projects at the American Society of Health-System Pharmacists Midyear (Dec 2017) and Texas Society of Health-System Pharmacists ALCALDE (Apr 2018). In addition, pharmacy house staff earned the recognition below:

- Wanat, Matthew – inducted as a Fellow of American College of Critical Care Medicine (Feb 2018), University of Houston College of Pharmacy Preceptor of the Year (2017), UHCOP Rho Chi Teaching Excellence Award (2017), Society of Critical Care Medicine Texas Chapter President (2017-2018)
- Mitchell, Brian – College of Psychiatric & Neurologic Pharmacists poster presentation on Treatment resistant schizophrenia and the role of long-acting injectable antipsychotics: a case report (Apr 2018), MEDVAMC Pharmacy Residency Preceptor of the Year Award (June 2018)
- Sulik, Hannah – board certification in geriatric pharmacy (Nov 2017)
- Chi, Feibi – serves on VA National Workgroup on assessment of acute care clinical pharmacy practice throughout VHA
AWARDS & HONORS

• Dr. Lee Lu: Joseph R. Guittreau Consummate Physician Award, the highest GIM award given in honor of a former colleague
• Dr. Anita Kusnoor: D.A.V.E. Award for the dedicated academician who values excellence in patient care, teaching, and scholarly activity
• Drs. Allison Heinen and Elie Jarrouge: Hospitalist of the Year
• Dr. Cara Foldes: Outpatient Healer of the Year
• Dr. Anna Kolpakchi: Lifetime Achievement Award
• Dr. David Hyman, professor and chief of General Internal Medicine is listed in Castle Connolly's Top Doctors in Houston.
• Dr. David Hilmers, professor, General Internal Medicine was named as a top Internal Medicine doctor by Houstonia Magazine in July 2017
• Dr. Allison Heinen, assistant professor, General Internal Medicine was named as a Top doctor by Houstonia Magazine in August 2017
• Dr. Michelle Schmidt, assistant professor – Harris Health System was selected as one of the BCM Center of Excellence in Health Equity, Training and Research Junior Faculty Scholars for 2018-2019
• Dr. Priti Dangayach, Assistant Professor, General Internal Medicine – Ben Taub Hospital, has received a Certificate of Recognition from the Harris Health System for distinguished service. The award recognizes her excellence in leadership, mentoring and patient care
• Dr. Lubna Khawaja, assistant professor, General Internal Medicine - Ben Taub, has received a Certificate of Recognition from the Harris Health System for distinguished service, in recognition of her excellence in leadership, mentoring and patient care
• Dr. Lee Poythress, associate professor, General Internal Medicine, Ben Taub Hospital, has been awarded the Distinguished Consultant Award from the Department of Emergency Medicine. This award is given to the consultant who the residents and faculty feel embody professionalism, communication, teaching and outstanding patient care
• Dr. Meroe Morse, assistant professor, General Internal Medicine, is an ongoing fellow (’19) and scholarship recipient in Integrative Medicine through Arizona Center of Integrative Medicine
• Dr. Sabina Lee, associate professor, General Internal Medicine-VAMC, is a Texas ACP Wellbeing champion and will be involved with national ACP for the next 3 years for physician well-being
• Dr. Anita Kusnoor, associate professor, General Internal Medicine, received the Essential Skills in Medical Education (ESME) Faculty Scholarship last month from the Office of Faculty Development and the Academy of Distinguished Educators
• Dr. Sarah Candler, assistant professor, General Internal Medicine – MEDVAMC, received her certificate of completion of the Society of General Internal Medicine’s Leadership in Health Policy program
• Dr. Ricardo Nuila, assistant professor, General Internal medicine has received a MacDowell Fellowship to continue his journalistic work on health disparities in Texas. The MacDowell Fellowship program is one of the most competitive artistic residencies in the country. Based in New Hampshire, it provides room and board for up to two months for visual artists, filmmakers, and journalists. Nuila will complete the residency in summer 2018
• Dr. Joslyn Fisher, Dr. Cara Foldes were nominated for exemplary Baylor Women of Excellence – women who exemplify excellence as well as Baylor’s other values (respect, integrity, innovation and teamwork), in support of Women’s History Month
• Dr. Joslyn Fisher, associate professor, General internal Medicine participated in a panel discussion on Ethical Dilemmas in Health Policy with a focus on end of life care at the Texas Medical Center Headquarters in Houston
• Dr. Elizabeth Vaughan was honored by the BCM Office of Institutional Diversity, Inclusion and Equity for her efforts at the Community Health Worker Diabetes Education Program on June 30 at San Jose Clinic, where she helped educate the Health Equity Scholars in the BCM Center of Excellence in Health Equity
Fellow, Hospital Medicine, Society of Hospital Medicine
• Andrew Caruso, MD
• Cory Ritter, MD

Fellow, American College of Physicians
• Adelaide Adjobu, MD
• Anoop Agrawal, MD

Residency Program Graduation Awards
• Ambulatory – Jaime Rueda, MD
• Ben Taub – Stephanie Sherman, MD
• MEDVAMC – Zaven Sargsyan, MD

John P. McGovern Outstanding Teacher Excellence Award (Medical School)
• Lee Poythress, MD – Clinical Sciences
• Zaven Sargsyan, MD – Pre-clinical Sciences (2018), Clinical Sciences (2017)

Norton Rose Fulbright Award for Excellence in Teaching & Evaluation
• Andrew Caruso, MD
• Diana Stewart, MD
• Erica Lescinskas, MD

Norton Rose Fulbright Award for Excellence in Educational Leadership
• Erica Lescinskas, MD

Early Career Faculty Award for Excellence in Patient Care
• Dr. Stephanie Sherman
• Dr. Andrew Caruso

Graduating Class Outstanding Faculty Award
• Dr. Andrew Caruso, assistant professor
• Dr. Zaven Sargsyan, assistant professor
• Dr. Stephanie Sherman, assistant professor
• Dr. Lee Poythress, associate professor

RESEARCH FUNDING
• Hamilton, W (PI): Environmental Exposures, Health and Resilience before and after Hurricane Harvey in a Houston-Area Cohort of African-American Adults with Poorly Controlled Asthma. National Institute of Environmental Health Sciences (NIEHS), 1R21-ES029690-01 01, 2/1/2018- 1/31/2010
• Hamilton, W (PI): Pathways Linking Neighborhood Environments to Activity Behaviors. American Cancer Society. MRSG13145-01. Subcontract with University of Texas MD Anderson Cancer Center. 9/1/2014-6/30/2018
• Hamilton, W (PI): Protecting the Health of Houstonians and Texas Gulf coast residents. Philanthropic gift from Jacob and Terese Hershey Foundation. 1/15/2018-1/14/2019
• Lescinskas, E (Co-I): Identifying and reducing catheter related complications. Dept. of Veterans’ affairs, VA251-15-C-0187, 7/1/2015-5/31/2018
Books & Book Chapters

• Dr. Lee Lu, associate professor, General Internal Medicine – Harris Health System, is an editor on a recently released book, Leading an Academic Medical Practice. Dr. Lu led the group of Society of General Internal Medicine academic leaders to produce the book, which discusses the key elements on how to manage a medical clinic with learners.

• Dr. Wayne Shandera, assistant professor of General Internal Medicine is the editor of the recently published book entitled Sub-Specialty Care of HIV-Infected Patients. Nova Scientific, 2018. In the same book he also wrote a chapter "General medicine consultation for the HIV infected patient”.

• Dr. Wayne Shandera, assistant professor of General Internal Medicine is co-author of chapter “Viral and Rickettsial Diseases”, in Mcphee Sj, Papadakis et al, 2017 edition: Current Medical Diagnosis and Treatment, New York, NY: McGraw Hill.


Peer-Reviewed Publications


• Candler S. We didn’t get cold feet. Ann Int Med

• Shunk R, Candler S, Lieblow M. Will graduate medical education at VA hospitals survive the choice act? SGIM forum. 2018 April; 4 (4)


• De La Cruz A. Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression? Ment Health Clin [Internet] 2018;8(4):175-83


• Hyman D, Pavlik V. Controlling Hypertension: We Have the Tools-We Just Need to Use Them. J Gen Intern Med. 2017 Aug;32(8):860-862
• Przybyłowicz R, Millien V, Sethness J, Kurian B, Lu L. I’m Just PSAying Something Isn’t Right. J Gen Int Med 2017; 2(suppl)
• Schmidt M. Forgiveness. Literary AMWA. 2017 Dec 30 [Online]
• Tschaep M. Representations of patients experiences of autonomy in graphic medicine. AM J Ethics, 2018 Feb 1;20(1):122-129
• Vaughan E, Moreno J, Hyman D, Chen T, Foreyt J. Efficacy of oral versus insulin therapy for individuals with newly diagnosed type 2 diabetes in low-income settings. Arch Gen Int Med; 1(2). 17-22
• Vaughan E. Integrating CHWs as part of the team leading diabetes group visits: A randomized controlled feasibility study. Diab Educator. 43(6). 589-599
• Vaughan E. Dual therapy appears superior to monotherapy for low-income individuals with newly diagnosed type 2 diabetes. J Prim Care Comm Health. December 7, 2017
• Vaughan E. Impact of Child Summertime Obesity Prevention Interventions on BMI and Weight-Related Behaviors: A Systematic Review and Meta-Analysis Protocol. BMJ Open. 7:10
Abstracts, Presentations & Workshops

• Dr. Sabina Lee, associate professor and Dr. Sarah Candler, assistant professor, General Internal Medicine – MEDVAMC, recently participated and/or presented at the Texas Chapter of the American College of Physicians annual conference in San Antonio. Dr. Lee moderated the session presented by Dr. Hashem El-Serag, professor, Gastroenterology and Hepatology, and chairman, Department of Medicine, “GI Multiple Small Feedings of the Mind”

• Dr. Daniel DeBrule, assistant professor, General Internal Medicine, presented Leveraging Whole Health and Health Psychology Interventions to Prevent Suicide in Veterans: Creating Unique Pathways Through New VHA Initiatives at the Annual Conference for the American Association of Suicidology, Washington, D.C.

• Dr. Daniel DeBrule, assistant professor, General Internal Medicine, presented A Multidisciplinary, Multilayered Program for Veterans and Smoking Cessation: Vets Kick Butts. at the Annual Conference of the Society for Behavioral Medicine, New Orleans, LA

• Dr. Ricardo Nuila, served on a panel in the “Reporting Health” session at the Healthier Texas Summit in Austin on November 7. This meeting is organized by the University of Texas System and convenes thought leaders and practitioners statewide to discuss innovations and trends in community and public health

• Dr. Anoop Agrawal, assistant professor, General Internal Medicine, presented “Integration of Apps into Internal Medicine Residency curriculums: A survey of IM program directors” was presented at Association of Program Director’s for Internal Medicine (APDIM) in San Antonio on March 19, 2018

• Dr. Meroe Morse, assistant professor, General Internal Medicine Presented at ACGME Florida (March 2018) Workshop on Resident Wellness Initiative with Stacey Rose, MD

• Dr. Wayne Shandera presented his abstract titled “The relationship between music and medicine as evidenced in the medical literature” was accepted in annual meeting, European Society for the Philosophy of Medicine and Health Care


• Dr. Anita Kusnoor was a co-presenter of Streptococcus constellatus brain abscesses masquerading as metastases. Presented at the Texas Chapter Annual Meeting of the American College of Physicians, San Antonio, November 11, 2017 and in National Meeting of the American College of Physicians, New Orleans, LA, April 21, 2018. She also presented “It’s my fault!” Disclosing Medical Error; Assuming Blame in Interprofessional Education along with Dr. Nadia Ismail, associate professor, General Internal Medicine TEACH-S Conference, Houston, TX, May 11, 2018

• Dr. Michelle Sibille, Instructor, General Internal Medicine- VAMC presenting both a poster and a presentation titled “Morbidity and Mortality Conference: An Innovative Strategy to Teach Quality and Safety in the Outpatient Setting” at the AAMC Integrating Quality Conference, June 7-8. 2018. Her co-authors were Dr. Frene Lacour-Chestnut, Dr. Molly Horstman, assistant professor of General Internal Medicine-VAMC and Dr. Diana Stewart, assistant professor of General Internal Medicine-VAMC

• Arunthamakun J, Choi K, Amenta E, Kees J, Ritter C. Stranger Things: The connection between minimal change disease and childhood asbestos exposure. – Best Clinical Vignettes Top 8 Finalist

• Liebler H, Lim J, Sachs S, Sargsyan Z, Sherman S. Internal Medicine Upper Level Boot Camp: Baseline survey. SGIM, Denver, CO. 2018

• Amidi O, Averyt A, Shah C. The case of acidotic stabbing victim: Just follow your nose. SGIM. Denver, CO. 2018
• Mammen A, Sherman S, Arnell M. A case of non-occlusive acute gastric ischemia from hypotension during dialysis, SHM, Orlando, FL. 2018
• Kapuria M, Lin D. Not all psychosis is purely psychiatric- A case of Anti-NMDAR Encephalitis. SHM. Orlando, FL. 2018
• Bass, M, Lim J, Sargsyan Z. Left and right you see Staph: Find the source and trace the path. SHM. Orlando, FL. 2018
• Olmstead R, Sargsyan Z. Levofloxacin induced myoclonus. SHM. Orlando, FL. 2018
• Hilmers D. “Medical Care of Hepatitis B Infected Patients in North Korea” at the Japanese- Korean Medical Association Annual Meeting, Kobe, Japan, November 2017
• Candler S. “It’s like a John Deere Tractor: Finding Common Ground in Health Advocacy in the South.” Workshop at Society of General Internal Medicine 2018 Southern Regional Meeting, in New Orlean, Feb 2018
• Candler S. “Having Difficult Conversations as a Leader,” American College of Physicians' Board of Governors meeting, Montreal, Canada

Press
• Dr. Sarah Candler, assistant professor, General Internal Medicine – MEDVAMC, was interviewed for an April 23 article in MedPage Today titled “Do You Know Your Gen Xers from Your Millennials?”
• Dr. Ricardo Nuila, assistant professor, General Internal Medicine – Ben Taub - was interviewed for a June 6 TMC NEWS "On the Side" article, in which he talks about his penchant for great writing as well as practicing great medicine
• Dr. Niraj Mehta, associate professor, General Internal Medicine - Harris Health, was featured with a blog in kevinmd.com titled “A gentle reminder that healing begins with feeling”
• Dr. Winnie Hamilton, associate professor, General Internal Medicine, and director, Environmental Health Services, was part of a testing group that the New York Times created to study floodwaters around Houston. The resulting article, “Houston’s Floodwaters Are Tainted, Testing Shows,” ran on Sept. 11; Dr. Hamilton was heavily cited in the article. Her work and that of several others who participated in the Times’ analysis showed that two neighborhoods were contaminated with bacteria and toxins, possibly a result of several waste treatment plants, and that many other areas were also unsafe owing to bacteria and mold
• Dr. Ricardo Nuila and Dr. Michelle Schmidt were invited to speak on Pacifica Radio 90.1 KPFT – “So What’s Your Story?” in July 2018
• Dr. Rola El-Serag, assistant professor, General Internal Medicine, was interviewed by KPRC Channel 2 for an article about the VA's fastest growing patient population; young female veterans. She also interviewed for a March 30 segment on the Houston Public Media radio show Houston Matters. The segment covered a new VA campaign to curb harassment against female veterans
October 2018

The Section of Geriatrics had a very challenging year. We survive and continue to deliver high quality, compassionate healthcare at many venues. At Houston Methodist Hospital (HMH), Geriatrics was ranked 29th in the nation out of 1,516 hospitals by U.S. News, and Baylor Geriatrics is the only Geriatrics at HMH. At Baylor St. Luke’s Medical Center (BSLMC), Geriatrics was ranked as High Performing by U.S. News. Ownership changes at Park Plaza Hospital resulted in the displacement of our outpatient clinic. It was a very difficult move, but we have finally settled in affiliation with BSLMC to practice at Kirby Glen, a wonderful, accessible location less than 2 miles from the Medical Center. If the saying “Nothing worthwhile is easy” is true, then this arduous journey should lead us to the “promised land”. We hope to have fellows, faculty, and nurses caring for older people in a smoothly operating practice soon while enjoying free parking and easy access. We were also able to celebrate Dr. Robert J. Luchi’s 90th birthday. Dr. Luchi, who founded the Geriatrics section at BCM, and his wife, Jean, flew down from Kansas City for a wonderful opportunity, hosted by Rashmi Jaitly and the Huffington Center on Aging, to embrace successful aging and reflect on our incredible accomplishments.

Baylor Geriatrics is unique in providing care in numerous sites across institutional and geographic lines. Our private practice sees inpatients in consultation at BSLMC and HMH, provides continuing care in facilities close to the medical center and provides outpatient wound care. Our Harris Health practices at Ben Taub General and Quentin Mease Hospitals remain active and Harris Health provides the support for our House Calls program. The House Calls team was featured in a number of media outlets including Houston’s Channel 2. At the Michael E. DeBakey Veterans Affairs Medical Center, patient care is provided across the continuum from the nursing home (CLC) to the clinic with a growing interest in providing Geriatric and Palliative Care in hospital and at home. We are honored to have the last of the “Greatest Generation” entrusted to our care at the VA. The CLC has moved up in quality over the past years. It is now ranked 9th out of 135 CLCs in the nation by SAIL quality measures. A recent visit to the CLC resulted in zero findings. Usually only 2-3 CLC’s per year out of 135 achieve this distinction. We have developed wound care as an area of expertise, now providing outpatient wound care at BSLMC, HMH, MEDVAMC and to inpatients at HHS. Our Innovation interventions have decreased the exposure to drugs known to cause delirium for thousands of elders throughout the Methodist systems. Using EPIC to protect older patients from delirium was so novel that some of the team were invited to Wisconsin to the Epic User’s Group Meeting to present their work.
Our faculty continues to play an important role training future clinicians and researchers in geriatrics and gerontology. Our educational impact outweighs our modest size. The Geriatrics track for our BCM medical students is on hiatus, but the student interest group (SAGI) under the leadership of BCM medical student Koby Kaplan has been revitalized. Dr. Major has updated ARTS (Age-Related Themes), our didactic course that occurs at the end of the second year of medical school. The Capstone course, the last didactics before graduation for BCM students, includes important input from Geriatrics faculty including Ursula Braun. Every BCM student did a house call with Geriatrics faculty members; this is a unique teaching experience, reminding learners that patients are real people. The house calls clinicians take the medical student with a University of Houston pharmacy student to create an interdisciplinary learning experience. We teach geriatrics to medicine core clerkship students monthly at Ben Taub Hospital. Many medical students choose electives with Geriatrics faculty. All BCM physician assistant students get training and mentorship at the MEDVAMC, coordinated in part by Mike Anderson, PA-C. To get a clinical perspective on their basic science work, Ph.D. candidates from the Huffington Center on Aging rotate with us. All upper-level BCM internal medicine residents spend four weeks on Geriatrics in a unique experience where they work for two weeks on the inpatient consult service at BSLMC and then spend two weeks out of the hospital exploring the continuum of care for older people. This innovation has been greatly appreciated and has a lasting impact. We also train BCM family medicine residents and HMH family and internal medicine residents in a variety of venues. The Geriatrics PA residency is the only one of its type in the nation, recruiting excellent candidates from across the nation to do additional training in Geriatrics with our faculty. Its success with two slots spurred an increase to three slots for January 2019. Our Geriatric fellowship program, led by Angela Catic, is among the largest and most sought after in the nation. Six first year fellows started in July and six graduated the day before. Annie Smith was our most famous graduating fellow, transported by a Houston Fire Department dump truck to the hospital to deliver Adrielle during the peak of Hurricane Harvey. Annie, husband Gregg, and Adrielle had the highest impact factor of any BCM member, appearing in hundreds of news outlets across the world, including the Washington Post and People magazine. Another fellow finished her second year with a focus on quality improvement as it relates to house calls. This unique focus led Claire Campbell to be recognized as a national leader for education in this area and was vital to our program being chosen to be 1 of 9 programs nationally who will participate in the new Learning Collaborative for Quality Improvement in House Calls. Another fellow, Mariam Ahmed, started her second year focused on wound care. Under the leadership of Aimee Garcia, BCM Geriatrics created the only Geriatrics based academic wound care fellowship in the nation. New fellowship slots in palliative care in collaboration with M.D. Anderson Hospital have been organized through the efforts of Drs. Braun and Syed Imam.

These will be filled outside the “match” this year, but are planned as an important “non-oncology” focused component of the best in the nation M.D. Anderson palliative care training program. Our educational efforts were not limited to trainees as BCM Geriatrics held its first CME course in June under the leadership of Syed Imam. It was well attended, very well received and laid the foundation for further courses. The Elder Investor Fraud program, led by Bob Roush, has trained physicians, lawyers and financial advisers in more than half the states and is soon to be made electronic.

To advance the quality of late life through exemplary research, education, patient care, and community outreach.

The true strength of our section is its people. Lurie McAdow, PA-C retired after more than twenty years of leading the PA efforts at the VA, and Rose Dust, PA-C, one of the early graduates of the PA residency in Geriatrics, moved from the MEDVAMC to Colorado. Mike Anderson, PA-C, another graduate of the PA residency in Geriatrics, joined and will help direct the residency program. Marcia Yparraguirre, our long term administrator and steady hand upon our tiller, is now leading the AMS/HHS relationship at UT Houston. Khelli Simpson, joined BCM Geriatrics from billing to lead administration for the Section. Don Chen, a former fellow who helped develop Home based care at the VA, left as well. Vinh Nguyen, one of our former fellows, returned from California to join the Home Based Primary Care program at the VA. Francisco Loaiciga joined the MEDVAMC to provide palliative care in the homes of dying veterans. Kayla Hall, a nurse practitioner on the house calls team, left to join Methodist Orthopedics. And Nancy Wilson, who brought appreciation of social workers to multitudes of Geriatrics physicians, retired as well.

Our top-notch faculty received many accolades at the local and national levels. For example, we have more “super docs” than the other programs in Geriatrics in Houston. We represent BCM in major professional society meetings; our faculty holds leadership positions within the American Geriatrics Society, the Gerontological Society of America, American Academy of House Call Medicine and American Medical Directors Association.
Geriatrics Section members contributed to research funding in 2018. While none of the funds gets directly credited to the Section, key collaborations with Psychiatry, Surgery, Otolaryngology, Endocrinology, Cardiovascular Research, Health Systems Research and industry were critical to the successes of our collaborators. With our colleagues in the Huffington Center on Aging, a large number of papers were published in scientific journals, including the top journal in our field, Journal of the American Geriatrics Society. The enduring products include a wonderful book, Ethical Considerations and Challenges in Geriatrics, edited by Angela Catic that featured contributions of many of the BCM Geriatrics faculty, fellows and former fellows. The faculty has made a large number of local and regional presentations. The fellows and faculty had a major presence at the BCM Housestaff Research Day with all fellows presenting their efforts during that event. Similarly, the presence of the Geriatrics Section made up almost all the clinical poster presentation at the annual HCOA day.

In summary, despite the wandering in the desert this year, BCM Geriatrics faculty was able to keep their focus on the next generation of providers and our mission “to advance the quality of late life through exemplary research, education, patient care, and community outreach.”

Respectfully submitted,

George E. Taffet, M.D., FACP Professor in Medicine
Chief, Geriatrics
Geriatrics and Cardiovascular Sciences

Robert J. Luchi, M.D. Chair in Geriatric Medicine
Baylor College of Medicine
Head of the Division of Geriatrics

AWARDS & HONORS
• Agarwal, Major, Taffet: Top Doctors in the City of Houston 2018
• Garcia, Taffet: Top Geriatric Doctors Castle Connolly 2018
• Catic, Selleck, Taffet: Super Doctors, Houston 2018
• Agarwal: Woman of Excellence at Baylor College of Medicine. Co-Winner National Association of Hospital Pharmacy Prize 2017; Top Doctors in the City of Houston 2018
• Braun: Program Leader, Palliative Care Fellowship Program, MEDVAMC; Leader, Breaking Bad News, CAPSTONE Course BCM
• Catic: Program Director for Baylor Geriatrics Fellowship Program; Physician leader VA Physician Assistant Residency Program in Geriatrics; Leader, Educational Swaps Program, American Geriatrics Society; PA Collaborating Physician of 2018 MEDVAMC; Super Doctors, Houston 2018
• Cintron: Clinical Supervisor Ethics Program, Harris Health;
• Garcia: Director, MEDVAMC Wound Care Program; Top Geriatric Doctors Castle Connolly 2018
• Jaitly: Director, HMH Wound Care Program
• Johnson: Leader, Non-Physician Faculty Promotion Facilitator for BCM; Promotion to Assistant Professor, BCM
• Khin: Director, Geriatric selectives for BCM medical students, Physician champion, Harris Health Wound Care Committee
• Major: Leader, House Calls Program; Course Leader, Age-Related ThemeS, BCM; Education Committee, AACHM; Top Doctors in the City of Houston 2018
• Nguyen: Leader, Home Based Primary Care
• Reyser: Director, Continuity Experience BCM Family Medicine residency program.
• Roush: Leader, Elder Investor Fraud Program (with Naik and Kunik)
• Salmeron: Leader, Post-Acute care program
• Selleck: Super Doctors, Houston 2018;
• Taffet: Research Committee, AGS; Geroscience SIG founder, GSA
• Waterhouse: Promotion to Assistant Professor, BCM
• Williams: Clinic Director, Baylor Geriatrics Senior Care Clinic; Member FGP Leadership, Dept. of Medicine, BCM
PUBLICATIONS & PRESS


• Trial J, Heredia C, Taffet G, Entman M, Cieslik K. Dissecting the role of myeloid and mesenchymal fibroblasts in age-dependent cardiac fibrosis. *Basic Res Cardiol*. 2017 Jul;112(4):34


Section of
Health Services Research

OUR FACULTY

Laura Petersen
Amber (Amy) Amspoker
Hoda Badr
Israel Christie
Jessica Davila
Traber Giardina
Kyler Godwin
Vivian Ho
Molly Horstman

Sylvia Hysong
Jennifer Kramer
Lindsey Martin
Ashley Meyer
Whitney Mills
Daniel Murphy
Aanand Naik
Nancy Petersen
Peter Richardson
Kathryn Royse

Shubhada Sansgiry
Hardeep Singh
Richard Street, Jr.
Barbara Trautner
Annette Walder
Donna White
Lechauncy Woodard
Mark Kunik
Jeff Cully
The Center for Innovations in Quality, Effectiveness and Safety (IQuEST) is the largest center for health services research in the Southwest and has been continuously funded since 1990, providing strong scientific leadership and institutional infrastructure dedicated to a model of embedded health system research. Since 2007, when Dr. Petersen became the Director and Section Chief, the number of funded investigators has grown over 125%, from 17 to 39 core members, and there have been 31 academic promotions among core faculty. In the past 23 years, 70 career development awards (CDA) have been funded (seven are current), including two recent HSR Section CDAs. Moreover, total grant funding has more than doubled, with over $16 million in research funding for FY18. We have a nearly 20-year tradition of conducting research in partnership with the health care delivery system and responding to its needs, making us pioneers in the execution of the learning health care system model. The IQuEST mission, “Improving health and well-being through innovations in health care delivery,” emphasizes our commitment to transformative and innovative research.

A learning health care system “...is designed to generate and apply the best evidence for the collaborative health care choices of each patient and provider; to drive the process of discovery as a natural outgrowth of patient care; and to ensure innovation, quality, safety, and value in health care.” Our model for the learning health care system is founded on strong partnerships with clinical and policy stakeholders, implementation of best evidence and evaluation to ensure a continuous cycle of learning and improvement. You will find IQuEST Investigators embedded within the clinical practice of Baylor St. Luke’s Healthcare system, the Faculty Group Practice, Michael E. DeBakey VA Medical Center, Harris Health System, Texas Children’s Hospital and many others. We emphasize communication, coordination and collaboration between clinical staff, communities and patients/families to achieve our goals of quality, effectiveness and safety and the whole health model. We will continue to grow cross-disciplinary teams of clinician scientists, social scientists and others who are embedded in the health systems to ensure better understanding of challenges and potential for healthcare improvement.

IQuEST is ideally poised to contribute to making care more accessible, safer and more patient-centered with innovative research, rapid implementation of evidence, novel methodologies that match the complexity of problems under study, solid partnerships that are built on decades of work, key stakeholder engagement, career development of future scientists and infrastructure to promote a learning health care system within Baylor College of Medicine. Please join in a review of our achievements and recognition received during 2018.

Dr. Laura Petersen
Professor of Medicine, Chief, Section of Health Services Research BCM
MEDVAMC Associate Chief of Staff, Research; Director IQuEST
KEY IMPACTS

Publications


PMID: 26010222 Overtreatment of asymptomatic bacteriuria (ASB) in patients with urinary catheters remains high. Health care professionals have difficulty differentiating cases of ASB from catheter-associated urinary tract infections. A multifaceted intervention targeting health care professionals who diagnose and treat patients with urinary catheters reduced overtreatment of ASB compared with standard quality improvement methods. These improvements persisted during a low-intensity maintenance period. The impact was more pronounced in long-term care, an emerging domain for antimicrobial stewardship.


PMID: 25714664 Increasing access to psychotherapy for PTSD is a primary focus of the VA healthcare system. Delivery of treatment via video telehealth can expand availability of treatment and be equally effective as in-person treatment. Development of specific strategies is needed to implement video telehealth services in complex healthcare systems, like the VA. This project conducted at 5 CBOCs was guided by the Promoting Action on Research Implementation in Health Services framework and used external facilitation to increase access to psychotherapy via video telehealth. Findings suggest that external facilitation is an effective and acceptable strategy to support providers as they establish clinics and make complex practice changes, such as implementing video telehealth to deliver psychotherapy.

System Improvements


Diagnostic errors are major contributors to harmful patient outcomes, yet they remain a relatively understudied and unmeasured area of patient safety. Although they are estimated to affect about 12 million Americans each year in ambulatory care settings alone, both the conceptual and pragmatic scientific foundation for their measurement is under-developed. Health care organizations do not have the tools and strategies to measure diagnostic safety and most have not integrated diagnostic error into their existing patient safety programs.

Further progress toward reducing diagnostic errors will hinge on our ability to overcome measurement-related challenges. In order to lay a robust groundwork for measurement and monitoring techniques to ensure diagnostic safety, we recently developed a multifaceted framework to advance the science of measuring diagnostic errors (The Safer Dx framework). We posit that the Safer Dx framework can be used by a variety of stakeholders including researchers, clinicians, health care organizations and policymakers, to stimulate both retrospective and more proactive measurement of diagnostic errors. The feedback and learning that would result will help develop subsequent interventions that lead to safer diagnosis, improved value of health care delivery and improved patient outcomes.


Health information technology (health IT) has potential to improve patient safety but its implementation and use have led to unintended consequences and new safety concerns. A key challenge to improving safety in health IT-enabled healthcare systems is to develop valid, feasible strategies to measure safety concerns at the intersection of health IT and patient safety. In response to the fundamental conceptual and methodological gaps related to both defining and measuring health IT-related patient safety, we propose a new framework, the Health IT Safety (HITS) measurement framework, to provide a conceptual foundation for health IT-related patient safety measurement, monitoring, and improvement. The framework proposes to integrate both retrospective and prospective measurement of HIT safety with an organization’s existing clinical risk management and safety programs. It aims to facilitate organizational learning, comprehensive 360 degree assessment of HIT safety that includes vendor involvement, refinement of measurement tools and strategies, and shared responsibility to identify problems and implement solutions. A long term framework goal is to enable rigorous measurement that helps achieve the safety benefits of health IT in real-world clinical settings.

- **Menon S, Murphy DR, Singh H, Meyer AN, Sittig DF.** Workarounds and Test Results Follow-up in Electronic Health Record-Based Primary Care. *Applied clinical informatics.* 2016 Jun 22; 7(2):543-59.

Electronic health records (EHRs) have potential to facilitate reliable communication and follow-up of test results. However, limitations in EHR functionality remain, leading practitioners to use workarounds while managing test results. Workarounds can lead to patient safety concerns and signify indications as to how to build better EHR systems that meet provider needs. We conducted a secondary data analysis of quantitative and qualitative data from a national survey of PCPs practicing in the Department of Veterans Affairs (VA) and explored the use of workarounds in test results management.
We used multivariate logistic regression analysis to examine the association between key sociotechnical factors that could affect test results follow-up (e.g., both technology-related and those unrelated to technology, such as organizational support for patient notification) and workaround use. We conducted a qualitative content analysis of free text survey data to examine reasons for use of workarounds. Workarounds to manage EHR-based test results are common, and their use results from unmet provider information management needs. Future EHRs and the respective work systems around them need to evolve to meet these needs.


This publication was cited in The John A. Hartford Foundation Change AGEn ts Initiative white paper “Patient-Centered Medical Homes and the Care of Older Adults: How comprehensive care coordination, community connections, and person-directed care can make a difference”. The paper provides a roadmap to guide primary care practices in how to enhance care for older, complex patients and their families.

- VHA Directive 1088

Dr. Hardeep Singh co-chaired a work-group under The Office of Patient Care Services (1OP4) to revise a previous directive (VHA Directive 2009-019) and to establish new national policy regarding communication of test results to providers and patients. Timely communication of test results is essential to ensuring safe and effective health care. Lack of timely follow-up of abnormal test results has been identified as a contributor to poor outcomes and can be a source of considerable anxiety to patients and families. The Directive cites 11 publications from center members and provides policies and guidance on how to improve timeliness of follow-up of test results and is consistent with VHA’s goals of providing Veterans with quality health care. The Directive is now in place at all 150-plus VA facilities and impacting care for millions of veterans.

- Explicit Quality Indicator Set for Measurement of Quality of Care in Patients with Cirrhosis

Dr. Fasiha Kanwal’s work in cirrhosis quality measure development led to implementation of a performance measure as part of the Centers for Medicare and Medicare Service pay for performance program (HCC screening). This measure was also selected to be part of the GI measure set in AHIP, which is a national association representing nearly 1300 member companies providing health insurance coverage to more than 200 million Americans.

Research Product


We applied a trigger in a repository hosting EHR data from all Department of Veterans Affairs health-care facilities and analyzed data from seven facilities. Using literature reviews and expert input, we refined previously developed trigger criteria designed to identify patients potentially experiencing delays in diagnostic evaluation of chest imaging flagged as “suspicious for malignancy.” The trigger then excluded patients in whom further evaluation was unnecessary (ie, those with terminal illnesses or with already completed biopsies). The criteria were programmed into a computerized algorithm. Reviewers examined a random sample of trigger-positive (ie, patients with trigger-identified delay) and trigger-negative (ie, patients with an abnormal imaging result but no delay) records and confirmed the presence or absence of delay or need for additional tracking (eg, repeat imaging in 6 months). Analysis included calculating the trigger’s diagnostic performance (ie, positive predictive value, negative predictive value, sensitivity, specificity). Application of triggers on “big” EHR data may aid in identifying patients experiencing delays in diagnostic evaluation of chest imaging results suspicious for malignancy.

METHODS AND PRODUCTS

- 2X2 Functional Health Literacy/Patient Activation Matrix (PI: LeChauncy Woodard)

The Functional Health Literacy/Activation Matrix tool was developed to provide personalized health information to clinicians to improve communication and coordination of self-management at the point of care. Functional Health Literacy (FHL) and Patient Activation levels are directly related to levels of motivation to participate in chronic disease self-management. By classifying veterans into high/low categories for both FHL and Patient Activation, the 2x2 Literacy/Activation Matrix provides a concrete description of a prototypical veteran in each quadrant and suggests corresponding actions and communication strategies for clinicians to uniquely target self-management plans with Veterans. By assessing Veterans’ levels of Functional Health Literacy (FHL) and Patient Activation a priori, providers were able to tailor and personalize their approach to collaborative goal-setting. This personalization helped optimize chronic disease self-management for a costly population of Veterans with treated with uncontrolled Type II Diabetes Mellitus.
Abnormal test results do not always receive timely follow-up, even when providers are notified through electronic health record (EHR)-based alerts. Follow-up to abnormal test results in the outpatient setting is an important safety issue. The Houston Patient Safety team developed and did preliminary usability testing on a prototype software system to detect abnormal test result alerts lacking documented follow-up, and to present context-specific reminders to providers called the Alert Watch And Response Engine (AWARE).

With VA HSR&D funding, we have developed an intervention to encourage guideline compliant practices concerning antibiotic use for urinary tract infections. Specifically we used audit and feedback plus a “fast and frugal” algorithm to substitute incorrect biases towards excessive use of antibiotics for prescribing decisions that were compliant with guidelines.

The CBOC Mental Health Grand Rounds program is a partnership between the South Central Mental Illness, Research and Clinical Center (SC MIRECC) and Veterans Health Administration (VHA), Employee Education System (EES). Nationally known speakers from the VA and academia are invited to talk about cutting edge topics & evidence-based practices that address the mental health care needs of rural Veterans. The monthly live meetings are made available to CBOCs and parent facilities in VISN 16 through the VA Knowledge Network. Select programs are archived for delayed viewing. The VA EES provides Continuing Education Credits for a number of healthcare disciplines.

A Checklist to Improve CPRS ‘View Alert’ Notifications: Recommendations for VA Facility Leadership and Staff was developed by the Houston Patient Safety team and a group of subject matter experts to assist VHA facilities in addressing the complexities involved in managing View Alerts. The Checklist provides facility leaders and staff with actionable, practical recommendations in a checklist-based format to ensure that View Alert notifications remain valuable for patient care.

The Houston Patient Safety team and a VA Workgroup comprised of subject matter experts developed a toolkit that offers practical guidance for facilities and clinical care teams to meet the requirements of VHA Directive 1088 for timely communication of test results to patients. The objectives of the toolkit are to: 1) describe useful practices, example workflows, and processes necessary to implement a safe, effective, and efficient method of timely outpatient test result communication to providers and patients; and 2) provide recommendations for system-level monitoring of outpatient test result communication to patients, and define the parameters and methodology involved in achieving this. Topics addressed include test result follow-up responsibilities, test result categories, CPRS View Alerts, team-based approaches to facilitate test result follow-up, vulnerable areas including handoffs in care, current methods to notify patients and measurement and reporting of test result notification.

Dr. Laura Petersen’s team created customized peer facility groups for VISNs. These peer facility groups allow Network managers to fairly compare their facilities (often of varying sizes, scopes of service, and missions) to facilities in other Networks. In the past 13 years, 11 VISNs have sought out our team to provide peer facility groups for quality and efficiency comparisons and to help with resource allocation. VISNs 11 and 12 have reported continuous use of the Houston-generated peer groups across their component facilities since 2004.

The EHR Trigger Tool Methodology was developed for mining EHR data to detect delays in diagnostic evaluation of cancer. The computerized algorithms and SQL code to mine this data are products of this methodology. This tool is related to the Houston CREATE Project.

A pair of manuals was developed to guide the structure and delivery of a motivational interviewing and behavioral health intervention to improve chronic disease self-management. The manual reviewed by patients guided the content of the group sessions and ensured that materials were easily understood, even for those veterans with limited health literacy. The clinician manual contained the whole of the veteran manual, with specific notations and instructions for leading veterans through the group sessions. Together the manuals provided assurance for successful delivery of and fidelity to the content.
• NLP/ Structured Data Element Integration in EHRs (PI: Salim Virani)

Natural Language Processing (NLP) was applied to the problem of ensuring that patients receive evidence-based medication prescribing for cardiovascular disease. The CREATE 4 project developed a method to incorporate NLP with structured data elements from the electronic health record to provide decision support to clinicians at the point of care. The effectiveness of this method in improving care for lipid disease will be tested in new HSRD IIR that will start in FY 17.

• SAFER Guides (PI: Hardeep Singh)

Dr. Singh's Houston Patient Safety Center team worked with researchers at the University of Texas Health Science Center at Houston's School of Biomedical Informatics as well as researchers at the Oregon Health and Science University, the research corporation Westat, and the Office of the National Coordinator for Health Information Technology (ONC), who sponsored the project, to develop self-assessment guides intended to help organizations proactively detect and reduce patient safety risks associated with electronic health records (EHRs).

This group collaboratively developed and beta tested guides for nine different areas that contain recommended practices for optimizing the safety and use of EHRs. These guides are freely available nationally and are being increasingly used by both organizations and vendors.

• VA Directive 1088 (PI: Hardeep Singh)

The Houston Patient Safety team worked with The Office of Patient Care Services (10P4) to revise the previous directive (VHA Directive 2009-019) to establish policy regarding communication of test results to providers and patients. VHA is committed to the timely communication of test results, which is essential to ensuring safe and effective health care. Timely communication of test results to patients is essential for high quality patient-centered care. Lack of timely follow-up of abnormal test results has been identified as a contributor to poor outcomes and can be a source of considerable anxiety to patients and families. Patient involvement in test result follow-up is fundamental to improve safety in this area and is consistent with personalized proactive patient-driven care. Patients have a right to access personal health information and expect to be notified of test results in a timely manner. Enhancing timeliness of follow-up of test results is consistent with VHA’s goals of providing Veterans with quality health care.

• IDENTIFY: Toolkit for Patient Identification (PI: Hardeep Singh)

A Toolkit for the use of health IT in patient identification designed to improve health IT safety. This toolkit is the result of a multi-stakeholder collaborative workgroup chaired by Dr. Hardeep Singh through the Partnership for Health IT Patient Safety. This is the second set of Safe Practice Recommendations for the use of health IT in patient identification designed to improve health IT safety. IDENTIFY stands for: 1) INCLUDE: electronic fields containing patient identification data should consistently use standard identifier conventions; 2) DETECT: use a confirmation process to help match the patient and the documentation; 3) EVALUATE: use standard attributes and attribute formats in all transactions to improve matching; 4) NORMALIZE: use a standard display of patient attributes across the various systems; 5) TAILOR: include distinguishing information enhancing identification on screens printouts, and those areas that require interventions; 6) INNOVATE: integrate new technologies to facilitate and enhance identification; 7) FOLLOW-UP: implement monitoring systems to readily detect identification errors; 8) YIELD: include high-specificity active alerts and notifications to facilitate proper identification.
AWARDS & HONORS

AMSPOKER
• Journal Editorial Board: Clinical Gerontologist
• Journal Editorial Board: Journal of Clinical Psychology in Medical Settings

BADR
• Co-Leader, Cancer Prevention and Population Sciences Program, Dan L. Duncan Cancer Center
• Co-Leader, Cancer Survivorship Disease Oriented Working Group, Dan L Duncan Cancer Center
• Core Member, Head and Neck Disease Oriented Working Group, Dan L Duncan Comprehensive Cancer Center
• Member, Editorial Board, Journal of Psychosocial Oncology
• Member, Scientific Review Group, ZCA1 TCRB-Y (J3) S, Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control
• Member, Editorial Board, Journal of Psychosocial Oncology

BUSH
• Associate Editor, Global Journal of Medicine and Public Health
• Assistant Editor, Journal of Vascular Surgery, Venous and Lymphatics
• Journal Editorial Board, Journal of Vascular Surgery, Cases
• Journal Editorial Board, Annals of Vascular Surgery
• Journal Editorial Board, World Journal of Surgery
• Texas Medical Association, Council on Medical Education
• American College of Surgeons, ACS Foundation, Secretary
• American College of Surgeons, ACS Foundation Board of Directors
• American College of Surgeons, ACS Foundation/ CFR Committee

American Venous Forum, Chair, Education Council
• Association of VA Surgeons, Membership Committee
• Society for Vascular Surgery, Document Oversight Committee
• Vascular and Endovascular Surgery Society, Board of Directors, Foundation for Vascular Innovation
• Assistant Editor, Journal of Vascular Surgery: Venous and Lymphatic Disorders
• Vascular surgery oral examiner, American Board of Surgery
• VA HSR Review Panel, Learning Healthcare Initiative Randomized Program Evaluation
• Assistant Editor, Journal of Vascular Surgery: Venous and Lymphatic Disorders
• Board of Directors, American Venous Forum
• Co-organizer/facilitator, Early Career Venous Specialist Session for American Venous Forum Annual Meeting, Poster session

DAVILA
• Member, National VA VIREC Steering Committee
• Member, Dan L Duncan Cancer Center
• Member, Biostatistician Recruiting Committee, Dan L Duncan Cancer Center
• Member, National VA HSR&D Service Working Group on Data Access, Storage, and Analysis
• Member, BCM Faculty Research and Fellowship Support Committee
• Member, BCM Faculty Appointments and Promotions Committee
• Director, Design and Analysis Program, Center for AIDS Research (CFAR) BCM
• Editorial Board, World Journal of Gastroenterology
• Editorial Board, World Journal of Clinical Oncology

GODWIN
• BCM, Master Facilitator, Team Launch
• Module Leader, Team Launch, Launch Pad Module 3, Applying Teamwork Tools, Part 2:
• Coaching, Conflict, Capabilities and Conditions
• BCM, Co-Module Leader, Team Launch, Launch Pad Module 4, Putting it all together!
• BCM, Department of Medicine, Vice Chair Group for Quality Improvement and Innovation,
• Evaluation Specialist
• Co-Director –Advanced Fellows National Curriculum Workgroup, Office of Academic Affiliations,
• United States Department of Veterans Affairs
• Co-leader, Team Projects, Healthcare Quality Track, Quality Enhancement Program, Baylor College of Medicine
• Team Member, Quality Enhancement Program Committee, Baylor College of Medicine
• Co-Director, VA Quality Scholars Coordinating Center, Center for Innovations in Quality, Effectiveness and Safety (IQuEst), Michael E. DeBakey VA Medical Center
• Co-Director, Health Professions Education Evaluation and Research Fellowship, Center for Innovations in Quality, Effectiveness and Safety (IQuEst), Michael E. DeBakey VA Medical Center
• Associate Director, Education Core, Center for Innovations in Quality, Effectiveness and Safety (IQuEst), Michael E. DeBakey VA Medical Center

HORSTMAN
• BCM, GME Faculty Workgroup in Continuous Quality Improvement
• Society of Hospital Medicine, Committee Member, Performance Measurement and Reporting Committee

HYSONG
• Member, Baylor College of Medicine Liaison Committee on Medical Education
• Member, Fulbright & Jaworski Faculty Excellence Award Review Committee
• Subject Matter Expert. U.S. Department of Veterans Affairs Modernization, Functional Review Panel
• Subject Matter Expert. VHA Physician Burnout Research Summit
• Associate Director, VA Quality Scholars Coordinating Center
• VA Scientific Merit Review Board (this is an undersecretary level appointment)
• Steering Committee Member, International Audit and Feedback Collaborative Meta-Laboratories
• Executive Advisory Board Member, Career Development Award Enhancement Initiative, Health Services Research and Development
• Review Panel: Annual Meeting of the Society for Industrial/Organizational Psychology – Program Committee
• National Scientific Review Panel: Department of Veterans Affairs Health Services Research and Development Scientific Merit Review Board – member
• Subject Matter Expert, VA Pay-for-Performance Initiative
• Steering Committee Member, International Audit and Feedback Meta-Laboratories
• Norton Rose Fulbright Faculty Excellence Award – Educational Leadership

MARTIN
• HSR&D Veteran Engagement Workgroup (national workgroup), Department of Veterans Affairs

MEYER
• Co-Chair The Society to Improve Diagnosis in Medicine’s Research Committee

MILLS
• Member – National Advisory Panel, Suicide Awareness in Veterans Exiting Community Living Centers, Department of Veterans Affairs
• Member – VA Decision Making Capacity Education Planning Group (national workgroup for VA Dementia Steering Committee) Department of Veterans Affairs
• Member, Public Policy Committee, Development Committee, Pioneer Network
• Member – Assessing Stage of Dementia and Decision-Making Capacity Workgroup Department of Veterans Affairs
• Member, Suicide Awareness in Veterans Exiting Community Living Centers National Advisory Panel, Department of Veterans Affairs
• Lead, Community Living Center Research Interest Group, Department of Veterans Affairs
• Member, Caring for Veterans with Serious Mental Illness in CLCs, Department of Veterans Affairs
• Member, Public Policy Committee, Development Committee, Pioneer Network
• Member, Houston Alliance to Address Dementia Leadership Council, Sheltering Arms Senior Services Division, Neighborhood Centers Inc.
• Member Leadership Council Evaluation Work Group, Direct Care Worker of the Year Award Committee, Care for Elders

MURPHY
• Medical Director, General Internal Medicine at Baylor Clinic
• Member, BCM Faculty Group Practice (FGP) Patient Quality & Safety Committee
• Director, Baylor St. Luke’s Medical Group Board of Directors
• Member, BCM Department of Medicine Quality Improvement and Innovations Vice Chair Group
• Member, BCM Faculty Group Practice (FGP) Business Intelligence Committee
• Member, BCM Faculty Group Practice (FGP) Pharmaceutical & Therapeutics (P & T) Committee
• Baylor College of Medicine Quality Improvement and Patient Safety, abstract review
NAIK
• Associate Editor & Editorial Board Member: Clinical Gerontology
• Standing member, Patient-Centered Outcomes Research Institute (PCORI)
• Member, Association of Specialty Professors (ASP)
• BCM, Longitudinal Ambulatory Care Education (LACE) Steering Committee
• BCM Faculty Committee on Medical Student Curriculum Standing Committee Member
• BCM Faculty Standing Committee on Research Member
• Texas Medical Center Health Policy Institute
• Vice Chair of Quality Improvement and Innovations, Alkek Department of Medicine, Baylor College of Medicine
• Director, Coordinating Center for VA Quality Scholars Program

PETERSEN, LAURA
• Associate Chief of Staff for Research, Michael E. DeBakey VA Medical Center
• Chair, Internal Advisory Committee, CPRIT Training Program, “Cancer Prevention Post-Graduate Training Program in Integrative Epidemiology
• Member, McNair Campus Steering Committee BCM Clinical Research Work Group
• Member, Boston/Bedford CHOIR VA HSR&D Center of Innovations Steering Committee
• Member, MEDVAMC Dean’s Committee (renamed Joint Executive Management Council in 2017)
• Member, MEDVAMC Quality, Safety, and Value (QSV) Board
• Member, Clinical Executive Board, MEDVAMC
• Member, Texas Medical Center Strategic Planning Initiative Steering Committee
• Member, Texas Medical Center Council of Research Directors
• Co-Chair, Texas Medical Center Clinical Research Design Team
• Health Policy Scholar, Center for Medical Ethics and Health Policy, BCM
• Member, Texas Medical Center Women's Leadership Council
• Chief, Health Services Research Section, Department of Medicine, Baylor College of Medicine
• VA HSR&D Quality Enhancement Research Initiative (QUERI) Strategic Advisory (formerly Research and Methodology) Committee
• Member, Association of Specialty Professors (ASP)
• Member, Executive Council, MEDVAMC
• Member, Texas Medical Center Health Policy Institute

PETERSEN, NANCY
• Chair, American Statistical Association, Committee on Membership Recruitment and Retention
• Member of abstract selection committee for American Heart Association
• Reviewer for HSRD/QUERI National Conference
• Member of abstract selection committee for American Heart Association

SANSGIRY
• Editorial Board Member, Journal of Pharmaceutical Analytics and Insights
• Member, Research & Development Committee, Veterans Affairs Medical Center
SINGH
• Member, VA Field Research Advisory Committee (FRAC)
• Appointed to the Harris County Medical Society (HCMS) Health Information Technology (HIT) Committee
• Nominated Member, National Quality Forum Improving Diagnostic Accuracy Committee
• Co-Chair, National Quality Forum Committee for Identification and Prioritization of HIT Patient Safety Measures
• Member, Editorial Board, International Journal for Quality in Health Care
• Associate Editor, Diagnosis
• Co-Chair, Closing the Referral Loop Expert Panel, National Patient Safety, Foundation – Institute for Healthcare Improvement, Boston, MA
• Patient Safety Expert of the Year 2017 – Texas award, Corporate Vision Magazine
• HHS Appointed Member, Clinical Laboratory Improvement Advisory Committee (CLIAC)
• Lead Research Consultant, VHA EPRP Measurement of Communication of Test Results Initiative
• International Journal for Quality in Health Care, Editorial Committee Board
• Steering Committee Member, Center for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, NHMRC Partnership Project: Delivering Safe and Effective Test Result Communication, Management and Follow-Up
• Editorial Advisory Board, The Joint Commission Journal on Quality and Patient Safety
• International Review Panel for India Alliance Fellowship, The Wellcome Trust/DBT India Alliance

TRAUTNER
• Ben and Margaret Love Foundation Bobby Alford Award for Academic Clinical Professionalism
• BCM, Director of Clinical Research, Department of Surgery, BCM
• Data Monitoring Committee member for VA Cooperative Studies Program #2004 “Microbiota or Placebo after Antimicrobial Therapy for Recurrent C. difficile at Home”
• Invited member of SHEA Public Policy and Government Affairs Committee
• Chair of Review Panel for 2017 Healthcare Innovations Seed Grants, Department of Medicine
• Member, Antimicrobial Stewardship Executive Committee, Houston Health Department
• Norton Rose Fulbright Faculty Excellence Award, Enduring Educational Materials
• Editorial Board Member, Journal of Surgical Research
• NIH NIDDK ZRG1 DKUS-R 90 study section (urology)

WHITE
• American Public Health Association, Epidemiology Section, National Research Meeting (Abstract reviewer)
• Texas Medical Center Digestive Diseases Center (DDC) at Baylor College of Medicine, Member (elected), NIDDK P30 site
• Dan L. Duncan Cancer Center at Baylor College of Medicine, Member (elected), NCI P30 site
• Center Translational Research in Inflammatory Disease (CTRiD) at the Michael E. DeBakey VA Medical Center, Associate Member (elected)
• BMC Gastroenterology (Ad hoc reviewer)
• Grant Reviewer, Pilot Research Grants, Dept. of Surgery, Michael E. DeBakey VA

WOODARD
• Elected BCM, Faculty Senate Secretary
• BCM, Academic Council Representative
• Deputy Editor, Journal of General Internal Medicine

RESEARCH FUNDING
• N. E. Hundt, PhD - Awardee, Houston. Integration of Peer Support Across the PTSD Continuum of Care. HSR&D. CDA 13-264. 10/1/2015-9/30/2020. Career Award. $269,100
• L. A. Petersen, MD, MPH - Center Director, Houston. Center for Innovations in Quality, Effectiveness and Safety (IQuESt). HSR&D. CIN 13-413. 10/1/2013-9/30/2018. Note: Funding renewed for another five years beginning 10/1/2018. HSR&D Core Funding. $2,166,300
• N. J. Petersen PhD - Co-Investigator, Houston. Adapting and Implementing the Blended Collaborative Care Model in CBOCs. HSR&D. CRE 12-310. 4/1/2016-9/30/2019. Data Collection. $7,952


• J. Davila PhD MS BS - PI, Houston. T. P. Giordano MD MPH - Co-Investigator, Houston F. Kanwal MBBS MD - Co-Investigator, Houston L. Martin PhD - Co-Investigator, Houston A. D. Naik MD BA - Co-Investigator, Houston S. Sansgiry PhD - Co-Investigator, Houston P. A. Richardson PhD MS BA - Biostatistician, Houston. Patient Priorities Care Pilot Study. VA GEC. 10/1/2017-9/30/2018. Data Collection. $70,000

• P. Kougias MD MSc - Co-Investigator, Houston. Alignement of Treatment Preferences and Repair Type for Veterans with AAA. HSR&D. IIR 15-085. 5/1/2015-4/30/2019. Data Collection. $2,473,983

• S. Virani MD - PI, Houston. Determining and targeting reasons for low statin use to improve guideline-concordant statin therapy in high-risk patients. HSR&D. IIR 16-072. 7/1/2017-6/30/2021. Start up Activities. $38,309

• J. A. Anderson PhD NP - Co-Investigator, Houston K. Godwin PhD MPH BS - Consultant, Houston. Telephone Assessment and Skill-Building Intervention for Informal Caregivers. HSR&D. NRI 12-415. 10/1/2012-9/30/2018. Data Collection. $186,528

• J. Cully PhD MEd - Co-Investigator, Houston S. Sansgiry PhD - Co-Investigator, Houston. Brief Psychotherapy for Depression in Primary Care: Identifying Successful Clinical Practices. HSR&D. PPO 16-106. 7/1/2017-6/30/2018. Start-Up Activities. $4,516

• L. A. Petersen MD MPH - Director, Houston. Training Program for Fellows (post Ph.D.s) at Houston COIN. HSR&D. TPP 97-004. 10/1/1996-9/30/2017. Supplemental Funding. $47,558


• H. Singh MD MPH - Awardee, Houston. Presidential Early Career Award for Scientists and Engineers. HSR&D. USA 14-274. 1/1/2014-12/31/2018. Career Award. $75,000

• L. A. Petersen MD MPH - Center Director, Houston. MC - Co-Investigator, Reno. ADMINISTRATIVE AND TRAVEL REIMBURSEMENTS - Field Based Science Advisors (FBSAs). HSR&D. 1/1/2000-9/30/2020. Administrative Funding. $24,432

• H. Badr, PhD - Principal Investigator, Houston. Psychosocial Intervention for Advanced Lung Cancer Patients and Caregivers. ACS. RSG 15-058. 7/1/2015-6/30/2019. Data Collection. $792,000

• H. Badr, PhD - Principal Investigator, Houston. A Psychosocial Intervention for the Caregivers of Advanced Lung Cancer Patients. NIH R01. CA 187143. 9/1/2014-8/31/2019. Data Collection. $2,473,983

• H. Badr, PhD - Principal Investigator, Houston. Using Implementation Science to Guide Survivorship Care Planning Efforts. DDCC. 6/1/2018-5/30/2019. Data Collection. $50,000

• K. Godwin, PhD - Principal Investigator, Houston. Leading Healthcare Improvement: Leadership Training for Applying Improvement Strategies, start-up funding. QUERI. QIS 18-201. 6/1/2018-9/30/2018. Data Collection. $56,275

• M. Horstman, MD - Principal Investigator, Houston. Optimizing Patient-Initiated Post-Discharge Care for Patients with Heart Failure. AHA. 17MCPRP3390011. 1/1/2017-12/31/2018. Data Collection. $70,000

• A. Naik, MD - Principal Investigator, Houston. Patient Priorities Care Pilot Study. VA GEC. 10/1/2017-9/30/2018. Data Collection. $100,000

• A. Naik, MD - Principal Investigator, Houston. Integrating Patient Priorities Care and Social Work Case Management. VA ORH OSW. 10/1/2017-9/30/2018. Data Collection. $230,000

• A. Naik, MD - Principal Investigator, Houston. Coordinating Center for the VA Quality Scholars Program. VA OAA. 7/1/2014-9/30/2019. Fellowship. $345,000

• F. Kanwal, MD - Co-Principal Investigator, Houston; A. Naik, MD - Co-Principal Investigator, Houston. Patient Centered Approach to Advanced Liver Disease. HSR&D. HX 16-075. 5/1/2018-9/30/2019. Data Collection. $980,000


• A. Naik, MD - Principal Investigator, Houston. Primary Specialty Care Redesign (Carealign) Implementation. Hartford Foundation. 1/1/2015-10/1/2018. Data Collection. $108,806
• A. Naik, MD - Principal Investigator, Houston. Improving Veteran Transitions from VA Community living Centers to the Community. VA CDA. IK2RX001241. 7/1/2014-6/30/2019. Data Collection

• A. Naik, MD - Principal Investigator, Houston. VA Advanced Fellowships in HSR. VA OAA. 10/1/2013 - 9/30/2018. Data Collection. $339,000

• A. Naik, MD - Principal Investigator, Houston. Houston BD-STEP program. VA OAA/NCI. 10/1/2015-9/30/2017. Fellowship. $180,000

• N. Massarweh MD – Principal Investigator; L. Petersen, MD, MPH - Co-Investigator; P. Richardson, PhD - Co-Investigator. Comparative Effectiveness of Alternative Strategies for Monitoring Hospital Surgical Performance. HSR&D. HX 17-066. 5/1/2017-4/30/2020. Data Collection. $407,802

• S. Virani, MD, PhD – Principal Investigator; L. Martin, PhD - Co-Investigator; L. Petersen, MD, MPH - Co-Investigator; P. Richardson, PhD - Co-Investigator; R. Street, PhD - Co-Investigator. Determining and targeting reasons for low statin use to improve guideline-concordant statin therapy in high-risk patients. HSR&D. HX 16-072. 7/1/2017-6/30/2021. Data Collection. $1,097,703


• B. Trautner, MD, PhD – Principal Investigator; L. Petersen, MD, MPH - Co-Investigator; S. Hysong, PhD - Co-Investigator; J. Kramer, PhD - Co-Investigator; A. Naik, MD - Co-Investigator. Less is More: Improving Antimicrobial Stewardship for Asymptomatic Bacteriuria. HSR&D. HX-16-025. 2/1/2018-1/31/2019. Data Collection. $1,095,924

• J. Davila PhD MS BS - Co-Investigator. Optimizing Alphafetoprotein as a Biomarker for Detecting Hepatocellular Carcinoma. NIH NCI R01. R01. 4/1/2015-3/31/2019. Data Collection. $1,200,000

• J. Davila PhD MS BS - Principal Investigator. A Multi-level Intervention to Improve Cancer Care for Hepatocellular Carcinoma. HSR&D. 10/1/2015-9/30/2019. Data Collection. $1,997,000

• J. Davila PhD MS BS - Co-Director. National Cancer Institute/Department of Veterans Affairs Big Data Fellowship in Cancer Research. NCI/VA. 10/1/2015-9/30/2018. Fellowship. $40,000

• J. Davila PhD MS BS - Principal Investigator. QUERI-OAA Centers of Excellence in Primary Care Training Program: Participant Survey. VA QUERI OAA. 10/1/2014-9/30/2018. Fellowship. $50,000

• J. Kramer, PhD - Co-PI. Effectiveness of Zepatier™ (elbasvir (EBR)/grazoprevir (GZR)) co-administered with Ribavirin (RBV) treatment for 16 weeks duration in chronic hepatitis C virus (HCV) genotype 1a (GT1a)-infected patients with selected baseline NSSA resistance associated substitutions: A retrospective observational analysis of the US Veterans Health Administration (VHA) National Data. Merck & Co. 1/1/2018-12/31/2018. Data Collection. $261,903

• D. White, PhD - Principal Investigator. Sex hormones and HCV- related liver disease progression. VA CSR&D. CX 001430. 7/1/2017-6/1/2021. Data Collection. $950,000

• D. White, PhD - Co-Investigator. Identifying Novel Pharmacologic Risk factors for Common Malignancies In Individuals with Well-controlled HIV Infection (PQ3). NCI R01. CA 206479. 7/1/2016-6/31/2020. Data Collection. $1,968,930


• T. Giardina, PhD – Principal Investigator; H. Singh, MD – Co-Investigator. Engaging Patients in Diagnostic Error Reporting. AHRQ K01. HS 025474. 9/1/2018-8/31/2023. Data Collection. $766,326

PUBLICATIONS & PRESS


• Badr H. Author’s response to Porter and Keefe letter to the editor regarding ‘new frontiers in couple-based interventions in cancer care: refining the prescription for spousal communication’. Acta Oncol. 2018 May;57(5):695-697


• Barrera T, McIngvale E, Lindsay J, Walder A. Obsessive-compulsive disorder in the Veterans Health Administration. *Psychol Serv.* 2018 May 24. [Epub ahead of print]


• Kwan J, Singh H. General Internists in Pursuit of Diagnostic Excellence in Primary Care: a #ProudToBeGIM Thread That Unites Us All. J Gen Intern Med. 2018 Apr;33(4):395-396


• Naik A, El-Serag H. Endoscopic ablation of low-grade dysplasia in Barrett’s esophagus: Have all the boxes been checked for us to move on? Gastrointest Endosc. 2017 Jul;86(1):130-132


• Sittig D, Belmont E, Singh H. Improving the safety of health information technology requires shared responsibility: It is time we all step up. Healthc (Amst). 2018 Mar;6(1):7-12


• Trautner B. Fluoroquinolones for urinary tract infection and within-household spread of resistant Enterobacteriaceae: the smoking gun. *Clin Microbiol Infect.* 2018 Apr 9. [Epub ahead of print]


• Tulsky J, Beach M, Street R Jr, et al. A Research Agenda for Communication Between Health Care Professionals and Patients Living With Serious Illness. *JAMA Intern Med.* 2017 Sep 1;177(9):1361-1366


• Virani S, Kennedy K, Petersen L, et al. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. *Circ Cardiovasc Qual Outcomes.* 2018 May;11(5):e004652


AWARDS & HONORS

- **Brenner**: European Society of Gene and Cell Therapy Outstanding Achievement Award
- **Ellis**: Forbes Physician Honor Roll December 2017
- **Kaochar**: American Association of Cancer Research (AACR) Prostate 2017 Scholar-in-Training Award
- **Kaochar**: American Association of Cancer Research (AACR) Women in Cancer Research Award
- **Kaochar**: 2018 Prostate Cancer Foundation Young Investigator Award
- **Heslop**: President American Society of Gene and Cell Therapy
- **Lulla**: ASH Scholar Award 2017
- **Miller-Chism**: ASH Medical Educators Institute Scholar
- **Miller-Chism**: Baylor Oncology Fellowship; Best Clinic Experience Teaching of the Year, for Hematology Clinic; 2017/18
- **Mims**: Houstonia Magazine Top Doctor
- **Mims**: Baylor Oncology Fellowship; Best Clinic Experience Teaching of the Year, for Hematology Clinic; 2017/18
- **Musher**: “Top Doctor” Harris Health System
- **Musher**: Baylor Oncology Fellowship; Best Clinic Experience Teaching of the Year, for GI Oncology Clinic; 2017/18
- **Musher**: Houstonia Magazine Top Doctor
- **Nangia**: Oncology Times Honorable Mention for Study Validating Safety and Efficacy of Scalp Cooling Technology
- **Osborne**: 2018 AACR Distinguished Award for Extraordinary Scientific Achievement and Leadership in Breast Cancer Research
- **Rivero**: Center of Excellence in Healthy Equity, Training, and Research (COE) Junior Faculty Scholar 2017-2018 Cohort
- **Sabichi**: Castle Connolly Top Doctors: 2017
- **Sada**: Early Career Faculty Award for Excellence in Patient Care
- **Smaglo**: Baylor Oncology Fellowship; Best Clinic Experience Teaching of the Year, for GI Oncology Clinic; 2017/18
- **Smaglo**: Duncan Cancer Center Early Phase Clinical Research Award
- **Sosa**: That’s The Way Player of the Month Award
• **Sosa**: Center of Excellence in Healthy Equity, Training, and Research (COE) Junior Faculty Scholar 2018-2019 Cohort
• **Udden**: Chair, American Board of Internal Medicine Hematology Board Baylor Oncology Fellowship; Best Clinic Experience Teaching of the Year, for Hematology Clinic; 2017/18
• **Yellapragada**: Star Faculty Award for Excellence in Patient Care
• **Yellapragada**: Baylor Hematology Fellows Award for Teaching in Hematology

PROFESSIONAL ORGANIZATIONS
• **Heslop, H**: American Society of Gene and Cell Therapy President
• **Heslop, H**: American Society of Hematology Member - Nominating Committee
• **Heslop, H**: Foundation for Accreditation of Cell Therapy President
• **Miller-Chism, C**: American Society of Hematology - Medical Educators Institute
• **Miller-Chism, C**: American Society of Hematology - Member, Question writing committee for ASH SAP
• **Mims, M**: American Society of Hematology - Member, ASH Committee on Training
• **Mims, M**: American Society of Hematology - Chair, ASH Training Awards Committee
• **Mims, M**: American Society of Hematology - Chair, ASH Research Training Award for Fellows Study Section
• **Mims, M**: American Society of Hematology - Director K2R Program for ASH
• **Mims, M**: American Society of Hematology - Member ASH Awards Committee
• **Mims, M**: American Society of Hematology - Member ASH Ambassador Program Faculty
• **Mims, M**: American Society of Clinical Oncology - Session Chair, Prostate Cancer 2018 Annual Meeting
• **Mims, M**: American Society of Cancer Institutes Physician Clinical Leadership Initiative Steering Committee Member
• **Mims, M**: Baylor Principal Investigator for Southwest Oncology Group - Member GU Oncology Committee of the Southwest Oncology Group
• **Mims, M**: Baylor Principal Investigator for Southwest Oncology Group - Member of SWOG Board of Governors
• **Mims, M**: Co-Chair Planning Committee for BCM/MDACC Comprehensive Board Review in Hematology and Medical Oncology
• **Mitsiades, N**: Southwest Oncology Group - Member GU Oncology Committee
• **Musher, B**: Southwest Oncology Group - Member GI Oncology Committee
• **Rivero, G**: Southwest Oncology Group - Member Leukemia Committee
• **Sabichi, A**: Southwest Oncology Group - Member Lung Cancer Committee
• **Sada, Y**: Southwest Oncology Group - Member GI Oncology Committee
• **Smaglo, B**: Southwest Oncology Group - Member GI Oncology Committee
• **Sosa, R**: American Society of Hematology - Member, Question writing committee for ASH SAP
• **Udden, M**: American Board of Internal Medicine - Chair, Hematology Board
• **Yen, A**: Southwest Oncology Group - Member GU Oncology Committee

RESEARCH FUNDING
• **Arber Barth, C**: Genetically Engineered Virus-Specific T Cells To Prevent And Treat Relapse And Infection After Allogeneic Hematopoietic Stem Cell Transplantation Leukemia & Lymphoma Society 6490-16 (10/1/2015 - 9/30/2018)
• **Brenner, M**: Engineering T Cells To Ensure Specificity For Tumor Cells And Their Environment Cancer Prevention & Research Institute Of Texas (CPRIT) RP160345 (9/15/2016 - 2/28/2019)
• **Brenner, M**: Amendment/NCE - To Extend Agreement- Followup For Lokon (Sample Analysis For The Clinical Trial) Lokon Pharma Ab (10/15/2017 - 10/14/2018)
• **Carrum, G**: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase Iii Trial Of The Flt3 Inhibitor Gilteritinib Administered As Maintenance Therapy Following Allogeneic Transplant For Patients With Flt3-Itd Aml Bmt Ctn Protocol #1506/Astellas Astellas Pharma Global Development, Inc. Protocol Rider 1501 (Amend1) (12/7/2017 - 8/31/2018)
• **Chamness, G**: NRG Oncology Biospecimen Bank National Institutes Of Health (NIH) U24-CA196067-04 (4/1/2015 - 3/31/2019)
• **Chamness, G**: A Phase II Clinical Trial Platform Of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) In Rectal Cancer (The “G1002 Project” National Surgical Adjuvant Breast And Bowel Project (NSABP) NRG-G1002 (11/1/2016 - 10/31/2018)
• **Chamness, G**: NCE - NSABP B47 Sub Study NIH: National Institutes Of Health NONE-NSABP (NCE) (8/1/2017 - 12/31/2017)
• **Creighton, C**: Mira / Core 2 - Integrated Analysis Of The Lung Cancer Microenvironment Cancer Prevention & Research Institute Of Texas (CPRIT) RP120713-C2 Year 6 (Year 1: 8/31/2017 - 8/31/2018)
Research Funding continued

- **Creighton, C:** BC150251: A Novel Preclinical Model Of Dormant Metastatic ER+ Breast Cancer Department Of Defense W81XWH-16-1-0044 (2/1/2018 - 1/31/2019)

- **Creighton, C:** Regulation Of Lung Cancer Metastasis By Zeb1 National Cancer Institute (NCI) R01-CA181184-04 (7/1/2014 - 6/30/2018)

- **Ellis, M:** Alternate Trial: A Neoadjuvant Biomarker Approach For Estrogen Receptor Positive Breast Cancer Breast Cancer Research Foundation BCRF-16-102 (10/1/2014 - 9/30/2018) $11,544


- **Ellis, M:** 16-Month NCE BCRF PDX Founders Fund - Investigation Of The Genomics And Biology Of Metastasis Using Patient-Derived-Xenografts (PDX) Breast Cancer Research Foundation ELFF-16-003 - NCE (amend5 MSK) (6/1/2018 - 6/30/2019)

- **Ellis, M:** BR003-A Randomized Phase III Trial Of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed By Weekly Paclitaxel With Or Without Carboplatin In Node-Positive Or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Breast Cancer Research Foundation BCRF-16-042 (10/1/2014 - 9/30/2018)

- **Ellis, M:** Established Investigator Recruit - Accelerating Breast Cancer Translational Medicine Through Genomics And Proteomics Cancer Prevention & Research Institute Of Texas (CPRIT) RR140033 (6/1/2014 - 5/31/2019)

- **Ellis, M:** Integrated Translational Genoproteomics Center At Washington University (Wu-18-361) National Institutes Of Health (NIH) U01-CA180860 (3/1/2014 - 2/28/2019)

- **Ellis, M:** NRG Oncology Network Group Operations Center National Institutes Of Health (NIH) U10-CA180860-05 (3/1/2014 - 2/28/2019)

- **Ellis, M:** Microscaled Proteogenomics For Cancer Clinical Trials (Cptac) National Institutes Of Health (NIH) U01-CA214125 -02 (Amend2 Bi) (6/1/2017 - 5/31/2022)

- **Ellis, M:** Somatic Mutation And Recurrence Risk For Early Stage Estrogen Receptor Positive Breast Cancer Susan G Komen Breast Cancer Foundation SAC170059 (YR2- WUSTL) (2/20/2017 - 2/19/2019)

- **Ellis, M:** Direct Regulation Of Estrogen Receptor Transcriptional Activity By Nf1 United States Army Medical Research & Materiel Command ( Department Of Defense ) W81XWH-16-1-0539 (9/30/2016 - 9/29/2019)

- **Fuqua, S:** Role Of Esr1 Mutations In Breast Cancer Progression Breast Cancer Research Foundation BCRF-16-056 (10/1/2014 - 9/30/2018)

- **Fuqua, S:** Mira/Project 2: Characterization Of Nuclear Receptor And Co-Regulator Expression And Function In Breast Cancers Cancer Prevention & Research Institute Of Texas (CPRIT) RP120732-P2 Attach F2 (8/31/2012 - 8/30/2018)

- **Fuqua, S:** Year 4 NCE: Effects Of Hormonal Therapy On Subclonal Evolution Of Breast Tumors With Esr1 Mutations Cancer Prevention & Research Institute Of Texas (CPRIT) RP150440 (3/1/2015 - 8/31/2018)

- **Fuqua, S:** Integration Of Predictive Biomarkers Of Hormone Resistance In Breast Cancer National Cancer Institute (NCI) R01-CA072038-19 (9/1/1996 - 8/31/2019)

- **He, H:** Role Of Gata2 In Prostate Cancer Development American Cancer Society RSG-13-061-01 (1/1/2015 - 12/31/2018)

- **Heslop, H:** Enhancing T Cell Therapy of Cancer National Institutes Of Health (NIH) SP01CA94237 (2/1/2017-1/31/2019)

- **Heslop, H.:** Cancer Cell and Gene Therapy Program (CCSG) National Institutes Of Health (NIH) 5P01CA125123 (7/1/2007-6/30/2019)

- **Heslop, H:** Translational Research In Lymphoma (SPORE) National Institutes Of Health (NIH) P50-CA126752 (4/1/2007-8/31/2022)

- **Heslop, H:** Training In Cell and Gene Therapy National Institutes of Health (NIH) ST32HL092332 (7/1/2003-7/31/2019)

- **Hoyos, V:** Recruitment Of First-Time, Tenure Track Faculty Member–Dr. Valentina Hoyos Velez (RFT) Cancer Prevention & Research Institute Of Texas (CPRIT) RR170024 (8/31/2017 - 8/30/2022)

- **Jiralerspong, S:** NCE 2- Metformin For The Treatment Of Breast Ductal Carcinoma In Situ (DCIS) Susan G Komen Breast Cancer Foundation CCR13263802 (8/27/2017 - 8/26/2018)

- **Kavuri, M:** BC170466: Targeting Ddr1 Aberrations In Metastatic Er+ Breast Cancer Department Of Defense Congressionally Directed Medical Research Programs W81XWH-18-1-0040 (2/15/2018 - 2/14/2019)

- **Kavuri, M:** Kinome Analysis To Rationalize Targeting HER2 And DDR1 Breast Cancer Mutations Susan G Komen Breast Cancer Foundation CCR16380599 (9/15/2016 - 9/14/2019)

- **Kavuri, M:** BC170276P1 Mismatch Repair Loss Renders Er+/Her2- Breast Cancer Susceptible To Her2/3 Inhibition United States Army Medical Research & Materiel Command ( Department Of Defense ) W81XWH-18-1-0035 (3/1/2018 - 2/28/2021)
• **Lin, W:** NCE: BC133678 Targeting A Convergent Point Of Multiple Oncogenic Pathways In Breast Cancer, A New Paradigm For Targeted Therapy Department Of Defense Congressionally Directed Medical Research Programs W81XWH-14-1-0339 (9/30/2017 - 9/29/2018)

• **Lin, W:** The ATM/E2F1 Pathway In Dna Damage And Growth Control National Institutes Of Health (NIH) R01-CA100857-14 (3/1/2003 - 2/28/2020)

• **Lin, W:** MPI-Novel Therapeutics For Targeting Checkpoint Dysfunction In Cancer National Institutes Of Health (NIH) R01-CA203624-02 (12/1/2016 - 11/30/2021)

• **Lin, W:** BCM Oncology Scholars Training Program The National Institutes Of Health T32-CA174647-04 (8/1/2014 - 7/31/2019)

• **Lulla, P:** T Cell Therapy For AML American Society For Blood & Marrow TR (7/1/2016 - 6/30/2019)

• **Lulla, P:** Safety And Efficacy Of Adoptively Transferred Multitaa Specific T Cells To Patients With Multiple Myeloma American Society Of Hematology (7/1/2017 - 6/30/2020)

• **Lulla, P:** Adoptively Transferred Multitaa-Specific T Cells As Treatment Or Prevention Of Aml Relapse Post-Allogeneic Stem Cell Transplant Leukemia Texas, Inc. (7/1/2016 - 6/30/2018)

• **Mamonkin, M:** Increasing Safety Of Cds Car For The Treatment Of T Cell Malignancies American Society Of Hematology (7/1/2016 - 6/30/2019)

• **Mitsiades, N:** Ubiquitination-Based Control Of Transcriptional Activity In Prostate Cancer American Cancer Society RSG-14-218-01-TBG (1/1/2015 - 12/31/2018)

• **Mitsiades, N:** PC160445: A First-In-Field Approach To Target A Previously Undruggable Oncogene Family In Prostate Cancer Department Of Defense Congressionally Directed Medical Research Programs W81XWH-17-1-0298 (7/1/2017 - 6/30/2020)

• **Mitsiades, N:** Developing Spop Inhibitors Diana Helis Henry Medical Research Foundation Cancer Cancer Program H-2017 (4/1/2017 - 3/31/2019)

• **Mitsiades, N:** Regulation Of Uveal Melanoma Cell Fate By Mitf Via The PKC Pathway National Cancer Institute (NCI) R01-CA193321-03 (8/1/2015 - 7/31/2020)

• **Mitsiades, N:** A Novel Therapeutic Target For Prostate Cancer Sidney Kimmel Foundation For Cancer R SKF-15-053 (7/1/2015 - 6/30/2018)

• **Nangia, J:** Breast Cancer Research And Education Program AstraZeneca (9/7/2017 - 9/6/2018)

• **Nangia, J:** Nanostring Educational Grant Nanostring Technologies NanoString (8/1/2017 - 7/31/2018)

• **Nangia, J:** Educational Retreat Pfizer, Inc (9/1/2016 - 8/31/2018)


• **Osborne, C K:** Baylor College Of Medicine Cancer Center National Cancer Institute (NCI) P30-CA125123-11 (7/1/2007 - 6/30/2020)

• **Osborne, C K:** P30 Administrative Supplement For P30 Cancer Center Support Grants To Support Research In Canine Immunotherapy Via Collaboration Of Nci-Designated Cancer Centers And Veterinary Medical Colleges (Identifying Neo-Epitopes For Cd8+ T Cells In Dog Tumors) National Cancer Institute (NCI) P30-CA125123-1054 (7/1/2017 - 12/31/2018)

• **Osborne, C K:** RFA: NCI Moonshot Initiative: Administrative Supplements For The P30 Cancer Center Support Grant To Develop Tobacco Cessation Treatment Capacity And Infrastructure For Cancer Patients National Cancer Institute (Nci) P30-CA125123 (7/1/2017 - 6/30/2018)

• **Osborne, C K:** 11S2 Underrepresented High School And Undergraduate Student Research Experiences (Cure) National Cancer Institute (NCI) P30-CA125123-11S2 (7/1/2017 - 6/30/2018)

• **Osborne, C K:** 11S1 Administrative Supplement To Strengthen NCI-Supported Community Outreach Capacity Through Community Health Educators (CHES) Of The National Outreach Network (NON) National Cancer Institute (NCI) P30-CA125123-11S1 (7/1/2017 - 6/30/2018)

• **Osborne, C K:** To Fund Year 11 Administrative Supplement Not Affiliated With The Experimental Therapeutic Clinical Trials Network (Etcnt) To Support Participation In The Etcnt Prior Year: 10 ( Brain 23664-S37) National Cancer Institute (NCI) P30-CA125123 (7/1/2017 - 6/30/2018)

• **Osborne, C K:** 11S3 : Improving Diagnostic Accuracy And Supportive Care For Children With Burkitt Lymphoma: Laying A Foundation For Treatment Trials In Sub-Sahara Africa National Cancer Institute (NCI) P50-CA125123 (7/1/2017 - 6/30/2018)

• **Osborne, C K:** Translational Research In Breast Cancer (SPore) National Institutes Of Health (NIH) P50-CA186784-04 (9/1/2014 - 8/31/2019)

• **Osborne, C K:** Amendment 2 To The Ventana Collaborative Research Agreement Ventana Medical Systems, Inc (1/24/2018 - 6/30/2018)

• **Ramos, C:** Amendment: HPV 16/18 E6/E7-Specific T Cells For Treatment Of HPV-Associated Cancers Tessa Therapeutics Pte. Ltd. (5/1/2018 - 4/30/2019)

• **Rimawi, M:** Pink For Life- Expanding And Improving Breast Cancer Care And Prevention In Minority And Economically Disadvantaged Women Avon Foundation 05- 2017-002 (7/1/2017 - 6/30/2018)
Research Funding continued


- **Rimawi, M:** BC161327: A New Paradigm For De-Escalation Of Treatment In Her2 Positive Breast Cancer: Revolutionizing Care With More Effective And Less Toxic Therapy. Department Of Defense Congressionally Directed Medical Research Programs W81XWH-17-1-0579 (9/15/2017 - 9/14/2020)

- **Rimawi, M:** Biological Samples For: A Phase II Randomized Study Evaluating The Biological And Clinical Effects Of The Combination Of Palbociclib With Letrozole As Neoadjuvant Therapy In Women With Estrogen Receptor-Positive Primary Breast Cancer” (The “Fb-11 Study) Pfizer, Inc Service Agreement (10/20/2017 - 10/19/2019)


- **Schiff, R:** 2017-2018: Mechanisms Of Resistance To HER2 And ER-Targeted Therapies And Novel Therapeutic Strategies Breast Cancer Research Foundation BCRF-17-143 (10/1/2017 - 9/30/2018)

- **Schiff, R:** Pre-Clinical Investigation Of Brd4 Inhibitors In Hormone-Insensitive Er+ Breast Cancer Gilead Sciences, Inc. (12/15/2017 - 2/17/2019)

- **Schiff, R:** NIK As Attractive Drug Target For Intractable Breast Cancer” (SR01CA18136) National Institutes Of Health (NIH) ROI-CA181368-04 (9/1/2014 - 8/31/2018)

- **Schiff, R:** Evaluate The Therapeutic Efficacy Of Neratinib In Combination With Trastuzumab For HER2-Positive Breast Cancer Puma Biotechnology Inc SRA (1/1/2018 - 12/31/2019)

- **Schiff, R:** BC133693P1: Targeting Gpr110 In Her2-Overexpressing Breast Cancer United States Army Medical Research & Materiel Command (Department Of Defense ) W81XWH-14-1-0341 (9/30/2014 - 9/29/2018)

- **Schiff, R:** Harvey Amendment BC133693P1: Targeting GPR110 In Her2- Overexpressing Breast Cancer United States Army Medical Research & Materiel Command (Department Of Defense ) W81XWH-14-1-0431 (4/26/2014 - 9/30/2018)

- **Schiff, R:** BC161327P1 : A New Paradigm For De-Escalation Of Treatment In HER2 Positive Breast Cancer: Revolutionizing Care With More Effective And Less Toxic Therapy. United States Army Medical Research & Materiel Command (Department Of Defense ) W81XWH-17-1-0580 (9/15/2017 - 9/14/2020) $692,420

- **Sosa, I R:** Resveratrol In Metabolic Syndrome: Effect On Platelet Hyper-Reactivity And Hdl Lipid Peroxidation American Heart Association Inc 13FTF174000111 (7/1/2014 - 6/30/2018)

- **Suzuki, M:** Combining Ad Gene Therapy With Car Ad-Specific T-Cell Therapy For HNSCC Concern Foundation (7/1/2016 - 6/30/2018)

- **Suzuki, M:** Amendment - Combinatorial Treatment With Armed Oncolytic Ad Gene Therapy And Car T-Cell Therapy For Squamous Cell Carcinoma Of The Head And Neck (HNSCC) Tessa Therapeutics Pte. Ltd. SRA Amendment 1 (1/1/2018 - 12/31/2018) $100,000

- **Vera Valdes, J:** Engineered T Cell Therapy For Advanced Prostate Cancer American Cancer Society MRSG-14-19701-LIB (1/1/2015 - 12/31/2018)

- **Watanabe, N:** Cook Regentec LLS SRA Cook Regentec Testing Agreement (9/21/2017 - 9/20/2018)

Cash Awards

- **Carrum, G:** Astellas Pharma Global Development , Inc. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial To Evaluate The Protective Efficacy And Safety Of A Therapeutic Vaccine, Asp0113, In Cytomegalovirus (Cmv)-Seropositive Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

- **Carrum, G:** National Institutes Of Health (NIH) U10HL069294 Prospective Multi-Center Cohort For The Evaluation Of Biomarkers Predicting Risk Of Complications And Mortality Following Allogeneic HCT, BMT CTN 1202

- **Carrum, G:** NIH: National Institutes Of Health U10CA180888 **Swog Purchase Service Agreement: Subaccount For Participation In Nci Nctn Clinical Trials** CTSU - H-39725 BMT CTN 1201 A051301 Alliance DLBC - A Randomized Double-Blind Phase IIIi Study Of Ibrutinib During And Following Autologous Stem Cell Transplantation Versus Placebo In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Of The Activated B-Cell Subtype

- **Chamness, G:** NIH: National Institutes Of Health NSABP B47 Sub Study

- **Heslop, H:** Cell Medica, Ltd Citadel-A Phase 2 Open Label Study To Investigate The Efficacy Of Autologous Ebv-Specific T-Cells For The Treatment Of Patients With Aggressive Extranodal Nk/T Cell Lymphoma (ENKTCL), CM-2013-01

- **Heslop, H:** Cell Medica, Ltd Prevale- Phase I Study Combining Nivolumab With Epstein Barr Virus Specific T Cells (Eb-Vsts) In Relapsed/Refractory Ebv Positive Lymphoma Patients

- **Kamble, R:** National Institutes Of Health (NIH) 2U10HL069294 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant To Hypomethylating Therapy Or Best Supportive Care In Patients Aged 50 - 75 With Intermediate-2 And High Risk Myelodysplastic Syndrome, BMT CTN 1102

- **Lulla, P:** National Institutes Of Health (NIH) U01HL128566-01 Year 3 Amendment - BMT CTN 1503: Hematopoietic Stem Cell Transplantation For Young Adults With Sickle Cell Disease
• **Lulla, P:** Tessa Therapeutics Pte. Ltd. A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First-Line Treatment For Advanced Nasopharyngeal Carcinoma Patients

• **Mims, M:** Aveo Pharmaceuticals A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study To Compare Tivozanib Hydrochloride To Sorafenib In Subjects With Refractory Advanced Renal Cell Carcinoma

• **Mims, M:** Bristol-Myers Squibb 1 Ca204006: A Phase 3, Randomized, Open Label Trial Of Lenalidomide/Dexamethasone With Or Without Elotuzumab In Subjects With Previously Untreated Multiple Myeloma

• **Mims, M:** Celgene Corporation Cc-5013-Nhl-008: A Phase 3B Randomized Study Of Lenalidomide (Cc-5013) Plus Rituximab Maintenance Therapy Followed By Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance In Subjects With Relapsed/Refractory Follicular, Marginal Zone Or Mantle Cell Lymphoma

• **Mims, M:** Imclone Systems Incorporated Cp02-0452: A Randomized Phase III Study Of Docetaxel Or Pemetrexed With Or Without Cetuximab In Patients With Recurrent Or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy

• **Mims, M:** Novartis Pharmaceuticals Corp 1 Rad001N2301: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Of Rad001 Adjuvant Therapy In Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Of Rad001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-Line Rituximab-Chemotherapy

• **Mims, M:** Prostate Cancer Clinical Trials Consortium, Llc Prostate Cancer Outcomes: An International Registry To Improve outcomes In Men With Advanced Prostate Cancer (Ironman)

• **Musher, B:** Aduro Biotech, Inc. A Phase 2, Open-Label Evaluation Of Crs-207 And Pembrolizumab In Adults With Recurrent Or Metastatic Gastric, Gastroesophageal Junction, Or Esophageal Adenocarcinomas

• **Musher, B:** Boston Biomedical, Inc Canstem111P: A Phase III Study Of Bbi-608 Plus Nab-Paclitaxel With Gemcitabine In Adult Patients With Metastatic Pancreatic Adenocarcinoma

• **Musher, B:** Celgene Corporation Abi-007-Panc-003 A Phase 3, Multicenter, Open-Label, Randomized Study Of Nab®-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone As Adjuvant Therapy In Subjects With Surgically Resected Pancreatic Adenocarcinoma

• **Musher, B:** Eli Lilly And Company A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Of Capecitabine And Cisplatin With Or Without Ramucirumab As First-Line Therapy In Patients With Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma (Rainfall)

• **Musher, B:** Halozyme Therapeutics A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of Pegylated Recombinant Human Hyaluronidase (Pegph20) In Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel And Gemcitabine In Subjects With Hyaluronan-High Stage IV Previouly Untreated Pancreatic Ductal Adenocarcinoma

• **Musher, B:** Loken Pharma Ab Phase I/II Trial Evaluating Safety Of Load703 An Armed Oncolytic Adenovirus For Pancreatic Cancer

• **Musher, B:** Merck Sharpe & Dohme Corp. A Phase III Study Of Pembrolizumab (Mk- 3475) Vs. Chemotherapy In Microsatellite Instability-High (Msi-H) Or Mismatch Repair Deficient (Dmmr) Stage IV Colorectal Carcinoma (Keynote-177)

• **Musher, B:** Newlink Genetics Corporation 1 Nlg-0505: A Phase III Study Of Folfirinox With Or Without Hyperacute-Pancreas (Algenpantucel-L) Immunotherapy In Subjects With Borderline Resectable Or Locally Advanced Unresectable Pancreatic Cancer

• **Nangia, J:** Calithera Biosciences H-41704: A Multicenter Phase 2 Study Of The Glutaminase Inhibitor Cb-839 In Combination With Paclitaxel In Patients With Advanced Triple Negative Breast Cancer (Tnbc) Including Patients Of African Ancestry And Non-African Ancestry

• **Nangia, J:** Cellcedx Therapeutics, Inc. A Randomized Multicenter Pivotal Study Of Cdx-011 (Cr011-Vcmmae) In Patients With Metastatic, GpnmB Over-Expressing, Triple-Negative Breast Cancer

• **Nangia, J:** Paxman Coolers Limited Scalp Cooling For Alopecia Prevention (Scalp)

• **Nangia, J:** Tesaro, Inc. H-42264: 3000-01-005 An Open-Label, Single-Arm Pilot Study Evaluating The Antitumor Activity And Safety Of Niraparib As Neoadjuvant Treatment In Localized, Her2- Negative, Brca-Mutant Breast Cancer Patients

• **Ramos, C:** Viralytics LLC A Phase I Study Using Most Closely Hla-Matched Adenovirus-Specific T-Lymphocytes For The Treatment Of Adenovirus Infections Post Allogeneic Stem Cell Transplant (Viralym-A)

• **Rimawi, M:** Abbvie Inc H-42427: An Open Label Study Of S6-005 In Subjects With Triple Negative Breast Cancer (Tnbc)

• **Rimawi, M:** Amgen, Inc. “A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study Of Denosumab As Adjuvant Treatment For Women With Early-Stage Breast Cancer At High Risk Of Recurrence (D-Care)

• **Rimawi, M:** Breast Cancer Research Foundation Tbcrc 026 Amendment 1: A Phase 2 Clinical Trial Assessing The Correlation Of Early Changes In Standardized Uptake Value (Suv) On Positron Emission Tomography (Pet) With Pathological Complete Response (Pcr) To Pertuzumab And Trastuzumab In Patients With Primary Operable Her2-Positive Breast Cancer
• Rimawi, M: Cascadian Therapeutics, Inc. 1 H-40306: Phase 2 Randomized, Double-Blinded, Controlled Study Of Ont-380 Vs. Placebo In Combination With Capecitabine And Ont-380-206: Trastuzumab In Patients With Pretreated Unresectable Locally Advanced Or Metastatic Her2+ Breast Carcinoma

• Rimawi, M: Dana Farber Cancer Institute Tcpcc030: A Randomized Phase II Study Of Preoperative Cisplatin Versus Paclitaxel In Patients With Triple Negative Breast Cancer Without Germline Brca Mutations: Evaluating The Homologous Recombination Deficiency (Hrd) Biomarker

• Rimawi, M: Galena Biopharma, Inc. Present: Prevention Of Recurrence In Early-Stage, Node-Positive Breast Cancer With Low To Intermediate Her2 Expression With Neuvax™ Treatment

• Rimawi, M: Genentech Foundation For Growth & Dev A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Of Gdc-0941 Or Gdc-0980 With Fulvestrant Versus Fulvestrant In Advanced Or Metastatic Breast Cancer In Patients Resistant To Aromatase Inhibitor Therapy

• Rimawi, M: Genentech, Inc. Pertain / Protocol Number Mo27775 / Ro43-68451 Pertuzumab

• Rimawi, M: Gilead Sciences, Inc. H-39960: Gsus3501937 A Phase 1B Study Followed By An Open Label, Parallel, Randomized Phase 2 Study Evaluating The Safety, Tolerability And Efficacy Of Gs-5829 In Combination With Exemestane Or Fulvestrant Comparing With Exemestane Or Fulvestrant Alone In Subjects With Advanced Estrogen Receptor Positive Her2- Breast Cancer

• Rimawi, M: Glaxo/Smithkline A Phase II Trial Of Lapatinib And Trastuzumab With Or Without Endocrine Therapy In Locally Advanced Her2 Overexpressing Breast Cancer Patients

• Rimawi, M: Glaxo/Smithkline Neoadjuvant Study Of Extended Lapatinib And Trastuzumab With Or Without Endocrine Therapy In Locally Advanced Her2- Overexpressing Breast Cancer Patients

• Rimawi, M: Novartis Pharmaceuticals Corp “A Randomized Phase III, Double-Blind, Placebo-Controlled, Multicenter Trial Of Daily Everolimus In Combination With Trastuzumab And Vinorelbine In Pretreated Women With Her2/Neu Over-Expressing Locally Advanced Or Metastatic Breast Cancer.”

• Rimawi, M: Novartis Pharmaceuticals Corp H 36350: Lee011: A Phase III Randomized, Double-Blind, Placebo-Controlled Study Of Lee011 Or Placebo In Combination With Tamoxifen And Goserelin Or A Non-Steroidal Aromatase Inhibitor (Nsai) / Clee011E2301 (Monaleesa-7) And Goserelin For The Treatment Of Premenopausal Women With Hormone Receptor Positive, Her2-Negative, Advanced Breast Cancer

• Rimawi, M: Pfizer, Inc Crizotinib And Sunitinib_ A Rationally Combined Targeted Therapy Strategy For Metastatic Triple Negative Breast Cancer

• Rimawi, M: Pfizer, Inc Nsabp Fb-11: A Phase II Randomized Study Evaluating The Biological And Clinical Effects Of The Combination Of Palbociclib With Letrozole As Neoadjuvant Therapy In Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer


• Rimawi, M: Syntho Biopharmaceuticals, B.V. H-41823: A Multi-Centre, Open-Label, Randomized Clinical Trial Comparing The Efficacy And Safety Of The Antibody-Drug Conjugate Syd985 To Physician’S Choice In Patients With Her2-Positive Unresectable Locally Advanced Or Metastatic Breast Cancer

• Sada, Y: Merck & Co, Inc. Keynote-224: A Phase II Study Of Pembrolizumab (Mk-3475) As Monotherapy In Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma

• Smaglo, B: Mitra Biotech A Prospective, Multicenter, Observational Study Examining The Clinical Utility Of Canscripttm In Routine Clinical Practice

• Zhang, J: Advaxis Window-Of Opportunity Trial Of Neoadjuvant Adxs11-001 Vaccination Prior To Transoral Resection Of Hpv-Positive Oropharyngeal Squamous Cell Carcinoma

• Zhang, J: Astrazeneca A Phase Iii, Randomized, Multicenter, Open-Label, Comparative Study To Determine The Efficacy Of Durvalumab Or Durvalumab And Tremelimumab In Combination With Platinum-Based Chemotherapy For The First-Line Treatment In Patients With Extensive Disease (Stage Iv) Small-Cell Lung Cancer (Sclc)

• Zhang, J: Regeneron Pharmaceuticals, Inc 1 A First-In-Human Study Of Repeat Dosing With Regn2810, A Monoclonal, Fully Human Antibody To Programmed Death – 1 (Pd-1), As Single Therapy And In Combination With Other Anti-Cancer Therapies, In Patients With Advanced Malignancies

PUBLICATIONS & PRESS


• Brenner M. Onward and upward for immuno-oncology. Chin Clin Oncol. 2018 Apr;7(2):18
Publications & Press continued

- Geng C, Kaochar S, Mitsiades N, et al. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitinization and turnover of cMYC oncoprotein. Oncogene 2017 Aug 17;36(33):4767-4777

EDITORIAL POSITIONS

• Brenner, M: Editor and Chief Molecular Therapy
• Heslop, H: Editorial Board: Blood Journal, Hematology News, Cytotherapy, Deputy Editor: Molecular Therapy, Associate Editor: Blood
• Mims, M: Associate Editor: Translational Research
• Mitsiades, N: Editorial Board: Endocrine Related Cancer, International Journal of Oncology, Journal of the Endocrine Society
• Mushar, B: Clinical Gastroenterology and Hepatology reviewer (ad hoc); New England Journal of Medicine reviewer (ad hoc)
• Osborne, C K: Editorial Board: Breast Cancer Research, Cancer Research
• Rivero, G: Associate Editor: Blood Research and Disorders Journal
• Sabichi, A: Editorial Board, The Scientific World Journal; Editorial Board, New Journal of Science
The year 2018 has been a year of transitions and successes that will serve as the foundation for future growth of The Section of Immunology, Allergy and Rheumatology. We are a small faculty, but truly represent the “little engine that could.” Our faculty, trainees and staff make important contributions to the education, research and clinical missions of Baylor College of Medicine, which we herein recognize.

First, I would like to thank Dr. David Corry for his leadership and service to our Section. Dr. Corry has served as Chief of our Section since 2011. Under his leadership, the section has developed a strong foundation of excellence in medical education, research and patient care upon which we will grow in coming years. In February of 2018, Dr. Corry transitioned to the role of Vice-Chair of Immunology in the Department of Pathology, while maintaining many of his commitments to our Section. As such, I was appointed Chief of the Section of Immunology, Allergy and Rheumatology in February of 2018.

In the past year, faculty members in the Section have published 46 peer-reviewed manuscripts. Research programs were supported by 14 grants from the National Institutes of Health, CPRIT and foundations, including one grant supporting the start of our clinic trials program. Faculty members have also given 12 invited seminars to local, national and international audiences. Finally, our Section is the home of the Biology of Inflammation Center, which provides research and educational support for immune-related diseases across the entire College.

I would also like to recognize all of the important contributions that our Section makes in the clinical and educational missions. Our physicians provide outstanding, patient-centered care across all of our clinical pavilions, including the Baylor Clinic, Baylor St. Luke’s Medical Center, the Michael E. DeBakey VA Medical Center, Texas Children’s Hospital, Harris Health Smith Clinic and Ben Taub General Hospital. All levels of trainees, including medical students, graduate students, physician-assistant students, internal medicine residents, postdoctoral fellows and clinical fellows benefit greatly from our commitment to mentoring and teaching. Our clinical fellowship training programs, led by Dr. Agarwal (Rheumatology) and Dr. Corry (Immunology and Allergy), are completely dedicated to the clinical and scholarly development of our fellows and continue to train outstanding physicians.

This report contains some of the achievements of the year past. This is our foundation from which we will build the future of Immunology, Allergy and Rheumatology at Baylor College of Medicine. I am honored and excited to lead our Section into a bright future.

Sandeep K. Agarwal, M.D., Ph.D.
Chief, Section of Immunology, Allergy and Rheumatology
Rheumatology Fellowship Program Director
Director, Biology of Inflammation Center
Cullen Trust for Healthcare Endowed Chair in Immunology
AWARDS & HONORS

- Sandeep K. Agarwal, MD, PhD: Appointed Chief, Section of Immunology, Allergy and Rheumatology
- Sandeep K. Agarwal, MD, PhD: Cullen Trust for Healthcare Endowed Chair in Immunology (2018- current)
- Sandeep K. Agarwal, MD, PhD: Rheumatology Research Foundation Study Section C, Chairman
- Sandeep K. Agarwal, MD, PhD: Scleroderma Foundation, Grant Review Study Section, Chairman
- Joan Appleyard, MD: Invited to join Spondyloarthritis research and treatment network (SPARTAN)
- David Corry, MD: Clarence and Irene H. Fulbright Chair in Pathology (March, 2018- current)
- David Corry, MD: Appointed Vice Chair for Immunology, Department of Pathology & Immunology
- David Corry, MD: Serving as Executive Director, Baylor Scott and White Research Institute-Baylor College of Medicine Affiliation
- Grace Lo, MD, MS: Editorial board member for Osteoarthritis and Cartilage
- Rashmi Maganti, MD: Appointed Medical Director of Rheumatology Clinic at the Baylor College of Medicine Faculty Group Practice
- Antony Rodriguez, PhD: Gillson Longenbaugh Foundation Award
- Tiphanie Vogel, MD, PhD: Thrasher Early Career Award
- Tiphanie Vogel, MD, PhD: The Kelly Award for Juvenile Arthritis Research
- Tiphanie Vogel, MD, PhD: Arthritis National Research Foundation Scholar
- Tiphanie Vogel, MD, PhD: Editorial board member, Frontiers in Immunology, Primary Immunodeficiencies
- Tiphanie Vogel, MD, PhD: Editorial board member, Frontiers in Pediatrics, Pediatric Immunology
PROFESSIONAL ORGANIZATIONS

• Sandeep K. Agarwal, MD, PhD: American Association of Immunology – Member
• Sandeep K. Agarwal, MD, PhD: American College of Rheumatology – Member
• Sandeep K. Agarwal, MD, PhD: American Thoracic Society – Member
• Joan Appleyard, MD: American College of Rheumatology – Member
• Joan Appleyard, MD: Spondylitis Research and Treatment Network (SPARTAN) – Member
• David Corry, MD: American Association of Allergy, Asthma, and Immunology – Member
• David Corry, MD: American Clinical and Climatological Association – Member
• David Corry, MD: American Society for Clinical Investigation – Member
• David Corry, MD: Association of American Physicians – Member
• David Corry, MD: Society for Mucosal Immunology – Member
• Sana Hasan, MD: Allergy, Asthma & Immunology Society
• Sana Hasan, MD: The Greater Houston Allergy, Asthma & Immunology Society
• Onome Ifoeze (Whiteru), MD: Alliance for Academic Internal Medicine – Member
• Onome Ifoeze (Whiteru), MD: American College of Physicians – Member
• Onome Ifoeze (Whiteru), MD: American College of Rheumatology – Member
• Onome Ifoeze (Whiteru), MD: S.L.E. Lupus Foundation – Member
• Grace Lo, MD, MS: American College of Rheumatology – Member
• Grace Lo, MD, MS: Osteoarthritis Research Society International – Member
• Rashmi Maganti, MD: American College of Rheumatology – Member
• Donald Marcus, MD: American College of Rheumatology – Master
• Antony Rodriguez, PhD: Genetics Society - Member
• Tiphanie Vogel, MD, PhD: American Academy of Pediatrics—Member
• Tiphanie Vogel, MD, PhD: American College of Rheumatology—Member
• AMIGO Mentorship Program—Mentor and Mentee
• Tiphanie Vogel, MD, PhD: American Association of Immunologists--Member
• Tiphanie Vogel, MD, PhD: Clinical Immunology Society—Member
• Tiphanie Vogel, MD, PhD: Federation of Clinical Immunology Societies—Member

RESEARCH FUNDING

• Sandeep K. Agarwal, MD, PhD: Cadherin-11 Regulation of Dermal Fibrosis and Macrophage Function. Funding Agency: NIH/NIAMS, R01, 1R01AR062056-01A. Role: Principal Investigator
• Sandeep K. Agarwal, MD, PhD: Targeting STAT3 in systemic sclerosis and dermal fibrosis. Established Investigator Award. Funding Agency: Scleroderma Foundation. Role: Principal Investigator
• David Corry, MD: Fungal Pathogenesis of Moderate to Severe Asthma. Funding Agency: NIH; R01, AI135803. Role: Principal Investigator

“We are a small faculty, but truly represent the ‘little engine that could.’
• David Corry, MD: Immunology Scientist Training Grant Funding Agency: NIH/NIAID, T32, A1053831. Role: Principal Investigator

• David Corry, MD: Mechanism and function of Let-7, a novel modulator of Th17-dependent emphysema. Funding Agency: NIH/NHLBI, R01 HL140398. Role: Principal Investigator

• Grace Lo, MD, MS: Feasibility of a Novel Approach to Studying Early Knee Osteoarthritis: an Offspring Study. Funding Agency: NIH/NIAMS, R03 AR069323. Role: Principal Investigator

• Grace Lo, MD, MS: Modifiable Risk Factors for Incident and Progressive Early Knee Osteoarthritis (Lo). Funding Agency: NIH/NIAMS, K32, 1K23AR062127-01. Role: Principal Investigator

• Rashmi Maganti, MD: A randomized, double-blind, placebo controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of multiple VA736 doses administered subcutaneously in patients with moderate to severe primary Sjogren's syndrome. Funding Agency: Novartis Pharmaceuticals. Role: Site Principal Investigator

• Antony Rodriguez, PhD: Role of let-7 microRNA in chronic obstructive pulmonary disease. Funding Agency: Gillson Longenbaugh Foundation Award. Role: Principal Investigator

• Antony Rodriguez, PhD: Mechanism and function of let-7, a novel modulator of Th17-dependent emphysema. Funding agency: NIH/NHLBI, R01 HL140398. Role: Co-Investigator

• Tiphanie Vogel, MD, PhD: BRIDGE, Baylor Rheumatology Initiative: Developing and Guiding Engagement. Funding Agency: Rheumatology Research Foundation Medical Student Preceptorship Role: Principal Investigator

• Tiphanie Vogel, MD, PhD: Undiagnosed Diseases Network (UDN). Funding Agency: NIH, 1 U01 HG007709-01 (Brendan Lee, PI). Role: Co-Investigator

• Tiphanie Vogel, MD, PhD: A Targeted Approach to Cytokine Blockade in Juvenile Arthritis (Vogel) Funding Agency: Thrasher Research Fund Role: Principal Investigator

• Tiphanie Vogel, MD, PhD: Validating STAT3 as a Therapeutic Target in Arthritis (Vogel) Funding Agency: Arthritis National Research Foundation Grant Role: Principal Investigator

• Li-yuan Yu-Lee, PhD: Endothelial-to-osteoblast conversion in prostate cancer bone metastasis. Funding Agency: NIH Multi-Pi RO1; CA174798-06A1. Role: Principal Investigator

• Li-yuan Yu-Lee, PhD: Polo-like Kinase 1 as a Novel Molecular Target for the Treatment of Asthma. Funding Agency: Biology of Inflammation Center. Role: Principal Investigator

• Li-yuan Yu-Lee, PhD: Regulation of Dormancy of Metastatic Prostate Cancer Cells by Bone Microenvironment. Funding Agency: Cancer Prevention and Research Institute of Texas. Role: Co-Investigator

PUBLICATIONS & PRESS

Journal Articles


• Liang D, Tian L, Corry D, et al. AIMp1 Potentiates TH1 Polarization and Is Critical for Effective Antitumor and Antiviral Immunity. Frontiers Immunology 2017; 8:1801


• Cho M., Lee J, Corry D, et al. Fibrinogen cleavage products and Toll-like receptor 4 promote the generation of programmed cell death 1 ligand 2-positive dendritic cells in allergic asthma. Journal Allergy Clinical Immunology 2018. 142:530-541.e6


Journal Articles continued


- Marcus D. Noninvasive treatments for acute, subacute and chronic low back pain. Annals Internal Medicine 2017; 167:832


- Romberg N, Vogel T, Canna S. NLRC4 inflammasomopathies. Current Opinion in Allergy and Clinical Immunology (2017) 6:398


Books, Book Chapters, and Videos

Presentations and Seminars
• Sandeep K. Agarwal, MD, PhD: “Joint Pain and Arthritis”, Weekley YMCA Silver Sneakers Seminar, Houston, TX. October 2017
• Sandeep K. Agarwal, MD, PhD: “Case Based Problem Solving in Psoriatic Disease and Atopic Dermatitis” PRIME Federal Seminar Series, Orlando, FL. October 2017
• Sandeep K. Agarwal, MD, PhD: “Case Based Problem Solving in Psoriatic Disease and Atopic Dermatitis” PRIME Federal Seminar Series, Chicago, IL. October 2017
• Sandeep K. Agarwal, MD, PhD: “Autoimmune interstitial lung disease”, BCM Pulmonary Seminar, Houston, TX. December 2017
• Sandeep K. Agarwal, MD, PhD: “Update on Psoriatic Arthritis”, Northwest Houston Medical Center Grand Rounds. Houston, TX. April 2018.
• Joan Appleyard, MD: “Perioperative management of anti-rheumatic medications,” Michael E. DeBakey Veterans Administration Medical Center Grand Rounds. May 2018
• David Corry, MD: Airway mycosis and allergic airway disease, Aberdeen Scotland, January 2018
• David Corry, MD: The coagulation-immune nexus in allergic inflammation, Suzhou, China, December 2017
• Tiphanie Vogel, MD: “Introduction to Tissue Culture.” Developing Investigative Scholars Program Lecture Series. Texas Children’s Hospital, Houston, Texas. July 2017
• Tiphanie Vogel, MD: “STAT3 GOF syndrome: Searching for Broad Insight using a Rare Disease.” Texas Children’s Research Seminars, Houston, Texas. November 2017
• Tiphanie Vogel, MD: “Autoinflammation.” Adult Rheumatology Fellows’ Research Conference

Media Releases
• Sandeep K. Agarwal, MD, PhD: NIH-NIAMS Spotlight on Research. Interview by NIH-NIAMS regarding publication in Arthritis and Rheumatology. https://www.niams.nih.gov/newsroom/spotlight-on-research/researchers-identify-potential-biomarker-serious-scleroderma
• David Corry, MD: “David vs Goliath: how small molecule can defeat asthma attacks” Baylor College of Medicine, From the Labs https://blogs.bcm.edu/2018/06/12/david-vs-goliath-how-a-small-molecule-can-defeat-asthma-attacks/
• Grace Lo, MD, MS: Online report by Helio.com summarizing and highlighting publication in Arthritis Care and Research on crepitus and symptomatic knee osteoarthritis. https://www.healio.com/rheumatology/osteoarthritis-and-bone-disorders/news.online/%7Bb40c17a6-5591-4a17-a901-57fabc25308f%7D/creaky-knees-can-predict-symptomatic-oa
• Grace Lo, MD, MS: Online video by Arthritis Care and Research highlighting publication in Arthritis Care and Research on crepitus and symptomatic knee osteoarthritis. https://vimeo.com/246493963
Section of
Infectious Diseases

OUR FACULTY

Ume Abbas
Mayar Al Mohajer
Monisha Arya
Robert Atmar
Major Bradshaw
Katharine Breaux
Galant Chan
Elizabeth Chiao
Andrew Chou
Bich Dang
Charlene Flash
Thomas Giordano
Richard Hamill
Vagish Hemmige
Penny Jaffe
Oyebunmi Kutemi
Daniel Mendoza
Cezarina Mindru
Daniel Mushar
George Parkerson
Shital Patel
Alejandro Restrepo
Maria Rodriguez-Barradas
Stacey Rose
Jose Serpa-Alvarez
Shahriar Tavakoli Tabasi
Laila Woc-Colburn
Edward Young
Rabih Darouiche
Andrew DiNardo
Hana El Sahly
Wendy Keitel
Rojelio Mejia
Jill Weatherhead

The Section of Infectious Diseases in the Department of Medicine provides outstanding state-of-the-art clinical care and creates and applies knowledge through research, scientific discovery and medical education and training locally and globally; all done with innovation and compassion to advance health and wellness. The Section is the primary academic unit serving the clinical adult infectious diseases research community within Baylor College of Medicine. As such, the Section is a critical force in achieving both the strategic and mission objectives of the College.

Dr. Thomas Giordano is the Chief of the Section. Dr. Robert Atmar is Chief of the Infectious Diseases Service at Ben Taub Hospital, Dr. Maria Rodriguez-Barradas is Chief of the Infectious Diseases Service at the Michael E. DeBakey VA Medical Center and Dr. Laila Woc-Colburn is Medical Director of Infectious Diseases for the Baylor Faculty Group Practice. Dr. Jose Serpa is Program Director for the Infectious Diseases fellowship training program, and Dr. Prathit Kulkarni is Associate Program Director. Ms. Regina Davis is the Section Administrator.
The Section provides most of the adult infectious diseases clinical care at BSLMC; all of the adult infectious diseases care at the McNair Clinic, MEDVAMC, BTH and Smith Clinic; about half of the HIV care at TSHC (McGovern School of Medicine faculty also staff the clinic); and all of the adult infectious diseases consultation services at the Pavilion for Women and Texas Children’s Hospital. The Section provides critical Infectious Diseases clinical expertise to many of the Transplant Services at BSLMC and McNair clinic. The Section provides critical Infection Prevention and Antibiotic Stewardship services at BSLMC, MEDVAMC and BTH. Decreasing hospital-acquired infections is essential for patient safety, hospital reputation and hospital rankings.

The Section provides outstanding medical education leadership and teaching to the College, including the School of Medicine, the School of Allied Health Sciences, the Graduate School of Biomedical Sciences and the National School of Tropical Medicine. The Section’s faculty lead and provide the majority of lectures for the School of Medicine’s core course on Infectious Diseases, the National School of Tropical Medicine’s Diploma in Tropical Medicine course and the School of Allied Health Sciences’ lectures and case studies on infectious diseases. In addition, at the School of Medicine the faculty host elective clinical rotations, and provide leadership in research electives, wellness and specialty electives, the International Medicine Program and the Global Health Track and serve on the Curriculum Committee.

The Section is research-focused, with support from NIH, VA, CDC, HRSA, industry and other sources and over 200 non-duplicated publications since January 2015.

The Section’s faculty serve vital administrative and service roles in the College, including serving on the Curriculum Committee, the Faculty Senate, Institutional Review Boards, the Biosafety Committee, the Environmental Safety Committee, the Medical Education Committee, the Dean’s Residency Manpower Committee, the College’s Rising Star and Master Clinician Awards Steering Committee, the Institutional Dual Use of Research Concern Committee, the Faculty Development Forum and as Faculty Inclusion Ambassadors.

Congratulations and thank you to the faculty, administrators and staff for another outstanding year for the Section of Infectious Diseases.

Sincerely,

Thomas P. Giordano, MD, MPH
Decreasing hospital-acquired infections is essential for patient safety, hospital reputation and hospital rankings.
**Giordano**  
- Chief, Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine  
- Medical Director of HIV Services and the Thomas Street Health Center, Harris Health System, Houston, TX  
- Chief, Clinical Epidemiology and Comparative Effectiveness Program, Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, TX  
- Co-Chair, Policy and Research Work Group, END HIV Houston  
- Member, Faculty Development Forum, Baylor College of Medicine  
- Vice-Chair, Faculty and Staff Development, Department of Medicine, May 2017 to June 2018  

**Hamill**  
- Vice-Chair for Education, Department of Medicine, Baylor College of Medicine  
- Chair, Subcommittee for Research Safety, Michael E. DeBakey VA Medical Center  

**Mindru**  
- President, Houston Infectious Diseases Society  

**Rose**  
- Co-chair, Texas ACP Wellness Committee  
- National Well-being Champion, ACP (Texas representative)  
- Invited Member / BCM Representative, Physician Engagement Resiliency Task Force, Resident Well-being Subgroup, The Methodist Hospital  
- BCM Medical Student Liaison program, January 2016 – present  
- BCM BeWell Wellness Champion, August 2017 – present  
- Member, BCM Resident Service and Evaluation Committee  
- Member, BCM Department of Medicine Grand Rounds Planning Committee  
- Faculty Chair, BCM Internal Medicine Resident Wellness Committee  
- Member, BCM Department of Medicine Education Vice Chair Group and Liaison for Infectious Diseases Section  

**Weatherhead**  
- American Society of Tropical Medicine and Hygiene Certificate of Knowledge Exam (cTropMed), Committee Member  

**Woc-Colburn**  
- Member, BCM Department of Medicine Faculty and Staff Development Vice Chair Group and Liaison for Infectious Diseases Section  
- Member and Chair-Elect, Baylor College of Medicine Faculty Senate  

**RESEARCH FUNDING**  
- **Chiao, Elizabeth Yu** - Annual Anal Sampling Using Dna Screening To Identify Men Who Have Sex With Men At Increased Risk For Anal Cancer. National Institutes Of Health (Nih). R01-ca215403 01a1. (9/15/2017 - 8/31/2018)  
- **Chiao, Elizabeth Yu** - Annual Anal Sampling Using Dna Screening To Identify Men Who Have Sex With Men At Increased Risk For Anal Cancer. National Institutes Of Health (Nih). R01-ca215403 01. (9/15/2017 - 8/31/2018)  
- **Dang, Bich Ngoc** - Year 4: Patient Satisfaction, Retention In Hiv Care, And Adherence To Art. National Institute Of Mental Health (Nimh). K23-mh100965- 04. 7/1/2017 - 6/30/2018)  
- **Dang, Bich Ngoc** - Junior Faculty Seed Award. Bcm. (7/1/2017 - 6/30/2018)  
- **Dang, Bich Ngoc** - Seed. Medvamc. (10/1/2017 - 9/30/2018)  
- **Darouiche, Rabih** - Air Barrier System To Reduce Contamination Of Wounds During Surgery. Nih. 3 R44 Gm095005- 07s2. (01/2010 - 08/2019)  
- **Darouiche, Rabih** - Air Barrier System To Reduce Contamination Of Wounds During Surgery. Nih. 3 R44 Gm095005- 07s1. (01/2010 - 08/2019)  
- **Darouiche, Rabih** - Air Barrier System To Reduce Contamination Of Wounds During Surgery. Nih. 5 R44 Gm095005-07. (01/2010 - 08/2019)  
- **El Sahly, Hana M.** - Task Orders 17 - Up: Vaccine And Treatment Evaluation Units (Vteu). Nih. 5 Hhsn 272201300015i To13 Mod1. (09/2013 - 09/2023)
Research Funding continued


- **Mindru, Cesarina** - Va Cooperative Study (Csp2001 Trial-Investigation Of Rifampin To Reduce Pedal Amputations For Osteomyelitis In Diabetics - va Intrepid. Department Of Veterans Affairs. (12/1/2017 - 11/30/2020)

- **Patel, Shital Mahendra** - Medical Director For South Central Aids Education And Training Center Region 6- Scaetc Program. Health Resources & Services Administration (Hrsa). U10-ha29290. (7/1/2017 - 6/30/2018)


- **Rodriguez-Barradas, Maria C** - Year 7: Alcohol And Multisubstance Use In The Veterans Aging Cohort Study: 2/6 Compaas U01: Observation Study. National Institute On Alcohol Abuse And Alcoholism (Niaaa). U01-aa020790- 07. (9/1/2017 - 8/31/2018)


- **Serpa-Alvarez, Jose A**. - 2017 Idsa Annual Meeting - Id Fellowship Travel Grant. Janssen Scientific Affairs, Llc. F116465. (9/12/2017 - 12/31/2017)

- **Weatherhead, Jill** - Pediatric Pilot Award. Texas Children’s Hospital.( 07/01/17 - 12/30/18)

**PUBLICATIONS & PRESS**


• Deshmukh A, Chiao E, et al. Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now. Vaccine. 2017 Sep 12;35(38):5102-5109


Publications & Press continued

The Section of Infectious Diseases provides outstanding state-of-the-art clinical care and creates and applies knowledge through research, scientific discovery and medical education and training locally and globally.


Weatherhead J and Mejia R. Chapter 34: Eosinophilic Meningitis. Feigin and Cherry’s Textbook of Pediatric Infectious Diseases. 8th edition. 2017


EDITORIAL POSITIONS

Al Mohajer
• Ad hoc Reviewer, Transition Medicine Ligums Family Grant Reviews

Atmar
• North American editor, Journal of Infection
• Editorial Board, Journal of Infectious Diseases
• NIH/NIAID/DMID, Member, Scientific Review Group, Member Conflict: Topics in Virology, ZRG1 IDM-X, July 25, 2017
• DSMB - NIH/NHLBI – Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED), DSMB Member
• DSMB - NIH/NIAID/DMID Protocol No. 16-0092 – A Phase 2 Multi-Center, Prospective, Randomized, Double-Blind Study to Assess the Clinical and Antiviral Efficacy and Safety of Nitazoxanide for the Treatment of Norovirus in Hematopoietic Stem Cell and Solid Organ Transplant Recipients, DSMB Chairman
• Member, Advisory Committee on Immunization Practices (ACIP), CDC

Chiao
• Ad hoc member NCI Board of Scientific Advisers for AIDS Malignancies
• Ad hoc member of NCI Committee to Develop an Important Questions on HIV Malignancy RFA
• Organizing committee for the International Conference on HIV Malignancies
• Organizing committee for Eurogin (European Conference on Gynecology)

Chou
• Infectious Diseases Society of America Diagnostic Committee (Voting Member)
• Section Editor, Current Tropical Medicine Reports
• IDweek Abstract Reviewer

DiNardo
• NIH/NIAID Member, Scientific Review Group, NIAID Clinical Trial Implementation Cooperative Agreement (U01), ZAI1 JRR-A (M2)

Giordano
• Grant Reviewer, MEDVAMC Seed Grant Program, July 2017
• Ad hoc Reviewer, Einstein-Rockefeller-CUNY Center for AIDS Research Developmental Grant Program, August 2017
• Grant reviewer, Baylor College of Medicine Population Medicine – Precision Health pilot grant program, April 2018

Hamill
• Associate Editor, Journal of Infection
• Member, NIH/CDC/HIV Medicine Association of the IDSA Cryptococcosis & Coccidioides Guideline Writing Subcommittee, HHS Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
• Member, NIAID Division of Microbiology & Infectious Diseases Data & Safety Monitoring Board for DMID Protocol 14-0053; a randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia (CAP) in endemic areas

Mejia
• Associate Editor for Current Tropical Medicine Reports
• Associate Editor PLoS Neglected Tropical Diseases

Mendoza
• Member, Infectious Diseases Society of America Journal Club
• Member, AIDS Clinical Trials Group End Organ Disease / Inflammation Transformative Group

Mindru
• Judge, BCM Annual Resident Research Symposium

Rose
• Monthly contributor (audio reviews) for Practical Reviews, Oakstone Publishing
• Abstract judge, Houston ACP Associates Day, Baylor College of Medicine
The academic year 2018 has been an exciting one for the Section of Nephrology. Our world-class faculty have made outstanding contributions in research and scholarship, education and clinical care. They have participated in numerous national and international activities and organizations. And our outpatient practice has moved to our brand-new, state-of-the-art facility at the McNair Campus on 7200 Cambridge.

This report lists some of the more tangible products delivered and awards and recognitions received during the 12-month period ending in June 2018. In addition, we have continued to provide top quality specialized kidney health care to our patients at our clinical sites within the Texas Medical Center and beyond. Our faculty group practice continues to excel in patient satisfaction and productivity.

Please enjoy and thank you for your interest.

Wolfgang C. Winkelmayer, MD, MPH, ScD
Chief, Section of Nephrology

Gordon A. Cain Chair in Nephrology
AWARDS & HONORS
- Section FGP Faculty and Staff: “That’s The Way 10k Award” Nephrology section award for most improvement in patient satisfaction (July 2017 to June 2018)
- Section FGP Faculty and Staff: Highest Ranking in Patient Experience – All-Star Winner for FY18 Quarter 3
- Adrogue: Senior Faculty Teaching Award, Section of Nephrology, Baylor College of Medicine, June 2018
- Murthy: “Unsung Hero” Fellowship Award, Section of Nephrology, Baylor College of Medicine, June 2018
- Perez: Invited Delegate, KDIGO Controversies Conference on Dialysis Initiation, Madrid, Spain, January 2018
- Raghavan: PEEPSS – Inaugural member, Team Leader, BCM Center for Professionalism (February to September 2018)
- Saridey: Norton Rose Fulbright Faculty Excellence Award for Teaching and Evaluation, Baylor College of Medicine, May 2018
- Yan: Junior Faculty Teaching Award, Section of Nephrology, Baylor College of Medicine, June 2018

PROFESSIONAL ORGANIZATIONS
- Erickson: Member, Quality, Patient Safety, and Clinical Practice Committee, American Society of Nephrology, Washington, D.C.
- Erickson: Member, PTAC Joint Working Group, American Society of Nephrology, Washington, D.C.
- Winkelmayer: Member, Quality, Patient Safety, and Clinical Practice Committee, American Society of Nephrology, Washington, D.C.
- Winkelmayer: Co-Chair, Kidney Disease: Improving Global Outcomes (KDIGO), Brussels, Belgium
- Winkelmayer: Member, Advisory Board, Chronic Kidney Disease Surveillance System, Center for Disease Control, Atlanta, GA
- Winkelmayer: Member, External Expert Panel, United States Renal Data System, National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
- Zhang: American Diabetes Association: Member, Research Grant Review Committee, Arlington, VA

RESEARCH FUNDING
- Cheng (PI): Chronic kidney disease adversely influences vascular functions. NIH/NIDDK; R01 DK095867; 3/15/2013–1/31/2019
- Cheng (PI): Epigenetic alterations of GSTA4 regulate CKD-induced vascular remodeling American Heart Association; 7/1/2015–6/30/2018
- Erickson (PI): The Effect of Provider Market Competition of Health Outcomes in Dialysis. NIH/NIDDK, K23 DK101693; 4/1/2014–1/31/2019
- Erickson (PI): Dialysis Facility Closures and their Effect on Costs, Health Outcomes, and Access to Care. Carl W. Gottschalk Research Scholar Grant, American Society of Nephrology; 7/1/2017- 6/30/2019
- Erickson (PI): Junior Faculty Seed Funding Award; Baylor College of Medicine; 6/15/2018-6/30-2019
- Klotman (PI): Long-term Consequences of HIV in the Kidney. NIH/NIDDK, P01 DK056402; 9/15/1999 - 4/30/2022
- Mitch (PI): Protein nutrition in experimental uremia. NIH/ NIDDK, R01/R37 DK037175; 9/1/1987- 3/31/2022
- Navaneethan (PI): Visceral adiposity and physical function in CKD. NIH/NIDDK R01 DK101500; 9/22/2015- 7/31/2019
- Navaneethan (PI): Prevalence, management and outcomes of iron deficiency anemia in CKD. Keryx Biopharmaceuticals; 1/12/2018- 12/31/2019
- Pan (PI): Stanniocalcin-1, Kidney Protection by AMPK. VA/CDA, IK2 BX002912; 1/1/2017-12/31/2021
- Raghavan (PI): Difficult Conversations in Nephrology: Communications Workshop; BCM Education Grant; 7/2017-6/2018
- Thomas (PI): Chronic Kidney Disease and Impaired Actions of Insulin. VA/CDA, IK2 BX002492; 4/1/2015-3/31/2020
Journal Articles

- Deger S, Hung A, Mitch W, et al. Systemic Inflammation is Associated with Exaggerated Skeletal Muscle Protein Catabolism in Maintenance Hemodialysis Patients. JCI Insight 2017; Nov 16; 2(22)
- Dong J, Dong Y, Chen Z, Mitch WE, Zhang L. In the pathway to muscle fibrosis depends on myostatin stimulating the differentiation of fibro/adipogenic progenitor cells. Kidney Int 91:119-128, 2017
- Guan C, Li Q, Song X, Xu W, Li L, Xu A. Antroquinonol Exerts Immunosuppressive Effect on CD8+ T Cell Proliferation and Activation to Resist Depigmentation Induced by H2O2. Oxid Med Cell Longev 2017;2017:9303054. 2017 Dec 31


• Navaneethan S, Virani S. Omega-3 Fatty Acids (Fish Oil) Supplementation and Albuminuria: Not a Slam Dunk. J Am Heart Assoc 2017; Jul;14(6(7)


Journal Articles continued

Books and Book Chapters

EDITORIAL POSITIONS
• Erickson: Editorial Board, American Journal of Kidney Diseases
• Erickson: Public Policy Forum Steering Committee, American Journal of Kidney Diseases
• Erickson: Guest Editor, Special Issue on Health Policy, Seminars in Dialysis
• Mitch: Editorial Board, Kidney International
• Mitch: International Advisory Board, Clinical and Experimental Nephrology
• Mitch: Editorial Board, Journal of the American Society of Nephrology
• Navaneethan: Associate Editor, American Journal of Kidney Diseases
• Navaneethan: Associate Editor, NephSAP (Nephrology - Self Assessment Program)
• Navaneethan: Associate Editor, CardioRenal Medicine
• Navaneethan: Editorial Board, Clinical Journal of American Society of Nephrology
• Navaneethan: Editorial Board, American Journal of Nephrology
• Pan: Editorial Board, American Journal of Physiology-Renal Physiology
• Sheikh-Hamad: Editorial Board, American Journal of Physiology-Renal Physiology
• Wang: Editorial Board, Scientific Reports
• Wang: Editorial Board, Journal of Nephrology and Therapeutics
• Wang: Editorial Board, Science Postprint
• Wang: Editorial Board, International Journal of Transplantation Research and Medicine
• Wang: Editorial Board, Journal of Nephrology Research
• Winkelmayer: Associate Editor, Journal of the American Medical Association
• Winkelmayer: Editorial Board, American Journal of Kidney Diseases
• Winkelmayer: Public Policy Forum Steering Committee, American Journal of Kidney Diseases
• Winkelmayer: Editorial Board, American Journal of Nephrology
• Winkelmayer: Editorial Board, Clinical Journal of American Society of Nephrology
• Winkelmayer: Editorial Board, Seminars in Dialysis
• Winkelmayer: Guest Editor, Special Issue on Health Policy, Seminars in Dialysis
• Winkelmayer: Editorial Board, Clinical Journal of American Society of Nephrology
• Zhang: Editorial Board, Austin Diabetes Research
• Zhang: Editorial Board, Journal of Nephrology & Therapeutics
The Pulmonary, Critical Care, and Sleep Medicine Section in the Department of Medicine oversees the clinical, education and research activities in these three related disciplines at Baylor College of Medicine and its affiliated hospitals. Its 44 full-time faculty members direct these activities at Ben Taub Hospital/Harris County Hospital District, the Michael E. DeBakey VA Medical Center (MEDVAMC), the Baylor Faculty Group Practice, Baylor St. Luke’s Medical Center (BSLMC) and the Pavilion for Women (PFW) at Texas Children’s Hospital.

Section of Pulmonary, Critical Care and Sleep Medicine

OUR FACULTY

Non-Clinician Research Faculty
Aladin Boriek
Mustafa Atik
Monica Jeongsoo Hong

Clinician Faculty
Kalpalatha Guntupalli
Philip Alapat
Nicola Hanania
Elizabeth Guy
Resmi George
Dharani Narendra
Purve Patel
Pralay Sarkar
Venkata Bandi
Charlie Lan
Ray Lazarus
Steve Bujarski
Farrah Kheradmand
Lavannya Pandit
Rolando Rumbaut
Amir Sharafkhaneh
Supriya Singh
Kanta Velamuri
Uma Ayyala
Shahram Moghtader
Ritwik Agrawal
Fidaa Shaib
Prasad Manian
Ali Jiwani
Gloria Li
Jigna Zatakia
Dipa Modi
Thomas Monaco
N. Tony Eissa
Annise Wilson
Tara Barto
Amit Parulekar
Goutham Dronavalli
Christina Kao
James Herlihy
Muhammad Asim Siddique
Jairo Barrantes-Perez
Christopher Howard
Christopher Morgan
DeReddi Reddy
Babith Mankidy
Andrea Braun
Ali Omranian
David Muigai

The Pulmonary, Critical Care, and Sleep Medicine Section in the Department of Medicine oversees the clinical, education and research activities in these three related disciplines at Baylor College of Medicine and its affiliated hospitals. Its 44 full-time faculty members direct these activities at Ben Taub Hospital/Harris County Hospital District, the Michael E. DeBakey VA Medical Center (MEDVAMC), the Baylor Faculty Group Practice, Baylor St. Luke’s Medical Center (BSLMC) and the Pavilion for Women (PFW) at Texas Children’s Hospital.
RESEARCH FUNDING

- **Kheradmand, Farrah** (MPI). Fungal pathogenesis of moderate to severe asthma. National Institute of Allergy and Infectious Diseases (NIAID). 1R01AI135803-01. 3/23/18-2/28/23. Total funding $555,952

- **Kheradmand, Farrah.** Innate and Acquired Immune Responses in Human COPD. Michael E. DeBakey VA Medical Center. 2S01cx00104-09. 7/1/17-6/30/18. Total funding $150,000

- **Rumbaut, Rolando.** Platelets and Microvascular Thrombosis in Inflammation. Michael E. DeBakey VA Medical Center. S101BX002551-03. 04/01/18-03/31/19. Total funding $150,000

- **Eissa, Tony.** Lyssosomal Origin for Emphysema. Alpha One Foundation. 501272. 7/1/17-6/30/18. Total funding $100,000

- **Parulekar, Amit D.** Yr 2: The Impact of Fungal Sensitization and Airway Fungal Microbiome on Asthma Severity. American Lung Association. CG-415676-Year 2. 7/1/17-6/30/18. Total funding $40,000

- **Hanania, Nicola Alexander.** Airways Clinical Research Centers (ACRC). American Lung Association. Year 2. 7/1/17-6/30/18. Total funding $100,000

- **Kheradmand, Farrah.** Yr 1: PR140593P1: enhancement of immune memory responses to respiratory infection. Department of Defense Congressionally Directed Medical Research Programs. W81XWH-16-1-0361 YR 2. 8/1/17-7/31/18. Total funding $365,350


- **Hanania, Nicola Alexander.** NCE to 6/30/2018 “Spirometry Toolkit” to Improve Knowledge and Appropriate Use of Spirometry in the Primary Care Setting. The Chest Foundation. DS RH 2013 Yr 3 NCE. 4/1/2018-6/30/2018. Total funding $0.00


- **Guntupalli, Kalpalathak.** Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF-PRO). Boehringer Ingelheim Ltd. 2018. Total funding $2,500

- **Hanania, Nicola Alexander.** Observational Study in Healthy Subjects and Patients With COPD to Assess the Relationship Between Clinical, Imaging and Biomarker Measurements, and Progression of Emphysema Over Two Years. Boehringer Ingelheim Pharmaceutical, Inc. 2018. Total funding $51,645.07

- **Barto, Tara Lynn.** JBT101-CF-001: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Multicenter Study To Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Cystic Fibrosis. Corbus Pharmaceuticals. 2018. Total funding $1,563.78

- **Hanania, Nicola Alexander.** A Phase II, Randomized, Double-blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Lebrikizumab In Patients With Chronic Obstructive Pulmonary Disease And A History Of Exacerbations. F. Hoffmann-La Roche Ltd. 2018. Total funding $5,194.76

- **Hanania, Nicola Alexander.** A Prospective, Single Arm, Longitudinal Cohort Study To Assess Biomarkers In Real World Patients With Severe Asthma. Genentech, Inc. 2018. Total funding $22,293.80

- **Hanania, Nicola Alexander.** A Randomized, Double-blind, Sponsor Open, Placebo- Controlled, 52 Week Study Evaluation The Effect Of Danirixin (Gsk1325756) On Lung Function And Health Related Quality Of Life In Participants With Mild To Moderate Chronic Obstructive Pulmonary Disease (Copd). Glaxo/SmithKline. 2018. Total funding $14,358.17


- **Hanania, Nicola Alexander.** Yr 3: Network Management Core (Nemo) for the Pulmonary Trials Cooperative (Ptc) (Rethinc). National Heart, Lung, And Blood Institute (NHLBI). 2018. Total funding $1,000

- **Hanania, Nicola Alexander.** Yr 2: Network Management Core (Nemo) for the Pulmonary Trials Cooperative (Ptc)/ Insight: Pulmonary Trials Cooperative’s (PTC) Intervention Study in Overweight Patients With COPD (Insight COPD) TRIAL. National Heart, Lung, And Blood Institute (NHLBI). 2018. Total funding $1,000

- **Hanania, Nicola Alexander.** Amendment - The Genetics Epidemiology of COPD. National Institutes of Health (NIH). 2018. Total funding $24,013.19

- **Hanania, Nicola Alexander.** Yr 3: Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) (Insight). NIH: National Institutes of Health. Total funding $1,173.33

- **Lazarus, Donald.** Spirometry Pivotal II Trial (EMPROVE). Olympus/Spiration (EMPROVE). 2018. Total funding $12,596.24

- **Pandit, Lavannya.** A Randomized, Placebo-Controlled Study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease Protocol Number: #RIN-PH-201. United Therapeutics. 2017-2020. Total funding $125,000
- Yohannes A, Kaplan A, Hanania N. COPD in Primary Care: Key Considerations for Optimized Management: Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. J Fam Pract. 2018 Feb;67(2 Suppl):S11-S18
- Yohannes A, Hanania N. “Depression and Anxiety in Adults Patients with Asthma” In: Sharafkhanhe A. Yohannes A, Hanania N, Kunik ME eds. Depression and Anxiety in Patients with Chronic Respiratory Diseases. Springer 2017: 73-84
- Bujarski S, Parulekar A, Hanania N. “Asthma, COPD, and asthma-COPD overlap in special populations.” In: Bernstein JA, Boulet LP, Wechsler ME eds. Asthma, COPD, and the Overlap: A Case-Based Overview of Similarities and Differences. 1st ed. CRC Press; 2018:135-144
AWARDS & HONORS

• Fremion: “That’s the Way” Baylor College of Medicine award in recognition of exceptional care feedback from patients 11/2017

• Peacock, Acosta, Fremion, Kim, Kemere: “All Star: Highest Rank” Baylor College of Medicine award for exceptional patient satisfaction, quality, and safety. Quarters 1, 2, and 4.

OUR FACULTY

Cynthia Peacock
Elisha Acosta
Ellen Fremion
Judy Kim
K. Jordan Kemere
PROFESSIONAL ORGANIZATIONS
- **Acosta**: American Academy of Pediatrics, American College of Physicians, American Academy of Developmental Medicine and Dentistry
- **Fremion**: Spina Bifida Association Transition to Adult Care Healthcare Guidelines Workgroup Chair (2014-2018); Spina Bifida Association provider advisory committee (2016-present), American College of Physicians, American Academy of Pediatrics, The American Academy of Developmental Medicine and Dentistry
- **Kemere**: American College of Physicians, American Academy of Developmental Medicine and Dentistry

PUBLICATIONS & PRESS

RESEARCH FUNDING
- **Acosta**: SOI/AADMD National Curriculum in Developmental medicine, Funding Dates: 2017
- **Acosta, Kim**: “Complex Care Transition Readiness Program”, Ligums Family Transition Medicine Grant, Co-Principal Investigators, Funding dates: October 2016-October 2017, re-funding October 2017-October 2018
- **Fremion**: “Self-Management Improvement for Teens with Spina Bifida”, Ligums Family Transition Medicine Grant, Principle Investigator, Funding dates: October 2016-October 2017, re-funding October 2017-October 2018
- **Kemere**: “Planning Transition in the Texas Children’s Hospital Metabolic Clinic”, Ligums Family Transition Medicine Grant, Co-Principal Investigator, Funding dates: October 2016-October 2017, re-funding October 2017-October 2018
- **Peacock**: “Transition Health Care for Children and Youth with Special Health Care Needs”, Healthy Tomorrows Partnership for Children Program from Maternal and Child Health Bureau at HRSA, Principle Investigator, Funding dates: March 2016-2021

EDITORIAL POSITIONS
- **Peacock**: American Academy of Developmental Medicine and Dentistry Board Member 2018-2020
Chair
Dr. Hashem El-Serag
Margaret M. Alkek Distinguished Chair

Vice Chairs
Mandeep Bajaj, M.B.B.S.
Vice Chair for Clinical Affairs
Professor, Endocrinology,
Diabetes and Metabolism

Richard J. Hamill, M.D.
Vice Chair for Education
Professor, Infectious Diseases

Joslyn Fisher, M.D., M.P.H.
Vice Chair for Faculty and Staff
Development
Associate Professor, General Internal
Medicine

Stephen Greenberg, M.D., MACP
Vice Chair for Harris Health System/Ben
Taub Hospital
Distinguished Service Professor, General Internal Medicine

Aanand D. Naik, M.D.
Vice Chair for Quality Improvement and
Innovations
Associate Professor, Health Services
Research

Christie M. Ballantyne, M.D.
Vice Chair for Research
Chief, Cardiology and Cardiovascular
Research

Biykem Bozkurt, M.D., Ph.D.
Vice Chair for Veterans Affairs
Professor, Cardiology

Section Chiefs
Christie Ballantyne, M.D.
Chief, Cardiology and
Cardiovascular Research

Marco Marcelli, M.D.
Interim Chief, Endocrinology,
Diabetes and Metabolism

Melissa Bondy, M.D.
Chief, Epidemiology and Population
Sciences

Fasiha Kanwal, M.D. M.S.H.S.
Chief, Gastroenterology and Hepatology

David Hyman, M.D.
Chief, General Internal Medicine

George Taffet, M.D.
Chief, Geriatrics

Laura Petersen, M.D., MPH, FACP
Chief, Health Services Research

Martha Mims, M.D.
Chief, Hematology and Oncology

Sandeep Agarwal, M.D., Ph.D.
Chief, Immunology, Allergy and
Rheumatology

Thomas Giordano, M.D., M.P.H.
Chief, Infectious Diseases

Wolfgang Winkelmayer, M.D., Sc.D.
Chief, Nephrology

Rolando Rumbaut, M.D., Ph.D.
Interim Chief, Pulmonary, Critical Care
and Sleep Medicine

Cynthia Peacock, M.D.
Chief, Transition Medicine

CONTACT
Margaret M. and Albert B Alkek
Department of Medicine

Baylor College of Medicine
1 Baylor Plaza
Houston, Texas 77030
DoM Administration Phone (713) 798-2450
DoM Patient Care Phone: (713) 798-1000

www.bcm.edu/medicine